[{"title01":"Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity","title02":"Co-operative epigenetic remodelling by Setd2<\/i> deficiency and Kras<\/i> mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity","journal":"Br J Haematol","issue":"2025 Aug 4. doi: 10.1111\/bjh.70060. Online ahead of print.","author":"Munyurangabo G, Zhang L, Zhou Y, Zhang P, Yu X, Qu D, Yang D, Ren X, Liu H, Wu Y, Kong G, Yang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40755378"},{"title01":"HOX11 gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia","title02":"HOX11<\/i> gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2025 Aug 5. doi: 10.1111\/bjh.70071. Online ahead of print.","author":"Zhong M, Yin C, Wang Y, Zeng L, Yang Q, Feng B, Chang Y, Zhang J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40762137"},{"title01":"Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A::MLLT3 and U2AF1 mutation","title02":"Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A<\/i>::MLLT3<\/i> and U2AF1<\/i> mutation","journal":"Blood","issue":"2025 Aug 7;146(6):765.","author":"Chen S, Xiao Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40773175"},{"title01":"Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study","title02":"Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study","journal":"Br J Haematol","issue":"2025 Aug 8. doi: 10.1111\/bjh.70082. Online ahead of print.","author":"Trab T, Ranad\u00f3ttir T, Chanchiri I, Ludvigsen Al-Mashhadi A, Berggreen Dall E, Rasch S, Johansen M, Haunstrup LM, Cunsolo G, Poulsen CB, Larsen TS, Husby S, Brown P, Hawkes EA, El-Galaly TC, Gr\u00f8nb\u00e6k K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781827"},{"title01":"T-cell lymphoblastic lymphoma in children, adolescents and young adults","title02":"T-cell lymphoblastic lymphoma in children, adolescents and young adults","journal":"Br J Haematol","issue":"2025 Aug 13. doi: 10.1111\/bjh.70053. Online ahead of print.","author":"Te Vrugt M, Newman H, Teachey DT, Burkhardt B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40808247"},{"title01":"Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma","title02":"Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"2025 Aug 11. doi: 10.1111\/bjh.70090. Online ahead of print.","author":"Morimoto S, Jo T, Kitawaki T, Sakamoto T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Nagao M, Takaori-Kondo A, Arai Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40785504"},{"title01":"Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma","title02":"Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma","journal":"Blood","issue":"2025 Aug 1:blood.2025028863. doi: 10.1182\/blood.2025028863. Online ahead of print.","author":"Sam J, Leclercq-Cohen G, Gebhardt S, Surowka M, Herter S, Lechner K, Relf J, Briner S, Varol A, Appelt B, Domocos I, Nicolini VG, Bez M, Bommer E, Jenni S, Schoenle A, Le Clech M, Colombetti S, Klein C, Uma\u00f1a P, Lundberg P, Korfi K, Bottos A, Bacac M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749164"},{"title01":"Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma","title02":"Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma","journal":"N Engl J Med","issue":"2025 Jul 31;393(5):498-500.","author":"Richardson PG, Munshi NC, Longo DL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40742264"},{"title01":"Daratumumab for High-Risk Smoldering Multiple Myeloma. Reply","title02":"Daratumumab for High-Risk Smoldering Multiple Myeloma. Reply","journal":"N Engl J Med","issue":"2025 Aug 7;393(6):617.","author":"Dimopoulos MA, Voorhees PM, Rajkumar SV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40768726"},{"title01":"Daratumumab for High-Risk Smoldering Multiple Myeloma","title02":"Daratumumab for High-Risk Smoldering Multiple Myeloma","journal":"N Engl J Med","issue":"2025 Aug 7;393(6):616-617.","author":"Shanmugam SP, Awwad A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40768725"},{"title01":"Simultaneous whole-body multi-parametric 2-[(18)F]FDG-PET\/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact","title02":"Simultaneous whole-body multi-parametric 2-[(18)F]FDG-PET\/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact","journal":"Leukemia","issue":"2025 Aug 7. doi: 10.1038\/s41375-025-02717-0. Online ahead of print.","author":"Jamet B, Touzeau C, Necib H, Frampas \u00c9, Sun H, Francois C, Blin N, Carlier T, Monnet A, Lilli N, Bodet-Milin C, Moreau P, Kraeber-Bodere F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40775455"},{"title01":"The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma","title02":"The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma","journal":"Leukemia","issue":"2025 Aug 1. doi: 10.1038\/s41375-025-02712-5. Online ahead of print.","author":"Wang Y, Chen S, Liang Z, Gale RP, Liu S, Chen X, Chi P, Song Y, Zhang Y, Wang W, Li J, Xia Z, Liang Y, Huang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40750676"},{"title01":"Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial","title02":"Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e621-e634.","author":"Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769686"},{"title01":"Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed\/refractory multiple myeloma patients: a target trial emulation using real-world data","title02":"Comparison of isatuximab-pomalidomide-dexamethasone versus<\/i> elotuzumab-pomalidomide-dexamethasone in relapsed\/refractory multiple myeloma patients: a target trial emulation using real-world data","journal":"Haematologica","issue":"2025 Mar 6;110(8):1875-1881.","author":"Martino EA, Pitino A, Offidani M, Pepa RD, Gozzetti A, Bongarzoni V, Maroccia A, Amico V, Stefanoni P, Zamagni E, Terlizzi S, Derudas D, Palmieri S, Bianco R, Conticello C, Brunori M, Rago A, Lotti F, Fontana R, Sgherza N, Rossi E, Cafro AM, Febbo MA, Quinto AM, Cerchione C, Casaluci GM, Citro A, Califano C, Zambello R, Mangiacavalli S, Liberatore C, Buda G, De Magistris C, Amendola A, Vigna E, Bruzzese A, Barbieri E, Quaresima M, Roccotelli D, Farina F, Micozzi J, Vincelli ID, Tarantini G, Antonioli E, Aquino S, Maggi A, Lombardo A, Bertuglia G, Furlan A, Mele A, Annibali O, Cotzia E, Benvenuti P, De Paoli L, Baril\u00e0 G, Mor\u00e8 S, De Stefano V, Di Raimondo F, Petrucci MT, Bolli N, Musto P, Neri A, Morabito F, Tripepi G, Gentile M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40761134"},{"title01":"Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy","title02":"Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy","journal":"Blood","issue":"2025 Aug 1:blood.2025029773. doi: 10.1182\/blood.2025029773. Online ahead of print.","author":"Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749169"},{"title01":"Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression","title02":"Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression","journal":"N Engl J Med","issue":"2025 Aug 4. doi: 10.1056\/NEJMoa2503822. Online ahead of print.","author":"Carlsson PO, Hu X, Scholz H, Ingvast S, Lundgren T, Scholz T, Eriksson O, Liss P, Yu D, Deuse T, Korsgren O, Schrepfer S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40757665"},{"title01":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial","title02":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"2025 Aug 7:S2352-3026(25)00172-3. doi: 10.1016\/S2352-3026(25)00172-3. Online ahead of print.","author":"Robin M, D'Aveni M, Stamatoullas A, Raffoux E, Chevallier P, Garnier A, Mediavilla C, Carre M, Himberlin C, S\u00e9bert M, Ravinet A, Desseaux K, Labussi\u00e8re H, Alani M, Rubio MT, Huynh A, Ad\u00e8s L, de Latour RP, Paul F, Chermat F, Petit R, Mokeddem C, Charbonnier A, Th\u00e9pot S, Chevret S, Fenaux P; Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC) and the Groupe Francophone des My\u00e9lodysplasies (GFM).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40784355"},{"title01":"Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial","title02":"Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e621-e634.","author":"Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769686"},{"title01":"A multimodal sexual dysfunction intervention versus enhanced usual care for survivors of haematopoietic stem-cell transplantation: a single-centre, open-label, randomised clinical trial","title02":"A multimodal sexual dysfunction intervention versus enhanced usual care for survivors of haematopoietic stem-cell transplantation: a single-centre, open-label, randomised clinical trial","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e611-e620.","author":"El-Jawahri A, Traeger L, Reese JB, Dizon D, Bober SL, Greer JA, Vanderklish J, Horick N, Ufere N, Reynolds MJ, Rice J, Clay M, Newcomb R, DeFilipp Z, Chen YB, Temel JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769685"},{"title01":"Enhancing sexual function after haematopoietic transplantation","title02":"Enhancing sexual function after haematopoietic transplantation","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e562-e563.","author":"Stratton P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769679"},{"title01":"Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation","title02":"Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation","journal":"Br J Haematol","issue":"2025 Aug 7. doi: 10.1111\/bjh.70050. Online ahead of print.","author":"Capes A, Mooyaart JE, Blaise D, Bramanti S, Kwon M, Mohty M, Chevallier P, Vydra J, Rem\u00e9nyi P, Forcade E, L\u00f3pez Corral L, It\u00e4l\u00e4-Remes M, Bazarbachi A, Derenzini E, Hoogenboom JD, Kuball J, Battipaglia G, Malard F, Ruggeri A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40772384"},{"title01":"A pragmatic monitoring model for risk of non-relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem-cell transplantation","title02":"A pragmatic monitoring model for risk of non-relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem-cell transplantation","journal":"Br J Haematol","issue":"2025 Aug 11. doi: 10.1111\/bjh.70070. Online ahead of print.","author":"Shao Y, Yang J, Li X, He Y, Guan D, Xu R, Miao L, Wen J, Feng X, Wu T, Yang F, Song Z, Liu R, Wang D, Wei Z, Wang J, Liu X, He Y, Dou L, Liu D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40789768"},{"title01":"High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation","title02":"High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Aug 11. doi: 10.1111\/bjh.70058. Online ahead of print.","author":"Ramzi M, Hesamadini M, Sanaei M, Golmoghaddam H, Kalani M, Arandi N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40785639"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT","journal":"Blood","issue":"2025 Aug 1:blood.2025028418. doi: 10.1182\/blood.2025028418. Online ahead of print.","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SGR, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial","title02":"Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e621-e634.","author":"Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769686"},{"title01":"A multimodal sexual dysfunction intervention versus enhanced usual care for survivors of haematopoietic stem-cell transplantation: a single-centre, open-label, randomised clinical trial","title02":"A multimodal sexual dysfunction intervention versus enhanced usual care for survivors of haematopoietic stem-cell transplantation: a single-centre, open-label, randomised clinical trial","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e611-e620.","author":"El-Jawahri A, Traeger L, Reese JB, Dizon D, Bober SL, Greer JA, Vanderklish J, Horick N, Ufere N, Reynolds MJ, Rice J, Clay M, Newcomb R, DeFilipp Z, Chen YB, Temel JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769685"},{"title01":"High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation","title02":"High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Aug 11. doi: 10.1111\/bjh.70058. Online ahead of print.","author":"Ramzi M, Hesamadini M, Sanaei M, Golmoghaddam H, Kalani M, Arandi N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40785639"},{"title01":"Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study","title02":"Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study","journal":"Br J Haematol","issue":"2025 Aug 12. doi: 10.1111\/bjh.70068. Online ahead of print.","author":"Tolosa-Ridao C, Gonz\u00e1lez MB, G\u00f3mez MA, Fox L, P\u00e9rez Artigas MDM, Santamar\u00eda A, Quintela Gonz\u00e1lez MDC, Salinas AS, Salmer\u00f3n Camacho JM, Illana \u00c1lvaro V, Abdallahi-Lefdil Z, Navascues JC, Pardo L, Fern\u00e1ndez-Luis S, Vega Su\u00e1rez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo Garc\u00eda I, Ribes-Amor\u00f3s J, Lavilla E, Lopez-Mar\u00edn J, Basalobre P, Filaferro S, Cedillo \u00c1, Bento L, Sureda A, Salas MQ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40796522"},{"title01":"HSCs with the “SUPER” power to make blood forever","title02":"HSCs with the “SUPER” power to make blood forever","journal":"Blood","issue":"2025 Jul 31;146(5):521-522.","author":"Wojtowicz EE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40742727"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT","journal":"Blood","issue":"2025 Aug 1:blood.2025028418. doi: 10.1182\/blood.2025028418. Online ahead of print.","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SGR, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Impact of lifetime anaemia and iron control on outcomes in \u03b2-thalassaemia: Data from the longitudinal de-LIGHT study","title02":"Impact of lifetime anaemia and iron control on outcomes in \u03b2-thalassaemia: Data from the longitudinal de-LIGHT study","journal":"Br J Haematol","issue":"2025 Jul 31. doi: 10.1111\/bjh.70047. Online ahead of print.","author":"Musallam KM, Vitrano A, Inzerillo A, Di Maggio R, Barone R, Giangreco A, Renda MC, Fecarotta E, Troia A, Giambona A, Ruffo GB, Vlachaki E, Venou TM, Ricchi P, Ziello B, Serra M, Colizzi E, Longo F, Culcasi M, Maggio A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40745912"},{"title01":"Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid-resistant immune thrombocytopenia","title02":"Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid-resistant immune thrombocytopenia","journal":"Br J Haematol","issue":"2025 Aug 8. doi: 10.1111\/bjh.70072. Online ahead of print.","author":"Yu Y, Xie X, Chen Z, Wei J, Ouyang J, Lin Z, Ma J, Guo P, Wu R, Jia L, Gui J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781812"},{"title01":"Predictors of response to emergent therapies in paediatric immune thrombocytopenia","title02":"Predictors of response to emergent therapies in paediatric immune thrombocytopenia","journal":"Br J Haematol","issue":"2025 Aug 5. doi: 10.1111\/bjh.70064. Online ahead of print.","author":"O'Farrell C, Luckie TM, Willis MJ, Kirk SE, Lucari BR, Scheurer ME, Gao X, Grimes AB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40762147"},{"title01":"Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL)","title02":"Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL)","journal":"Leukemia","issue":"2025 Aug 8. doi: 10.1038\/s41375-025-02714-3. Online ahead of print.","author":"Smith C, Charbonnier G, Simonin M, Balducci E, Steimle T, Andrieu GP, Cieslak A, Courgeon M, LeLorc'h M, Mayakonda A, Plass C, Le Nezet A, Latiri M, Ifrah N, Dombret H, Huguet F, Baruchel A, Macintyre E, Petit A, Boissel N, Asnafi V, Touzart A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781485"},{"title01":"Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients","title02":"Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients","journal":"Leukemia","issue":"2025 Aug 11. doi: 10.1038\/s41375-025-02741-0. Online ahead of print.","author":"Wu K, Liu H, Hu W, Liu Y, Wu W, Cui B, Wang H, Zhao S, Tang Y, Cai J, Wang Y, Wang X, Chen X, Mo Y, Liu T, Xie Y, Sun H, Zhong Y, Rao J, Fan R, Wang Y, Chen C, Wang Z, Wang R, Huang Y, Shi Q, Wang L, Chen J, Chen J, Li B, Chen X, Liu Y, Shen S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40789916"},{"title01":"Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-\u03b2 axis in adult T-cell leukemia\/lymphoma","title02":"Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-\u03b2 axis in adult T-cell leukemia\/lymphoma","journal":"Leukemia","issue":"2025 Aug 4. doi: 10.1038\/s41375-025-02725-0. Online ahead of print.","author":"Suzuki K, Kusayanagi S, Kuze Y, Hata M, Kozuma S, Jimbo K, Nannya Y, Suzuki Y, Uchimaru K, Yamagishi M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40759773"},{"title01":"A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias","title02":"A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias","journal":"Leukemia","issue":"2025 Aug 6. doi: 10.1038\/s41375-025-02705-4. Online ahead of print.","author":"P\u00e9rez-Amill L, Armand-Ug\u00f3n M, Val-Casals M, Mart\u00edn-Herreros B, \u00c1lamo JR, Pe\u00f1a S, Frigola G, Altuna A, Santos C, Guijarro F, Minguela A, Bataller \u00c0, Casanovas-Albert\u00ed B, Uribe-Herranz M, Navarro I, Guerreiro M, S\u00e1nchez-Mart\u00ednez D, Tirado N, Velasco-Hernandez T, Men\u00e9ndez P, Mart\u00ednez A, Rovira M, Colomer D, Gonz\u00e1lez-Navarro EA, Esteve J, Urbano-Ispizua \u00c1, Montesinos P, Delgado J, Juan M, Klein-Gonz\u00e1lez N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40770072"},{"title01":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial","title02":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"2025 Aug 7:S2352-3026(25)00172-3. doi: 10.1016\/S2352-3026(25)00172-3. Online ahead of print.","author":"Robin M, D'Aveni M, Stamatoullas A, Raffoux E, Chevallier P, Garnier A, Mediavilla C, Carre M, Himberlin C, S\u00e9bert M, Ravinet A, Desseaux K, Labussi\u00e8re H, Alani M, Rubio MT, Huynh A, Ad\u00e8s L, de Latour RP, Paul F, Chermat F, Petit R, Mokeddem C, Charbonnier A, Th\u00e9pot S, Chevret S, Fenaux P; Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC) and the Groupe Francophone des My\u00e9lodysplasies (GFM).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40784355"},{"title01":"Acute lymphocytic leukaemia","title02":"Acute lymphocytic leukaemia","journal":"Lancet","issue":"2025 Aug 1:S0140-6736(25)00864-5. doi: 10.1016\/S0140-6736(25)00864-5. Online ahead of print.","author":"Kantarjian H, Pui CH, Jabbour E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40759141"},{"title01":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol","title02":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol","journal":"Br J Haematol","issue":"2025 Aug 9. doi: 10.1111\/bjh.70085. Online ahead of print.","author":"Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, P\u00f6yh\u00f6nen T, Suo-Palosaari M, Utriainen P, J\u00e4rvel\u00e4 L, Niinim\u00e4ki R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781902"},{"title01":"Single-cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia","title02":"Single-cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Aug 8. doi: 10.1111\/bjh.70077. Online ahead of print.","author":"Liu Y, Liu W, Mei Y, Huang Q, Liu X, Guo C, Chen M, Mou J, Wang S, Xie W, Tian Z, Tang K, Xing H, Wang Y, Wei H, Gu R, Rao Q, Wang M, Qiu S, Wang J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781784"},{"title01":"Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure","title02":"Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure","journal":"Br J Haematol","issue":"2025 Aug 13. doi: 10.1111\/bjh.70080. Online ahead of print.","author":"Yuan M, Zhang Y, Liu B, Zhou L, Zhu Y, Li Z, Zang S, Liu Z, Li W, Jiang Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40799021"},{"title01":"Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study","title02":"Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study","journal":"Br J Haematol","issue":"2025 Jul 31. doi: 10.1111\/bjh.70046. Online ahead of print.","author":"Sch\u00f6nung M, Rathmann S, Ramamoorthy S, Lebrecht D, Klingebiel T, Locatelli F, Nysom K, Rossig C, Star\u00fd J, Zecca M, Patturajan M, Erlacher M, Strahm B, Niemeyer CM, Lipka DB, Flotho C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40740143"},{"title01":"Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I\/II study","title02":"Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I\/II study","journal":"Br J Haematol","issue":"2025 Aug 1. doi: 10.1111\/bjh.70035. Online ahead of print.","author":"Danylesko I, Shimoni A, Avigdor A, Kedmi M, Amitai I, Shem-Tov N, Yerushalmi R, Andersson BS, Nagler A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40746302"},{"title01":"Synergistic potential of CDK4\/6 inhibitors and ATRA in non-APL AML","title02":"Synergistic potential of CDK4\/6 inhibitors and ATRA in non-APL AML","journal":"Br J Haematol","issue":"2025 Aug 4. doi: 10.1111\/bjh.70057. Online ahead of print.","author":"Skopek R, \u00d6zcan SG, Chmiel P, Morgner S, Sch\u00fctt J, Ghazvini Zadegan F, Stanko C, Palusi\u0144ska M, Ma\u015bli\u0144ska-Gromadka K, Sbirkov Y, Stengel S, Fischer M, Brioli A, Zelent A, Szyma\u0144ski \u0141, Schenk T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40755307"},{"title01":"Immunoglobulin-containing vacuoles in CLL","title02":"Immunoglobulin-containing vacuoles in CLL","journal":"Blood","issue":"2025 Jul 31;146(5):647.","author":"Qamar A, Zhao C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40742719"},{"title01":"Magrolimab and the tale of indigestible AML","title02":"Magrolimab and the tale of indigestible AML","journal":"Blood","issue":"2025 Jul 31;146(5):527-528.","author":"R\u00f6llig C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40742723"},{"title01":"Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells","title02":"Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells","journal":"Blood","issue":"2025 Aug 1:blood.2024027822. doi: 10.1182\/blood.2024027822. Online ahead of print.","author":"Pauli C, Kienh\u00f6fer M, Blank MF, Begik O, Rohde C, Zimmermann SM, Werner L, Heid D, Xu F, Weidenauer K, Delaunay S, Krall N, Trunk K, Zhao D, Zhou F, Llovera L, Alexane O, Heit-Mondrzyk A, Platzbecker U, Baldus CD, Serve H, Bornh\u00e4user M, V\u00e5gb\u00f8 CB, Benitah SA, Krijgsveld J, Novoa EM, M\u00fcller-Tidow C, Frye M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749163"},{"title01":"How I Manage Chronic Myeloid Leukemia During Pregnancy","title02":"How I Manage Chronic Myeloid Leukemia During Pregnancy","journal":"Blood","issue":"2025 Aug 4:blood.2024026513. doi: 10.1182\/blood.2024026513. Online ahead of print.","author":"Abruzzese E, Chelysheva E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758938"},{"title01":"Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML","title02":"Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML","journal":"Blood","issue":"2025 Aug 6:blood.2025029556. doi: 10.1182\/blood.2025029556. Online ahead of print.","author":"Othman J, Potter N, Freeman SD, McCarthy N, Jovanovic J, Runglall M, Canham J, Thomas I, Johnson S, Gilkes AF, Cavenagh JD, Kottaridis P, Taussig DC, Arnold C, Hemmaway CJ Dr, Culligan D, Overgaard UM, Dennis M, Burnett AK, Russell NH, Dillon RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40768751"},{"title01":"Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply","title02":"Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply","journal":"N Engl J Med","issue":"2025 Aug 7;393(6):620.","author":"Svoboda J, Hexner E, June CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40768731"},{"title01":"Enhanced CAR T-Cell Therapy for Relapsed Lymphoma","title02":"Enhanced CAR T-Cell Therapy for Relapsed Lymphoma","journal":"N Engl J Med","issue":"2025 Aug 7;393(6):619-620.","author":"Vairamoorthy N, Kazi B, Patil V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40768730"},{"title01":"Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma","title02":"Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma","journal":"Leukemia","issue":"2025 Jul 30. doi: 10.1038\/s41375-025-02697-1. Online ahead of print.","author":"Heavican-Foral TB, Korell F, Scarf\u00f2 I, Wiggers CRM, B AT, Eisenbies Z, Powers F, Hegel J, Liu J, Kulp S, Silva H, Wu G, Letai A, Stegmaier K, Lohr JG, Weinstock DM, Maus MV, Knoechel B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40739330"},{"title01":"Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-\u03b2 axis in adult T-cell leukemia\/lymphoma","title02":"Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-\u03b2 axis in adult T-cell leukemia\/lymphoma","journal":"Leukemia","issue":"2025 Aug 4. doi: 10.1038\/s41375-025-02725-0. Online ahead of print.","author":"Suzuki K, Kusayanagi S, Kuze Y, Hata M, Kozuma S, Jimbo K, Nannya Y, Suzuki Y, Uchimaru K, Yamagishi M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40759773"},{"title01":"Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma","title02":"Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma","journal":"J Clin Oncol","issue":"2025 Aug 13:101200JCO2501534. doi: 10.1200\/JCO-25-01534. Online ahead of print.","author":"Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, Sworder BJ, Cherng HJ, Kuffer C, Blair D, Brown K, Goldstein JS, Schultz A, Close S, Chabon JJ, Diehn M, Wilson WH, Alizadeh AA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40802906"},{"title01":"Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma","title02":"Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma","journal":"J Clin Oncol","issue":"2025 Aug 13:101200JCO2501534. doi: 10.1200\/JCO-25-01534. Online ahead of print.","author":"Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, Sworder BJ, Cherng HJ, Kuffer C, Blair D, Brown K, Goldstein JS, Schultz A, Close S, Chabon JJ, Diehn M, Wilson WH, Alizadeh AA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40802906"},{"title01":"Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial","title02":"Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e588-e598.","author":"Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosi\u00f1ol L, Montes YG, Bargay J, Garc\u00eda MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garz\u00f3n S, Montero FC, Caba\u00f1as V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casas\u00fas AIT, Delgado-Beltr\u00e1n MP, Prieto E, Lahuerta JJ, Blad\u00e9 J, San-Miguel J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769684"},{"title01":"A new chapter in relapsed or refractory multiple myeloma","title02":"A new chapter in relapsed or refractory multiple myeloma","journal":"Lancet Haematol","issue":"2025 Aug;12(8):e561.","author":"The Lancet Haematology.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40769678"},{"title01":"Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study","title02":"Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study","journal":"Br J Haematol","issue":"2025 Aug 12. doi: 10.1111\/bjh.70068. Online ahead of print.","author":"Tolosa-Ridao C, Gonz\u00e1lez MB, G\u00f3mez MA, Fox L, P\u00e9rez Artigas MDM, Santamar\u00eda A, Quintela Gonz\u00e1lez MDC, Salinas AS, Salmer\u00f3n Camacho JM, Illana \u00c1lvaro V, Abdallahi-Lefdil Z, Navascues JC, Pardo L, Fern\u00e1ndez-Luis S, Vega Su\u00e1rez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo Garc\u00eda I, Ribes-Amor\u00f3s J, Lavilla E, Lopez-Mar\u00edn J, Basalobre P, Filaferro S, Cedillo \u00c1, Bento L, Sureda A, Salas MQ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40796522"},{"title01":"Myeloma: a sky full of MRD stars","title02":"Myeloma: a sky full of MRD stars","journal":"Blood","issue":"2025 Aug 7;146(6):649-650.","author":"Paiva B, San-Miguel JF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40773178"},{"title01":"Time-tested safety: FCARH143’s 5-year myeloma journey","title02":"Time-tested safety: FCARH143’s 5-year myeloma journey","journal":"Blood","issue":"2025 Jul 31;146(5):519-520.","author":"Al Hadidi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40742722"},{"title01":"Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma","title02":"Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma","journal":"Blood","issue":"2025 Aug 4:blood.2025028963. doi: 10.1182\/blood.2025028963. Online ahead of print.","author":"Rivera J, Yan Q, Daneshmandi S, Lannes R, Katsuta E, Choi JE, Singh PK, Belal A, Alberico R, Lund I, Schaefer M, Hassan H, Parker S, Anderson KC, Munshi NC, Samur MK, McCarthy PL, Hillengass J, Mohammadpour H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758944"},{"title01":"Impact of TP53 variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms","title02":"Impact of TP53<\/i> variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms","journal":"Leukemia","issue":"2025 Jul 14. doi: 10.1038\/s41375-025-02672-w. Online ahead of print.","author":"Zhao Y, Cao W, Shi J, Cao Y, Lu Y, Luo Y, Ouyang G, Chen L, Lan J, Song X, Chen Y, Yu L, Yu J, Lai X, Liu L, Fu H, Ye Y, Yang L, Mo X, Hu X, Huang H, Zhao Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40659988"},{"title01":"DNA demethylation-mediated downregulation of MNX1 in acute myeloid leukemia","title02":"DNA demethylation-mediated downregulation of MNX1<\/i> in acute myeloid leukemia","journal":"Leukemia","issue":"2025 Jul 14. doi: 10.1038\/s41375-025-02680-w. Online ahead of print.","author":"Kelek\u00e7i S, Kelly K, Goyal A, Wehrwein N, Riedel A, Weichenhan D, Scherer M, Michels BE, K\u00f6rner C, Orzella I, Hakobyan M, B\u00e4hr M, Everatt E, Dunford J, Lipka DB, Lutsik P, Oppermann U, Plass C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40659989"},{"title01":"Leukemia stem cells in acute myeloid leukemia-mimicking “space and time continuum”?","title02":"Leukemia stem cells in acute myeloid leukemia-mimicking “space and time continuum”?","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.288003. Online ahead of print.","author":"Plesa A, Roumier C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671495"},{"title01":"A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22alt case","title02":"A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22<\/i>alt<\/sup> case","journal":"Blood","issue":"2025 Jul 10;146(2):260. doi: 10.1182\/blood.2025028986.","author":"Al Jabri M, Sakhdari A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40638196"},{"title01":"Impact of TP53 variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms","title02":"Impact of TP53<\/i> variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms","journal":"Leukemia","issue":"2025 Jul 14. doi: 10.1038\/s41375-025-02672-w. Online ahead of print.","author":"Zhao Y, Cao W, Shi J, Cao Y, Lu Y, Luo Y, Ouyang G, Chen L, Lan J, Song X, Chen Y, Yu L, Yu J, Lai X, Liu L, Fu H, Ye Y, Yang L, Mo X, Hu X, Huang H, Zhao Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40659988"},{"title01":"The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation","title02":"The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation","journal":"Br J Haematol","issue":"2025 Jul 29. doi: 10.1111\/bjh.70049. Online ahead of print.","author":"Bertz H, Sahlmann J, McMillan DC, Wehr C, Duque-Afonso J, Maas-Bauer K, W\u00e4sch R, Nikolaychuk J, Greil C, Arends J, Finke J, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40731308"},{"title01":"Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell\u00a0transplantation","title02":"Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell\u00a0transplantation","journal":"Br J Haematol","issue":"2025 Jul 19. doi: 10.1111\/bjh.70006. Online ahead of print.","author":"Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Remberger M, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40682490"},{"title01":"The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy","title02":"The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy","journal":"Br J Haematol","issue":"2025 Jul 21. doi: 10.1111\/bjh.70016. Online ahead of print.","author":"Zhen S, Liu L, Liu F, Shen Y, Zhang T, Fan Y, Cui Y, Pan L, Liang C, Cao Y, Cao W, Wei J, Zhai W, Chen X, Ma Q, Zhang R, Yang D, He Y, Pang A, Han M, Jiang E, Feng S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40691838"},{"title01":"Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCR\u03b1\u03b2\/CD19 depletion or post-transplant cyclophosphamide","title02":"Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCR\u03b1\u03b2\/CD19 depletion or post-transplant cyclophosphamide","journal":"Br J Haematol","issue":"2025 Jul 21. doi: 10.1111\/bjh.70004. Online ahead of print.","author":"Masetti R, Leardini D, Gottardi F, Baccelli F, Ottaviano GAM, Vendemini F, Saglio F, Pierri F, Algeri M, Del Bufalo F, Merli P, Prete A, Cesaro S, Ussowicz M, Faraci M, Zecca M, Fagioli F, Balduzzi A, Dalle JH, Locatelli F, Pagliara D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40692189"},{"title01":"Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes","title02":"Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes","journal":"Br J Haematol","issue":"2025 Jul 22. doi: 10.1111\/bjh.70010. Online ahead of print.","author":"Barone A, De Philippis C, Stella F, Dodero A, Sarina B, Pennisi M, Santoro A, Carlo-Stella C, Guidetti A, Bramanti S, Corradini P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40695357"},{"title01":"Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study","title02":"Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study","journal":"Br J Haematol","issue":"2025 Jul 13. doi: 10.1111\/bjh.20262. Online ahead of print.","author":"Severinsen FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, Jensen RK, S\u00f8gaard KK, Jensen P, Brown PN, M\u00e9sz\u00e1ros J\u00f8rgensen J, Larsen TS, Poulsen CB, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40653138"},{"title01":"A win ratio approach for comparing graft-versus-host disease-free, relapse-free survival among alternative donors","title02":"A win ratio approach for comparing graft-versus-host disease-free, relapse-free survival among alternative donors","journal":"Br J Haematol","issue":"2025 Jul 16. doi: 10.1111\/bjh.70008. Online ahead of print.","author":"Shimomura Y, Komukai S, Kitamura T, Yoshimura K, Inamoto Y, Akahoshi Y, Kuwatsuka Y, Usui Y, Uchida N, Tanaka M, Onizuka M, Sakata-Yanagimoto M, Doki N, Hasegawa Y, Ishiwata K, Nakamae H, Sawa M, Katayama Y, Kawakita T, Yoshimitsu M, Fukuda T, Kanda Y, Ohbiki M, Nakasone H, Kanda J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671206"},{"title01":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial","title02":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial","journal":"Blood","issue":"2025 Jul 30:blood.2025028730. doi: 10.1182\/blood.2025028730. Online ahead of print.","author":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Mueller LP, Schmid C, Krause SW, Bethge WA, Jost E, Platzbecker U, Klein S, Niederland J, Kaufmann M, Sch\u00e4fer-Eckart K, Baldauf H, St\u00f6lzel F, Trost S, R\u00f6llig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornh\u00e4user M, Schetelig J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737595"},{"title01":"RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT","title02":"RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT","journal":"Blood","issue":"2025 Jul 18:blood.2025029584. doi: 10.1182\/blood.2025029584. Online ahead of print.","author":"DeFilipp Z, Choe HK, Efebera YA, Saad A, Farhan S, Lekakis LJ, Yared JA, Schiller GJ, Mapara MY, Assal A, Gooley TA, Bui JD, Lee DD, Lane H, Chen YB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40680268"},{"title01":"Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease","title02":"Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease","journal":"Blood","issue":"2025 Jul 23:blood.2025028562. doi: 10.1182\/blood.2025028562. Online ahead of print.","author":"Ma L, Koehn BH, Zaiken MC, Hippen KL, Smith KD, Allred JR, Williams RL, Yao K, Fink J, Saha A, Kopp B, Payne N, Widelak R, Panoskaltsis-Mortari A, Riddle MJ, Tolar J, Eide C, Xia L, Witty AD, Mehta AK, Denholtz M, Hefazi M, Hani S, Kenderian SS, Miller JS, Molldrem JJ, Kean LS, Valamehr B, Blazar BR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700578"},{"title01":"Impact of TP53 variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms","title02":"Impact of TP53<\/i> variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms","journal":"Leukemia","issue":"2025 Jul 14. doi: 10.1038\/s41375-025-02672-w. Online ahead of print.","author":"Zhao Y, Cao W, Shi J, Cao Y, Lu Y, Luo Y, Ouyang G, Chen L, Lan J, Song X, Chen Y, Yu L, Yu J, Lai X, Liu L, Fu H, Ye Y, Yang L, Mo X, Hu X, Huang H, Zhao Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40659988"},{"title01":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation","title02":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.287554. Online ahead of print.","author":"Ma R, Zhu XY, Lu Y, Chen J, Xuan L, Yuan HL, Cao Y, Cao WJ, Fang XS, Miao KR, Hu XX, Yi H, Zhao YM, Wu YB, Yang T, Wang HT, Yin Y, Zhang ZM, Zhang XH, Xu LP, Wang Y, Liu KY, Huang XJ, Sun YQ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671492"},{"title01":"Leukemia stem cells in acute myeloid leukemia-mimicking “space and time continuum”?","title02":"Leukemia stem cells in acute myeloid leukemia-mimicking “space and time continuum”?","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.288003. Online ahead of print.","author":"Plesa A, Roumier C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671495"},{"title01":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells","title02":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.287897. Online ahead of print.","author":"Shamie I, Bliss-Moreau M, Lee JC, Mathieu R, Hoffman HM, Geng B, Lewis NE, Zhu YP, Croker BA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671503"},{"title01":"The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation","title02":"The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation","journal":"Br J Haematol","issue":"2025 Jul 29. doi: 10.1111\/bjh.70049. Online ahead of print.","author":"Bertz H, Sahlmann J, McMillan DC, Wehr C, Duque-Afonso J, Maas-Bauer K, W\u00e4sch R, Nikolaychuk J, Greil C, Arends J, Finke J, Zeiser R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40731308"},{"title01":"Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell\u00a0transplantation","title02":"Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell\u00a0transplantation","journal":"Br J Haematol","issue":"2025 Jul 19. doi: 10.1111\/bjh.70006. Online ahead of print.","author":"Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Remberger M, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40682490"},{"title01":"The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy","title02":"The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy","journal":"Br J Haematol","issue":"2025 Jul 21. doi: 10.1111\/bjh.70016. Online ahead of print.","author":"Zhen S, Liu L, Liu F, Shen Y, Zhang T, Fan Y, Cui Y, Pan L, Liang C, Cao Y, Cao W, Wei J, Zhai W, Chen X, Ma Q, Zhang R, Yang D, He Y, Pang A, Han M, Jiang E, Feng S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40691838"},{"title01":"Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCR\u03b1\u03b2\/CD19 depletion or post-transplant cyclophosphamide","title02":"Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCR\u03b1\u03b2\/CD19 depletion or post-transplant cyclophosphamide","journal":"Br J Haematol","issue":"2025 Jul 21. doi: 10.1111\/bjh.70004. Online ahead of print.","author":"Masetti R, Leardini D, Gottardi F, Baccelli F, Ottaviano GAM, Vendemini F, Saglio F, Pierri F, Algeri M, Del Bufalo F, Merli P, Prete A, Cesaro S, Ussowicz M, Faraci M, Zecca M, Fagioli F, Balduzzi A, Dalle JH, Locatelli F, Pagliara D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40692189"},{"title01":"Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study","title02":"Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study","journal":"Br J Haematol","issue":"2025 Jul 13. doi: 10.1111\/bjh.20262. Online ahead of print.","author":"Severinsen FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, Jensen RK, S\u00f8gaard KK, Jensen P, Brown PN, M\u00e9sz\u00e1ros J\u00f8rgensen J, Larsen TS, Poulsen CB, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40653138"},{"title01":"Unusual suspects: a surprise cast in making blood stem cells","title02":"Unusual suspects: a surprise cast in making blood stem cells","journal":"Blood","issue":"2025 Jul 17;146(3):265-266.","author":"Hadland B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674120"},{"title01":"RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT","title02":"RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT","journal":"Blood","issue":"2025 Jul 18:blood.2025029584. doi: 10.1182\/blood.2025029584. Online ahead of print.","author":"DeFilipp Z, Choe HK, Efebera YA, Saad A, Farhan S, Lekakis LJ, Yared JA, Schiller GJ, Mapara MY, Assal A, Gooley TA, Bui JD, Lee DD, Lane H, Chen YB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40680268"},{"title01":"CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis","title02":"CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis","journal":"Blood","issue":"2025 Jul 23:blood.2024026271. doi: 10.1182\/blood.2024026271. Online ahead of print.","author":"Ji Y, Huang Y, Thomas T, Kapti EG, Tachibana R, Lark JA, Berezniuk I, Guo L, Ali MAE, Mims K, Kroger B, Hu W, Park CY, Chung SS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700577"},{"title01":"Loss of DCAF8 impairs hematopoietic stem cell function with cellular senescence via the DOCK11-CDC42 axis","title02":"Loss of DCAF8 impairs hematopoietic stem cell function with cellular senescence via the DOCK11-CDC42 axis","journal":"Blood","issue":"2025 Jul 10:blood.2024027335. doi: 10.1182\/blood.2024027335. Online ahead of print.","author":"Xu P, Zhang X, Li D, Jiao B, Nie J, Huang Y, Xia Z, Li J, Dan Y, Huang X, Yan L, Zhang R, Huang W, Wang X, Ji S, Cang Y, Ren R, Liu P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40643159"},{"title01":"Safety and efficacy of romiplostim in children with acquired aplastic anemia who are na\u00efve to immunosuppressive therapy","title02":"Safety and efficacy of romiplostim in children with acquired aplastic anemia who are na\u00efve to immunosuppressive therapy","journal":"Haematologica","issue":"2025 Jul 24. doi: 10.3324\/haematol.2025.288078. Online ahead of print.","author":"Bordbar M, Faghihi A, Zekavat OR, Shahriari M, Bordbar S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702901"},{"title01":"Alu-mediated FANCD2 exonic deletion contributes to Fanconi anaemia","title02":"Alu-mediated FANCD2 exonic deletion contributes to Fanconi anaemia","journal":"Br J Haematol","issue":"2025 Jul 28. doi: 10.1111\/bjh.70045. Online ahead of print.","author":"Shangguan S, Cui X, Li J, Li N, Liu R, Chen X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40726011"},{"title01":"Romiplostim with ciclosporin A in patients with aplastic anaemia na\u00efve to immunosuppressive therapy: A phase 2\/3 study","title02":"Romiplostim with ciclosporin A in patients with aplastic anaemia na\u00efve to immunosuppressive therapy: A phase 2\/3 study","journal":"Br J Haematol","issue":"2025 Jul 10. doi: 10.1111\/bjh.20206. Online ahead of print.","author":"Lee JW, Jang JH, Chiba S, Yoon SS, Oshikawa G, Usuki K, Mun YC, Kawakita T, Imada K, Cheong JW, Noshiro M, Matsuda A, Ozawa K, Mitani K, Kanda Y, Nakao S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40639944"},{"title01":"Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical care","title02":"Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical care","journal":"Br J Haematol","issue":"2025 Jul 15. doi: 10.1111\/bjh.20251. Online ahead of print.","author":"Ma J, Cui C, Ouyang J, Lin Z, Lin X, Hu Y, Wang Z, Dong S, Meng J, Zhang W, Cheng X, Chen Z, Tang Y, Wu R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40665492"},{"title01":"How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor","title02":"How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor","journal":"Blood","issue":"2025 Jul 29:blood.2024025482. doi: 10.1182\/blood.2024025482. Online ahead of print.","author":"Shadman M, Davids MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40729699"},{"title01":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial","title02":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial","journal":"Blood","issue":"2025 Jul 30:blood.2025028730. doi: 10.1182\/blood.2025028730. Online ahead of print.","author":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Mueller LP, Schmid C, Krause SW, Bethge WA, Jost E, Platzbecker U, Klein S, Niederland J, Kaufmann M, Sch\u00e4fer-Eckart K, Baldauf H, St\u00f6lzel F, Trost S, R\u00f6llig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornh\u00e4user M, Schetelig J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737595"},{"title01":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","title02":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","journal":"Blood","issue":"2025 Jul 30:blood.2024028205. doi: 10.1182\/blood.2024028205. Online ahead of print.","author":"Burger JA, Barr PM, Robak T Prof, Owen C, Tedeschi A, Sarma A, Patten PE, Grosicki S, McCarthy H Dr, Offner F, Szafer Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737596"},{"title01":"Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?","title02":"Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?","journal":"Blood","issue":"2025 Jul 17;146(3):396.","author":"Cheng J, Zhou J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674113"},{"title01":"PROTACtion against BCL-xL in post-MPN AML","title02":"PROTACtion against BCL-xL in post-MPN AML","journal":"Blood","issue":"2025 Jul 17;146(3):266-267.","author":"Arellano NS, Elf SE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674116"},{"title01":"Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial","title02":"Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial","journal":"J Clin Oncol","issue":"2025 Jul 17:JCO2500439. doi: 10.1200\/JCO-25-00439. Online ahead of print.","author":"Ferdinandus J, Kaul H, Foss\u00e5 A, H\u00fcttmann A, Keil F, Ko YD, Hitz F, Schwarz M, Trenker C, Kerkhoff A, Staib P, Wille K, Dresel I, Hahn D, Hertenstein B, Moosmann P, Mey U, Balabanov S, Armytage T, Roncolato F, Hellmuth JC, Hertzberg M, Kobe C, Klapper W, Baues C, Eich HT, Kreissl S, Fuchs M, Jablonski J, Schneider G, Tharmaseelan H, Eichenauer DA, von Tresckow B, Borchmann P, Br\u00f6ckelmann PJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674676"},{"title01":"Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients","title02":"Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients","journal":"J Clin Oncol","issue":"2025 Jul 17:JCO2501022. doi: 10.1200\/JCO-25-01022. Online ahead of print.","author":"Radhakrishnan VS, Johnson PWM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674680"},{"title01":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma","title02":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma","journal":"Haematologica","issue":"2025 Jul 24. doi: 10.3324\/haematol.2025.288114. Online ahead of print.","author":"Ghione P, Zinzani PL, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702895"},{"title01":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis","title02":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2025.287547. Online ahead of print.","author":"Alhomoud M, Ibrahim R, Demetres M, Rejeski K, Scordo M, Shouval R, Tix T, Martinet J, Foley M, Gomez-Arteaga A, Shore T, Pagnini P, Aljurf M, Guzman ML, Formenti S, Yahalom J, Van Besien K, Imber BS, Chen Z, Yamshon S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637750"},{"title01":"Long non-coding RNA LINC00926 is a biomarker for na\u00efve B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma","title02":"Long non-coding RNA LINC00926 is a biomarker for na\u00efve B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.287524. Online ahead of print.","author":"Iaccarino I, Beder T, Reinke S, Borchmann P, Von Tresckow B, Altenbuchinger M, Klapper W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671505"},{"title01":"Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma","title02":"Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.288033. Online ahead of print.","author":"Moskowitz AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671506"},{"title01":"A phase Ib\/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial","title02":"A phase Ib\/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial","journal":"Br J Haematol","issue":"2025 Jul 25. doi: 10.1111\/bjh.70028. Online ahead of print.","author":"Carpio C, de la Cruz-Vicente F, Garc\u00eda-Sanz R, Zeberio I, Barrenetxea C, Domingo-Domenech E, Bastos M, Rubio Martinez A, G\u00f3mez-Prieto P, Rodriguez A, Casanova M, Cladera-Serra A, Nu\u00f1ez Cespedes J, Mart\u00ednez C, Moreno-Vel\u00e1zquez M, Garcia-Galea E, Abrisqueta P, Bosch F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40714959"},{"title01":"A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis","title02":"A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis","journal":"Br J Haematol","issue":"2025 Jul 20. doi: 10.1111\/bjh.70017. Online ahead of print.","author":"Regazzo G, Vari G, Marchesi F, D\u00edaz M\u00e9ndez AB, Di Giuliani M, Sacconi A, Palombi F, Lulli V, Goeman F, Novello M, Tomassi M, Papa E, Bertoni F, Hohaus S, Mengarelli A, Rizzo MG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40685776"},{"title01":"Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS","title02":"Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS","journal":"Br J Haematol","issue":"2025 Jul 22. doi: 10.1111\/bjh.70020. Online ahead of print.","author":"Hossain NM, Ahn KW, Patel J, Lian Q, Abid B, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40693472"},{"title01":"Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival","title02":"Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival","journal":"Br J Haematol","issue":"2025 Jul 10. doi: 10.1111\/bjh.20253. Online ahead of print.","author":"Partanen A, R\u00f6nk\u00e4 A, Anttalainen A, Ukkola-Vuoti L, Toppila I, Kuitunen H, Miettinen T, Kuittinen O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40641050"},{"title01":"Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study","title02":"Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study","journal":"Br J Haematol","issue":"2025 Jul 13. doi: 10.1111\/bjh.20262. Online ahead of print.","author":"Severinsen FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, Jensen RK, S\u00f8gaard KK, Jensen P, Brown PN, M\u00e9sz\u00e1ros J\u00f8rgensen J, Larsen TS, Poulsen CB, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40653138"},{"title01":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","title02":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","journal":"Blood","issue":"2025 Jul 30:blood.2024028205. doi: 10.1182\/blood.2024028205. Online ahead of print.","author":"Burger JA, Barr PM, Robak T Prof, Owen C, Tedeschi A, Sarma A, Patten PE, Grosicki S, McCarthy H Dr, Offner F, Szafer Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737596"},{"title01":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma","title02":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma","journal":"Blood","issue":"2025 Jul 23:blood.2024026919. doi: 10.1182\/blood.2024026919. Online ahead of print.","author":"Wang W, Cai Q, Liu Y, Nie L, Lee HH, Yan F, Fei Y, Yao Y, Li Y, Tan L, Lorenzi PL, Wang YN, Yao J, Chen Z, McIntosh J, Yu CT, Jain P, Jiang V, Vargas J, Li X, Zhang T, Li S, Santos D, Thirumurthi S, Seeley EH, Simon LM, Flowers CR, Ok CY, Wang ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700581"},{"title01":"\u03b1-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development","title02":"\u03b1-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development","journal":"Blood","issue":"2025 Jul 23:blood.2024028069. doi: 10.1182\/blood.2024028069. Online ahead of print.","author":"Jaafar C, Ethiraj P, Qiu Z, Lin AP, Simonis Seabra Martins Ferrari P, Aguiar R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700634"},{"title01":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy","title02":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy","journal":"Blood","issue":"2025 Jul 15:blood.2025028964. doi: 10.1182\/blood.2025028964. Online ahead of print.","author":"Kaulen LD, Martinez-Lage M, Abramson JS, Karschnia P, Doubrovinskaia S, Shankar GM, Choi BD, Ramundo CM, Ehret F, Barnes JA, El-Jawahri A, Hochberg E, Johnson PC, Soumerai JD, Plotkin SR, Batchelor TT, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40663771"},{"title01":"A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification","title02":"A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification","journal":"Blood","issue":"2025 Jul 15:blood.2025029628. doi: 10.1182\/blood.2025029628. Online ahead of print.","author":"Scarisbrick JJ, Quaglino P, Whittaker SJ, Bagot M, Guenova E, Papadavid E, Prince HM, Sanches JA, Miyashiro D, Servitje O, Querfeld C, Akilov OE, Arumainathan A, Bennett L, Battistella M, Benstead K Dr, Berti EF, Beylot-Barry M, Busschots AM, Cowan RA, Dummer R, Dunnill G, Estrach MT, Evison F, Bashir AE, Geskin LJ, Gru A, Guitart J, Herrera MC, Hodak E, Horwitz SM, Jonak C, Klemke CD, Knobler R, McKay P, Marschalk\u00f3 M, Massone C, Matin R, Mitteldorf C, Novoa RA, Ortiz-Romero PL, Pimpinelli N, Pujol RM, Ranki A, Vankeva L, Rieger KE, Stadler R, Trautinger F, Latzka J, Vermeer MH, Wachsmuth R, Weatherhead S, Wehkamp U, Wobser M, Kim YH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40663780"},{"title01":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","title02":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","journal":"Blood","issue":"2025 Jul 15:blood.2025029117. doi: 10.1182\/blood.2025029117. Online ahead of print.","author":"Brooks TR, Zabor EC, Bedelu Y, Yang X MD, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J PharmD, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K MD, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C DO, Khan C, Bliven SP MD, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A MD, Hernandez-Ilizaliturri FJ, Chinyengetere F MDPhD, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40663785"},{"title01":"The Treatment of Marginal Zone Lymphoma","title02":"The Treatment of Marginal Zone Lymphoma","journal":"Blood","issue":"2025 Jul 15:blood.2024028269. doi: 10.1182\/blood.2024028269. Online ahead of print.","author":"Alderuccio JP, Noy A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40663786"},{"title01":"High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease","title02":"High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease","journal":"Leukemia","issue":"2025 Jul 28. doi: 10.1038\/s41375-025-02715-2. Online ahead of print.","author":"Toscani D, Lungu O, Chiu M, Maccari C, Raimondi V, Taurino G, Bianchi MG, Scita M, Dalla Palma B, Iannozzi NT, Vescovini R, Dessena M, Sitzia C, Storti P, Andreoli R, Bussolati O, Giuliani N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40721650"},{"title01":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","title02":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","journal":"Leukemia","issue":"2025 Jul 23. doi: 10.1038\/s41375-025-02654-y. Online ahead of print.","author":"Zanwar S, Rajkumar SV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702148"},{"title01":"Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis","title02":"Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis","journal":"Leukemia","issue":"2025 Jul 16. doi: 10.1038\/s41375-025-02702-7. Online ahead of print.","author":"Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin GR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40670671"},{"title01":"Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma","title02":"Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma","journal":"Leukemia","issue":"2025 Jul 16. doi: 10.1038\/s41375-025-02707-2. Online ahead of print.","author":"Cooperrider JH, Karaoglu DA, Kubicki T, Jiang CR, Postich E, Shimamoto K, Arnold O, Macaraeg J, Ramsland A, Pula A, Kishtagari A, Pershad Y, Mack TM, Jones A, Bick AG, Savona M, Drazer MW, Dytfeld D, Jakubowiak A, Derman BA, Saygin C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40670674"},{"title01":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","title02":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","journal":"Lancet Oncol","issue":"2025 Aug;26(8):1067-1080.","author":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, H\u00e1jek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balar\u00ed A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40680754"},{"title01":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","title02":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","journal":"Lancet Haematol","issue":"2025 Jul 15:S2352-3026(25)00163-2. doi: 10.1016\/S2352-3026(25)00163-2. Online ahead of print.","author":"Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40680752"},{"title01":"Rewriting Risk: A Data-Driven Look at Myeloma Genetics","title02":"Rewriting Risk: A Data-Driven Look at Myeloma Genetics","journal":"J Clin Oncol","issue":"2025 Jul 18:JCO2500988. doi: 10.1200\/JCO-25-00988. Online ahead of print.","author":"Patel K, Facon T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40680242"},{"title01":"Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma","title02":"Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2025.287783. Online ahead of print.","author":"Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637727"},{"title01":"Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma","title02":"Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma","journal":"Br J Haematol","issue":"2025 Jul 15. doi: 10.1111\/bjh.70012. Online ahead of print.","author":"Martin N, Thompson E, Stong N, Xu Y, Finney O, Rytlewski J, Flynt E, Marfo J, Descalzi-Montoya DB, Manrique I, Paiva B, Munshi N, Campbell TB, Kaiser SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40665490"},{"title01":"Cytolytic helper T cells: a new addition to myeloma immunity","title02":"Cytolytic helper T cells: a new addition to myeloma immunity","journal":"Blood","issue":"2025 Jul 24;146(4):402-403.","author":"Cupedo T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40705390"},{"title01":"New prognostic systems for multiple myeloma in the context of contemporary therapies","title02":"New prognostic systems for multiple myeloma in the context of contemporary therapies","journal":"Blood","issue":"2025 Jul 30:blood.2024023841. doi: 10.1182\/blood.2024023841. Online ahead of print.","author":"Spencer A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737601"},{"title01":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma","title02":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma","journal":"Blood","issue":"2025 Jul 23:blood.2025028597. doi: 10.1182\/blood.2025028597. Online ahead of print.","author":"Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700574"},{"title01":"Silence of the myeloma clones: GPRC5D epigenetic regulation","title02":"Silence of the myeloma clones: GPRC5D epigenetic regulation","journal":"Blood","issue":"2025 Jul 10;146(2):133-135.","author":"Lee H, Bahlis NJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40638200"},{"title01":"Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics","title02":"Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics","journal":"Blood","issue":"2025 Jul 11:blood.2025028896. doi: 10.1182\/blood.2025028896. Online ahead of print.","author":"Yip RKH, Er J, Qin L, Nguyen QH, Motyer A, Rimes JS, Light A, Mishi RD, Ling L, Anttila CJA, Tsui E, Amann-Zalcenstein D, Dowling MR, Rogers KL, Bowden R, Chen Y, Harrison SJ, Hawkins ED.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40643106"},{"title01":"Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death","title02":"Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death","journal":"N Engl J Med","issue":"2025 Jul 17;393(3):267-274.","author":"Williams AM, Trahanas JM, Bommareddi S, Lima B, DeVries SA, Lowman J, Ahmad A, Quintana E, Scholl SR, Tsai S, Pedrotty D, Warhoover M, Moneypenny H, Tapia-Ruano S, Bacchetta M, Schlendorf K, Shah AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40673585"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center","journal":"Haematologica","issue":"2025 Jul 24. doi: 10.3324\/haematol.2025.287628. Online ahead of print.","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21","title02":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2024.286719. Online ahead of print.","author":"Sakaguchi H, Sakaguchi K, Kato I, Noma H, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito AM, Takagi M, Okuno K, Taga T, Horibe K, Okamoto Y, Koh K, Manabe A, Umeda K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637726"},{"title01":"Integrating killer cell immunoglobulin-like receptor high-resolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation","title02":"Integrating killer cell immunoglobulin-like receptor high-resolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2024.287061. Online ahead of print.","author":"Sch\u00e4fer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, K\u00fcrsteiner O, Nair G, Halter J, G\u00fcng\u00f6r T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation","title02":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.287554. Online ahead of print.","author":"Ma R, Zhu XY, Lu Y, Chen J, Xuan L, Yuan HL, Cao Y, Cao WJ, Fang XS, Miao KR, Hu XX, Yi H, Zhao YM, Wu YB, Yang T, Wang HT, Yin Y, Zhang ZM, Zhang XH, Xu LP, Wang Y, Liu KY, Huang XJ, Sun YQ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671492"},{"title01":"ADH5\/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications","title02":"ADH5\/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications","journal":"Leukemia","issue":"2025 Jul 10. doi: 10.1038\/s41375-025-02687-3. Online ahead of print.","author":"Atkins J, Kukuyan AM, Toma M, Drzewiecka M, Vekariya U, Karami A, Nieborowska-Skorska M, Nejati R, Hadzijusufovic E, Valent P, Stoklosa T, Sliwinski T, Wasik M, Skorski T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40640557"},{"title01":"Integrating killer cell immunoglobulin-like receptor high-resolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation","title02":"Integrating killer cell immunoglobulin-like receptor high-resolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2024.287061. Online ahead of print.","author":"Sch\u00e4fer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, K\u00fcrsteiner O, Nair G, Halter J, G\u00fcng\u00f6r T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"On the mechanism of NPM1 mutations in acute myeloid leukemia","title02":"On the mechanism of NPM1 mutations in acute myeloid leukemia","journal":"Leukemia","issue":"2025 Jul 28. doi: 10.1038\/s41375-025-02722-3. Online ahead of print.","author":"Lieber MR, Hsieh CL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40721647"},{"title01":"Transcriptomic landscape of CD8+ and CD4\u2009+\u2009T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations","title02":"Transcriptomic landscape of CD8+ and CD4\u2009+\u2009T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations","journal":"Leukemia","issue":"2025 Jul 28. doi: 10.1038\/s41375-025-02708-1. Online ahead of print.","author":"Calabretto G, Binatti A, Teramo A, Buratin A, Baril\u00e0 G, Gasparini VR, Vicenzetto C, Gaffo E, Rampazzo E, Orsi S, Buson E, Trimarco V, Mariotti B, Facco M, Bazzoni F, Trentin L, Semenzato G, Zambello R, Bortoluzzi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40721648"},{"title01":"Rare germline variant in NFATC4 associated with familial CLL","title02":"Rare germline variant in NFATC4 associated with familial CLL","journal":"Leukemia","issue":"2025 Jul 28. doi: 10.1038\/s41375-025-02713-4. Online ahead of print.","author":"Itchaki G, Bai H, Tiao G, Improgo R, Oppenheimer BE, Kasar S, Tesar B, Fernandes SM, Pochet N, Machado JH, Thrash EM, Freedman AS, Getz G, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40721649"},{"title01":"Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal","title02":"Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal","journal":"Leukemia","issue":"2025 Jul 17. doi: 10.1038\/s41375-025-02693-5. Online ahead of print.","author":"Bond DR, Burnard SM, Uddipto K, Hunt KV, Harvey BM, Steffens Reinhardt L, Lawlor-O'Neill C, Roper EA, Humphries S, Murray HC, Mannan A, Dun MD, de Bock CE, Bowden NA, Enjeti AK, Verrills NM, Riveros C, L\u00ea Cao KA, Lee HJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40676205"},{"title01":"Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis","title02":"Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis","journal":"Leukemia","issue":"2025 Jul 21. doi: 10.1038\/s41375-025-02700-9. Online ahead of print.","author":"Ronnacker J, Muller PJ, Mikesch JH, Zukunft S, Weinbergerov\u00e1 B, \u0160r\u00e1mek J, Valka J, Novak J, Zak P, Szotkowski T, Koristek Z, Krekeler C, Unglaub JM, Sauer T, Ruhnke L, Kraus S, Schaffrath J, M\u00fcller LP, Kaes S, Niemann D, Fransecky L, Hess PP, Crysandt M, Jost E, Millo J, Gaertner J, Repp R, Jentzsch M, Hoppe L, Klein S, Modemann F, Michalowski N, Fischbach K, Blau W, Ruhs M, Ritter M, Lohmeyer J, Steffen B, Hauser S, Kaufmann M, Krause SW, Knabe R, Spiekermann K, Serve H, Platzbecker U, Baldus CD, M\u00fcller-Tidow C, Lenz G, Reinhardt HC, Mayer J, Bornh\u00e4user M, R\u00f6llig C, Schliemann C, Hanoun M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40691504"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center","journal":"Haematologica","issue":"2025 Jul 24. doi: 10.3324\/haematol.2025.287628. Online ahead of print.","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21","title02":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2024.286719. Online ahead of print.","author":"Sakaguchi H, Sakaguchi K, Kato I, Noma H, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito AM, Takagi M, Okuno K, Taga T, Horibe K, Okamoto Y, Koh K, Manabe A, Umeda K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637726"},{"title01":"Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood","title02":"Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2025.287942. Online ahead of print.","author":"Chevillon F, Labrune E, Clappier E, Lapillonne H, Ballerini P, Lange VB, Fortin A, Itzykson R, Soci\u00e9 G, Buzyn A, Leverger G, Dalle JH, Dh\u00e9din N, Boissel N, De Latour RP, Salle B, Roux C, Poirot C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637728"},{"title01":"Advancing quality of life research in chronic myeloid leukemia: where do we stand?","title02":"Advancing quality of life research in chronic myeloid leukemia: where do we stand?","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2025.288391. Online ahead of print.","author":"Lipton JH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637736"},{"title01":"Flow cytometric analysis of cerebrospinal fluid identifies patients with occult central nervous system involvement in relapsed pediatric acute lymphoblastic leukemia","title02":"Flow cytometric analysis of cerebrospinal fluid identifies patients with occult central nervous system involvement in relapsed pediatric acute lymphoblastic leukemia","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2025.287392. Online ahead of print.","author":"Thastrup M, Marquart HV, Levinsen M, Ulvmoen A, Albertsen BK, Pronk CJ, Olsen M, Wehner P, Taskinen M, Als-Nielsen B, Schmiegelow K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637739"},{"title01":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia","title02":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2025.287777. Online ahead of print.","author":"Murphy T, Zhang B, Zhang T, King I, Capo-Chichi JM, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee KWL, Arruda A, Lu Z, Khalaf D, Rockwell C, Leber B, Sabloff M, Tierens A, Stockley TL, Chan SM, Ng SWK, Wang JCY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637740"},{"title01":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia","title02":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2024.286228. Online ahead of print.","author":"Zhao HG, Cruz-Rodriguez N, Johnson KC, Pomicter AD, Bates B, Bateman B, Haferlach T, Gu T, Ahmann J, Yan D, Lee GS, Zhu W, Bishop J, Odelberg SJ, Deininger MW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637748"},{"title01":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey","title02":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2025.287772. Online ahead of print.","author":"Lang F, Pemberton-Whiteley Z, Clements J, Ruiz C, Rea D, Machado L, Takahashi N, Moon SH, Grigg A, Borowczak C, Schuld P, Frank P, Constantinescu C, Boquimpani C, Cortes JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637752"},{"title01":"PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia","title02":"PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"2025 Jul 10. doi: 10.3324\/haematol.2024.287124. Online ahead of print.","author":"Stanulovi\u0107 VS, Binhassan S, Jaber BA, Alazmi S, Saleman FMB, Potluri S, Pratt G, Ludwig C, Ward DG, Hoogenkamp M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637766"},{"title01":"Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia","title02":"Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2024.287253. Online ahead of print.","author":"Rockwell B, Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica AR, Kornblum N, Shah N, Levitz D, Shapiro LC, Gupta R, Munoz A, Dhawan A, Fehn K, Comas M, Verceles J, Cooper DL, Konopleva M, Feldman EJ, Verma A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671491"},{"title01":"Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment","title02":"Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment","journal":"Haematologica","issue":"2025 Jul 17. doi: 10.3324\/haematol.2025.288105. Online ahead of print.","author":"Alkabbani O, Jabban Y, He R, Viswanatha D, Bessonen K, Greipp P, Jevremovic D, Foran JM, Badar T, Yi CA, Kusne Y, Saliba AN, Hefazi M, Matin A, Hogan WJ, Mangaonkar A, Alkhateeb H, Patnaik M, Shah M, Begna K, Litzow MR, Al-Kali A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671498"},{"title01":"CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia","title02":"CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Jul 24. doi: 10.1111\/bjh.70019. Online ahead of print.","author":"Dreyzin A, Holtzman NG, Bonifant CL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40707180"},{"title01":"Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring","title02":"Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring","journal":"Br J Haematol","issue":"2025 Jul 29. doi: 10.1111\/bjh.70059. Online ahead of print.","author":"Angotzi F, Cellini A, Danesin N, Zoletto S, Serafin A, Cavarretta CA, Bevilacqua A, Forlani L, Tonini A, Frezzato F, Bonaldi L, Pizzi M, Faggian D, Trentin L, Visentin A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40734248"},{"title01":"The impact of secondary hypogammaglobulinaemia in children with acute lymphoblastic leukaemia receiving maintenance chemotherapy","title02":"The impact of secondary hypogammaglobulinaemia in children with acute lymphoblastic leukaemia receiving maintenance chemotherapy","journal":"Br J Haematol","issue":"2025 Jul 20. doi: 10.1111\/bjh.70027. Online ahead of print.","author":"Cheng CN, Yang YN, Yeh YH, Chen JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40685714"},{"title01":"Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling","title02":"Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling","journal":"Br J Haematol","issue":"2025 Jul 20. doi: 10.1111\/bjh.70011. Online ahead of print.","author":"Li X, Zhou Q, Hao X, Cao C, Adzraku SY, Song X, Sun C, Guo X, Li Y, Yuan S, Huang Y, Xu K, Qiao J, Zeng L, Ju W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40685774"},{"title01":"Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study","title02":"Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study","journal":"Br J Haematol","issue":"2025 Jul 21. doi: 10.1111\/bjh.70026. Online ahead of print.","author":"Jensen RH, Teglgaard C, Jensen JF, Baech J, Marcher CW, Roug AS, \u00d8rskov AD, Sch\u00f6llkopf C, Kristensen DT, Br\u00f8ndum RF, Severinsen MT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40692261"},{"title01":"Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML","title02":"Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML","journal":"Blood","issue":"2025 Jul 29:blood.2025028594. doi: 10.1182\/blood.2025028594. Online ahead of print.","author":"Nedumannil R, Ashby M, Rowland JP Dr, Malherbe JAJ, Fairbank J, Gray K, Loo S, Wright M, Reynolds J, Hiwase DK, Marlton P, Fleming SA, Bajel A, Wei AH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40729679"},{"title01":"Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients","title02":"Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients","journal":"Blood","issue":"2025 Jul 29:blood.2024028019. doi: 10.1182\/blood.2024028019. Online ahead of print.","author":"Smith A, Denny NDR, Chahrour C, Sharp K, Arachi M, Dopico-Fernandez AM, Elliott N, Harman J, Jackson T, Geng H, Smith O Professor, Bond J, Roberts I, Stam RWW, Crump N, Davies J, Roy A, Milne TA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40729681"},{"title01":"CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis","title02":"CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis","journal":"Blood","issue":"2025 Jul 23:blood.2024026271. doi: 10.1182\/blood.2024026271. Online ahead of print.","author":"Ji Y, Huang Y, Thomas T, Kapti EG, Tachibana R, Lark JA, Berezniuk I, Guo L, Ali MAE, Mims K, Kroger B, Hu W, Park CY, Chung SS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700577"},{"title01":"Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia","title02":"Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia","journal":"Blood","issue":"2025 Jul 23:blood.2025028993. doi: 10.1182\/blood.2025028993. Online ahead of print.","author":"Umeda M, Hiltenbrand RL, Michmerhuizen NL, Barajas JM, Thomas ME 3rd, Arthur B, Walsh MP, Song G, Ma JJ, Westover T, Kumar A, P\u00f6l\u00f6nen P, Mecucci C, Di Giacomo D, Locatelli F, Masetti R, Bertuccio SN, Pigazzi M, Pruett-Miller SM, Pounds SB, Rubnitz J, Inaba H, Papadopoulos KP, Wick MJ, Iacobucci I, Mullighan CG, Klco JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700635"},{"title01":"A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL","title02":"A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL","journal":"Blood","issue":"2025 Jul 10:blood.2025028529. doi: 10.1182\/blood.2025028529. Online ahead of print.","author":"Guo M, Memis T, Ehrmann AS, Pittrof A, Baumann B, Ferrante F, Tausch E, Fischer K, D\u00f6hner H, Borggrefe T, Stilgenbauer S, Pannicke U, Schwarz K, Mertens D, Oswald F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40638689"},{"title01":"The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF\u03baB signaling","title02":"The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF\u03baB signaling","journal":"Blood","issue":"2025 Jul 15:blood.2024028199. doi: 10.1182\/blood.2024028199. Online ahead of print.","author":"Goel P, Aryal S, Franceski AM, Kuznetsova V, Costa AFO, Luca F, Connelly AN, Phillips DW, Ennis CC, Curtiss BM, Karfa S, Crown BL, Larson CR, Carminita E, Camacho V, Welsch D, Cheng C, Yokota A, Cobo I, Hirai H, Lu R, Bhatia R, Datta PK, Ferrell PB Jr, Welner RS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40663784"},{"title01":"Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies","title02":"Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies","journal":"Leukemia","issue":"2025 Jul 24. doi: 10.1038\/s41375-025-02694-4. Online ahead of print.","author":"Chong SJF, Lai JXH, Iskandar K, Leong BJ, Wang C, Wang Y, Gui\u00e8ze R, Raman D, Lim RHF, Wu CJ, Chng WJ, Cheung AMS, Chuah C, Davids MS, Pervaiz S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40707672"},{"title01":"Liquid-liquid phase separation of ZHX2 protects DLBCL cells against ferroptosis through induction of SLC3A2","title02":"Liquid-liquid phase separation of ZHX2 protects DLBCL cells against ferroptosis through induction of SLC3A2","journal":"Leukemia","issue":"2025 Jul 29. doi: 10.1038\/s41375-025-02718-z. Online ahead of print.","author":"Zhang J, Wang D, Luan M, Liu X, Wang N, Sheng X, Li S, Li B, Sun T, Ma D, Ye J, Lu F, Ji C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40730912"},{"title01":"A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival","title02":"A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival","journal":"Leukemia","issue":"2025 Jul 11. doi: 10.1038\/s41375-025-02690-8. Online ahead of print.","author":"Dutta D, Gouveia MH, Gorman BR, Adu-Gyamfi A, Lee CH, Ogwang MD, Kerchan P, Reynolds SJ, Tenge CN, Were PA, Wekesa WN, Tenge RK, Masalu N, Kawira EL, Kinyera T, Otim I, Nabalende H, Dhudha H, Candia B, Abaru J, Yan W, Florez-Vargas O, Xie Y, Ho M, Ayers LW, Bhatia K, Goedert JJ, Pfeiffer RM, Manning M, Hutchinson A, Cole N, Luo W, Hicks B, Chagaluka G, Johnston WT, Mutalima N, Borgstein E, Liomba GN, Kamiza S, Mkandawire N, Molyneux EM, Mitambo C, Newton R, Siebert R, Dean M, Yeager M, Chanock SJ, Prokunina-Olsson L, Mbulaiteye SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40646133"},{"title01":"Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma","title02":"Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma","journal":"Leukemia","issue":"2025 Aug;39(8):2035-2038. doi: 10.1038\/s41375-025-02658-8. Epub 2025 Jul 12.","author":"Zhao SH, Zhu ZM, Yang T, Gao D, Liu LH, Yang W, Wang XB, Zhao YX, Li M, Gao YN, Ma RJ, Yang Y, Li HP, Li L, Ao XL, Xiao XB, Hu CL, Yuan SZ, Ding Y, Chen XL, He JX, Liu Y, Huang WR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40652061"},{"title01":"Genetic lesions in nodular lymphocyte-predominant Hodgkin lymphoma and T cell\/histiocyte-rich large B-cell lymphoma identified by whole genome sequencing","title02":"Genetic lesions in nodular lymphocyte-predominant Hodgkin lymphoma and T cell\/histiocyte-rich large B-cell lymphoma identified by whole genome sequencing","journal":"Leukemia","issue":"2025 Jul 16. doi: 10.1038\/s41375-025-02679-3. Online ahead of print.","author":"Rausch T, Sch\u00e4fer H, Bein J, M\u00f6lder F, Beeck LK, K\u00f6lsch B, Borchert S, Benes V, Halbsguth T, Brunnberg U, Oellerich T, Tousseyn T, Ponzoni M, K\u00f6ster J, Hansmann ML, K\u00fcppers R, Hartmann S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40670673"},{"title01":"Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial","title02":"Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial","journal":"Lancet Oncol","issue":"2025 Aug;26(8):1081-1090.","author":"Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, H\u00fcttmann A, Keil F, Dierlamm J, H\u00e4nel M, Novak U, Meissner J, Hellmuth JC, Mathas S, Zijlstra JM, Foss\u00e5 A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Jablonski J, Damaschin C, Robertz AS, Rosenbrock J, Fuchs M, Borchmann P, Behringer K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40652943"},{"title01":"Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias","title02":"Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias","journal":"Leukemia","issue":"2025 Jul 24. doi: 10.1038\/s41375-025-02710-7. Online ahead of print.","author":"Tirtakusuma R, Ghonim MA, Schattgen S, Muller B, Van de Velde LA, Khan TM, Crawford JC, Ma J, Abdelhamed S, Vegesana K, Awad W, Allen EK, Iacobucci I, Mullighan CG, Klco JM, Thomas PG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40707674"},{"title01":"Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia","title02":"Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia","journal":"Leukemia","issue":"2025 Jul 22. doi: 10.1038\/s41375-025-02709-0. Online ahead of print.","author":"Yang C, Kang YY, Zhu CY, Ma Y, Yu PH, Yang T, Liu YQ, Zhang ZY, Suzuki N, Ogra Y, Bj\u00f6rklund M, Naranmandura H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40696139"},{"title01":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","title02":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","journal":"Leukemia","issue":"2025 Aug;39(8):1797-1813. doi: 10.1038\/s41375-025-02664-w. Epub 2025 Jul 11.","author":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, Silver R, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M, Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40646132"},{"title01":"Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization","title02":"Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization","journal":"Leukemia","issue":"2025 Jul 16. doi: 10.1038\/s41375-025-02695-3. Online ahead of print.","author":"Vick EJ, Hassan A, Choi K, Bennett J, Muto T, Clough CA, Culver-Cochran AE, Hueneman K, Bolanos LC, Wunderlich M, Zhang X, McKnight C, Ceribelli M, Holland D, Klumpp-Thomas C, Greis KD, Thomas CJ, Starczynowski DT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40670672"},{"title01":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma","title02":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma","journal":"Haematologica","issue":"2025 Jul 24. doi: 10.3324\/haematol.2025.288114. Online ahead of print.","author":"Ghione P, Zinzani PL, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702895"},{"title01":"Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","title02":"Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","journal":"Haematologica","issue":"2025 Jul 24. doi: 10.3324\/haematol.2025.288085. Online ahead of print.","author":"Yates SJ, Weiss JJ, Sneider A, Geramita E, Murthy GSG, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer ES, Litzow MR, Atallah EL, Patel AA, Shallis RM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702896"},{"title01":"Genomic determinants of therapy response in ETV6::RUNX1 leukemia","title02":"Genomic determinants of therapy response in ETV6::RUNX1<\/i> leukemia","journal":"Leukemia","issue":"2025 Jul 9. doi: 10.1038\/s41375-025-02683-7. Online ahead of print.","author":"Oksa L, Moisio S, Maqbool K, Kramer R, Nikkil\u00e4 A, Jayasingha B, M\u00e4kinen A, Foroughi-Asl H, Rounioja S, Suhonen J, Krali O, Voutilainen M, Lahnalampi M, Veps\u00e4l\u00e4inen K, Huang S, Duque-Afonso J, Hauer J, Nordlund J, Wirta V, Lohi O, Hein\u00e4niemi M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40634509"},{"title01":"Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response","title02":"Chemoresistance of TP53<\/i> mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response","journal":"Leukemia","issue":"2025 Jul 9. doi: 10.1038\/s41375-025-02668-6. Online ahead of print.","author":"Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sill\u00e1 G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40634510"},{"title01":"CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia","title02":"CD6<\/i> expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2025.287564. Online ahead of print.","author":"Carrillo-Serradell L, Pi\u00f1eyroa JA, Bousquets-Mu\u00f1oz P, Planells-Romeo V, Arag\u00f3n-Serrano L, Casad\u00f3-Llombart S, Colomer D, Andr\u00e9s MV, Puente XS, Delgado J, Mozas P, Lozano F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605694"},{"title01":"B-lymphoblastic leukemia with KMT2A rearrangement with mature B-cell phenotype and surface \u03bb light-chain restriction","title02":"B-lymphoblastic leukemia with KMT2A<\/i> rearrangement with mature B-cell phenotype and surface \u03bb light-chain restriction","journal":"Blood","issue":"2025 Jun 26;145(26):3194.","author":"Deb PQ, Zhang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40569637"},{"title01":"Are we ready for an MRD-driven approach in multiple myeloma?","title02":"Are we ready for an MRD-driven approach in multiple myeloma?","journal":"Blood","issue":"2025 Jul 3;146(1):2-4.","author":"Gay F, Mina R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608349"},{"title01":"Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails","title02":"Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails","journal":"Blood","issue":"2025 Jul 3:blood.2025028403. doi: 10.1182\/blood.2025028403. Online ahead of print.","author":"Xiong S, Zhou J, Chng WJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608868"},{"title01":"Immune Alterations in Myeloma Evolution and Outcomes: Quo Vadis?","title02":"Immune Alterations in Myeloma Evolution and Outcomes: Quo Vadis?","journal":"Blood","issue":"2025 Jul 7:blood.2024026227. doi: 10.1182\/blood.2024026227. Online ahead of print.","author":"Dhodapkar MV, Paiva B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40623045"},{"title01":"More than myeloma: the trouble with “normal” plasma cells","title02":"More than myeloma: the trouble with “normal” plasma cells","journal":"Blood","issue":"2025 Jun 26;145(26):3066-3067..","author":"Firestone RS, Maura F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40569638"},{"title01":"When the silence speaks: T-cell dysfunction in myeloma","title02":"When the silence speaks: T-cell dysfunction in myeloma","journal":"Blood","issue":"2025 Jun 26;145(26):3064-3066.","author":"Friedrich MJ, Raab MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40569640"},{"title01":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","title02":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","journal":"Leukemia","issue":"2025 Jul 9. doi: 10.1038\/s41375-025-02685-5. Online ahead of print.","author":"Rettinger E, Heckl D, Gibson B, Sauer M, Turkiewicz D, Kleinschmidt K, Kalwak K, Reinhardt D, Locatelli F, Klusmann JH; Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40634512"},{"title01":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","title02":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e542-e554.","author":"Damaj G, Bazarbachi A, Berning P, Cottereau AS, Fox CP, Kyriakou C, Cwynarski K, Zinzani PL, Tournilhac O, Jurczak W, Karsten IE, Wang F, Marcais A, Tanase A, Nguyen-Quoc S, Serroukh Y, Aljurf M, Beauvais D, Wulf G, Sureda A, Corradini P, Hermine O, Hamadani M, Onida F, Ruggeri AL, Sanchez-Ortega I, Yakoub-Agha I, Dreger P, Schmitz N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610175"},{"title01":"Cardiac arrest linked to myeloid sarcoma after haematopoietic stem-cell transplantation","title02":"Cardiac arrest linked to myeloid sarcoma after haematopoietic stem-cell transplantation","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e560.","author":"Harrer DC, Mester P, Schmid S, Baborie A, Riemenschneider MJ, Fuchs A, Wolff D, Poeck H, Herr W, M\u00fcller M, Pavel V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610176"},{"title01":"The ESOT-Lancet Commission on Transplantation: a new vision for global sustainability, innovation, and equity in organ transplantation","title02":"The ESOT-Lancet<\/i> Commission on Transplantation: a new vision for global sustainability, innovation, and equity in organ transplantation","journal":"Lancet","issue":"2025 Jun 30:S0140-6736(25)01197-3. doi: 10.1016\/S0140-6736(25)01197-3. Online ahead of print.","author":"Oniscu GC, Muller E, Wilson C, Horton R; ESOT\u2013Lancet Commission on Transplantation.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40614742"},{"title01":"Policy innovations to advance equity in solid organ transplantation","title02":"Policy innovations to advance equity in solid organ transplantation","journal":"Lancet","issue":"2025 Jun 30:S0140-6736(25)00712-3. doi: 10.1016\/S0140-6736(25)00712-3. Online ahead of print.","author":"Jaure A, Jha V, McElroy LM, Muller E, Oniscu GC, Serper M, Purnell TS, Scholes-Robertson N, Reese PP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40614743"},{"title01":"Advancing patient monitoring, diagnostics, and treatment strategies for transplant precision medicine","title02":"Advancing patient monitoring, diagnostics, and treatment strategies for transplant precision medicine","journal":"Lancet","issue":"2025 Jun 30:S0140-6736(25)00195-3. doi: 10.1016\/S0140-6736(25)00195-3. Online ahead of print.","author":"Loupy A, Sablik M, Khush K, Reese PP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40614744"},{"title01":"Scientific advances in the assessment, modification, and generation of transplantable organs for patients with end-stage organ diseases","title02":"Scientific advances in the assessment, modification, and generation of transplantable organs for patients with end-stage organ diseases","journal":"Lancet","issue":"2025 Jun 30:S0140-6736(25)00239-9. doi: 10.1016\/S0140-6736(25)00239-9. Online ahead of print.","author":"Shaver CM, Reese PP, Griesemer A, Zuckermann A, Bacchetta M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40614745"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2024.287205. Online ahead of print.","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kr\u00f6ger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Precision transplant and cell therapies for non-malignant disorders-The path forward","title02":"Precision transplant and cell therapies for non-malignant disorders-The path forward","journal":"Br J Haematol","issue":"2025 Jul 5. doi: 10.1111\/bjh.20245. Online ahead of print.","author":"Lakkaraja M, Baker KS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40616382"},{"title01":"Aging-declined RNA exportation impairs hematopoietic stem cells by inducing R-loop","title02":"Aging-declined RNA exportation impairs hematopoietic stem cells by inducing R-loop","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2025.287765. Online ahead of print.","author":"Chen R, Dong Q, Zhou L, He H, Du Y, Sun Q, Suda T, Cheng T, Wang J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605703"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2024.287205. Online ahead of print.","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kr\u00f6ger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Haematopoietic stem cell transplant for inborn errors of immunity-Who and when?","title02":"Haematopoietic stem cell transplant for inborn errors of immunity-Who and when?","journal":"Br J Haematol","issue":"2025 Jul 7. doi: 10.1111\/bjh.20248. Online ahead of print.","author":"Oved JH, Marsh RA, Petrovic A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40619934"},{"title01":"Defining a CMV viral load threshold for pre-emptive therapy in paediatric haematopoietic stem cell transplant recipients","title02":"Defining a CMV viral load threshold for pre-emptive therapy in paediatric haematopoietic stem cell transplant recipients","journal":"Br J Haematol","issue":"2025 Jul 9. doi: 10.1111\/bjh.20254. Online ahead of print.","author":"Duret A, Charles O, Margetts BK, Booth J, Brown JR, Best T, Fernandes S, Amrolia P, Chiesa R, Silva J, Worth A, Standing JF, Rao K, Whittaker E, Gil E, Breuer J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40630011"},{"title01":"Diagnostic approaches for haematopoietic cell transplantation-associated membranous nephropathy: Novel underutilized tools","title02":"Diagnostic approaches for haematopoietic cell transplantation-associated membranous nephropathy: Novel underutilized tools","journal":"Br J Haematol","issue":"2025 Jun 30. doi: 10.1111\/bjh.20232. Online ahead of print.","author":"El Jurdi N, Waldman MA, Schulz E, Mina A, Li G, Carpenter A, Theis JD, Sethi S, Caza T, Seshan SV, Pavletic SZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40589069"},{"title01":"Clusterin(g) and decoding HSC aging","title02":"Clusterin<\/i>(g) and decoding HSC aging","journal":"Blood","issue":"2025 Jul 3;146(1):4-5..","author":"Gerbaulet A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608350"},{"title01":"Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis","title02":"Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis","journal":"Blood","issue":"lood. 2025 Jul 7:blood.2024027197. doi: 10.1182\/blood.2024027197. Online ahead of print.","author":"Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, Finel H, Kulagin AD, Glass B, Corradini P, Herrera AF, Blaise D, Kharfan-Dabaja MA, Halahleh K, Ahmed S, Martinez C, Giebel S, Montoto S, Jones RJ, Ahmed N, Lynch RC, de Lima MJ, Shadman M, Sauter CS, Ahn KW, Hamadani M, Bazarbachi A, Sureda A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40623049"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2024.287205. Online ahead of print.","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kr\u00f6ger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Splenectomy: still a life-saving treatment in immune thrombocytopenia","title02":"Splenectomy: still a life-saving treatment in immune thrombocytopenia","journal":"Haematologica","issue":"2025 Jul 1;110(7):1451-1453.","author":"Rodeghiero F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40590188"},{"title01":"Type I interferon as a pre-lupus marker in anti-nuclear antibody-associated childhood immune thrombocytopenic purpura","title02":"Type I interferon as a pre-lupus marker in anti-nuclear antibody-associated childhood immune thrombocytopenic purpura","journal":"Br J Haematol","issue":"2025 Jul 5. doi: 10.1111\/bjh.20241. Online ahead of print.","author":"Granel J, Fernandes H, Wojciechowski E, Pillet P, Richer O, Clet J, Fournier B, H\u00e9ritier S, Leblanc T, Foray AP, Nombel A, Garnier L, Leibler C, Blanco P, Belot A, Aladjidi N; French reference center for paediatric autoimmune cytopenia (CEREVANCE).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40616374"},{"title01":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study","title02":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e505-e515.","author":"Strati P, Castro J, Goodman A, Bachanova V, Kamdar M, Awan FT, Solomon SR, Wong L, Wong C, Patel D, Bickers C, Zhao W, Bashir Z, Valamehr B, Elstrom RL, Patel K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610174"},{"title01":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","title02":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e542-e554.","author":"Damaj G, Bazarbachi A, Berning P, Cottereau AS, Fox CP, Kyriakou C, Cwynarski K, Zinzani PL, Tournilhac O, Jurczak W, Karsten IE, Wang F, Marcais A, Tanase A, Nguyen-Quoc S, Serroukh Y, Aljurf M, Beauvais D, Wulf G, Sureda A, Corradini P, Hermine O, Hamadani M, Onida F, Ruggeri AL, Sanchez-Ortega I, Yakoub-Agha I, Dreger P, Schmitz N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610175"},{"title01":"Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed\/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study","title02":"Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed\/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study","journal":"J Clin Oncol","issue":"2025 Jul 7:JCO2500399. doi: 10.1200\/JCO-25-00399. Online ahead of print.","author":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40623279"},{"title01":"BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?","title02":"BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2025.288196. Online ahead of print.","author":"Dogliotti I, Federico M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605702"},{"title01":"Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial","title02":"Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2025.288057. Online ahead of print.","author":"Danilov AV, Li H, Shadman M, Rimsza L, Zebari A, Smith SM, LeBlanc M, Friedberg JW, Carlson C, Song JY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605713"},{"title01":"Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial","title02":"Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2024.286945. Online ahead of print.","author":"Shouse G, Chen C, Muir A, Popplewell L, Siddiqi T, Zain J, Herrera AF, Danilova O, Roleder C, Wang L, Spurgeon SEF, Kittai AS, Chen L, Xia Z, Davids MS, Danilov AV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605718"},{"title01":"We are on the right track for mantle cell lymphoma","title02":"We are on the right track for mantle cell lymphoma","journal":"Br J Haematol","issue":"2025 Jul 6. doi: 10.1111\/bjh.20259. Online ahead of print.","author":"Moioli A, Visco C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40619706"},{"title01":"Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with\u00a0relapsed\/refractory large B-cell lymphoma","title02":"Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with\u00a0relapsed\/refractory large B-cell lymphoma","journal":"Br J Haematol","issue":"2025 Jun 30. doi: 10.1111\/bjh.20240. Online ahead of print.","author":"Sharp J, Zhao Q, Voorhees TJ, Bond DA, Sawalha Y, Reneau J, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Brammer JE, Maddocks K, Christian B, Bezerra E, Denlinger N, Vasu S, De Lima M, Prosek J, Epperla N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40589093"},{"title01":"Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience","title02":"Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience","journal":"Br J Haematol","issue":"2025 Jul 1. doi: 10.1111\/bjh.20234. Online ahead of print.","author":"Cassanello G, Luttwak E, Brown S, Devlin SM, Imber B, Ip A, Leslie LA, Accav NG, Avigdor A, Marcus R, Beyar-Katz O, Corona M, Luna De Abia A, Calabrese De Feo J, Rivas Delgado A, Lue JK, Grommes C, Shah GL, Park J, Perales MA, Salles G, Shouval R, Scordo M, Palomba ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40589238"},{"title01":"Vitrectomy as a rapid diagnostic tool for lymphoma: Cytology and flow cytometry approach","title02":"Vitrectomy as a rapid diagnostic tool for lymphoma: Cytology and flow cytometry approach","journal":"Br J Haematol","issue":"2025 Jul 1. doi: 10.1111\/bjh.20250. Online ahead of print.","author":"Gascon P, Frankel D, Fritz S, Comet A, Matonti F, Ramtohul P, Conrath J, David T, Robert P, Schenone L, Harlay V, Chinot O, Tabouret E, Nanni I, Astier A, Roll P, Kaspi E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40589309"},{"title01":"Virtual twins for personalised CAR T-cell therapy in myeloma","title02":"Virtual twins for personalised CAR T-cell therapy in myeloma","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e490-e491.","author":"Reiche K, Weirauch U, Kreuz M, Fischer L, Gras L, Neumuth T, Platzbecker U, K\u00f6hl U, Demlova R, Kremer A, Fr\u00f6hlich H, Franke S, Merz M; CERTAINTY Consortium.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610172"},{"title01":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network","title02":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network","journal":"Lancet Haematol","issue":"2025 Jun 25:S2352-3026(25)00117-6. doi: 10.1016\/S2352-3026(25)00117-6. Online ahead of print.","author":"van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, Spencer A, Schjesvold F, Driessen C, Kaiser M, Perrot A, W\u00e4sch R, Korst CL, Broijl A, Touzeau C, Manier S, Hajek R, Ludwig H, Fernandez de Larrea C, Popat R, Musto P, Rodriguez-Otero P, Yong K, Rasche L, Terpos E, Raab MS, Boccadoro M, Sonneveld P, Einsele H; EMN Guidelines Committee.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40580975"},{"title01":"Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study","title02":"Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study","journal":"Lancet Haematol","issue":"2025 Jun 27:S2352-3026(25)00139-5. doi: 10.1016\/S2352-3026(25)00139-5. Online ahead of print.","author":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Onishi M, Ku G, Pothacamury R, Jalaluddin M, Zeng J, Ross JA, Dobkowska E, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40587991"},{"title01":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","title02":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","journal":"Lancet","issue":"2025 Jul 2:S0140-6736(25)01030-X. doi: 10.1016\/S0140-6736(25)01030-X. Online ahead of print.","author":"Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, Zhang J, Li C, Hu Y, Mei H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40617243"},{"title01":"Haematopoietic stem cell transplant for inborn errors of immunity-Who and when?","title02":"Haematopoietic stem cell transplant for inborn errors of immunity-Who and when?","journal":"Br J Haematol","issue":"2025 Jul 7. doi: 10.1111\/bjh.20248. Online ahead of print.","author":"Oved JH, Marsh RA, Petrovic A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40619934"},{"title01":"Defining a CMV viral load threshold for pre-emptive therapy in paediatric haematopoietic stem cell transplant recipients","title02":"Defining a CMV viral load threshold for pre-emptive therapy in paediatric haematopoietic stem cell transplant recipients","journal":"Br J Haematol","issue":"2025 Jul 9. doi: 10.1111\/bjh.20254. Online ahead of print.","author":"Duret A, Charles O, Margetts BK, Booth J, Brown JR, Best T, Fernandes S, Amrolia P, Chiesa R, Silva J, Worth A, Standing JF, Rao K, Whittaker E, Gil E, Breuer J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40630011"},{"title01":"Diagnostic approaches for haematopoietic cell transplantation-associated membranous nephropathy: Novel underutilized tools","title02":"Diagnostic approaches for haematopoietic cell transplantation-associated membranous nephropathy: Novel underutilized tools","journal":"Br J Haematol","issue":"2025 Jun 30. doi: 10.1111\/bjh.20232. Online ahead of print.","author":"El Jurdi N, Waldman MA, Schulz E, Mina A, Li G, Carpenter A, Theis JD, Sethi S, Caza T, Seshan SV, Pavletic SZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40589069"},{"title01":"An AI model of transplantation risk for myelofibrosis","title02":"An AI model of transplantation risk for myelofibrosis","journal":"Blood","issue":"2025 Jun 26;145(26):3068-3069.","author":"M\u00e9ndez-Ferrer S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40569639"},{"title01":"Microbiota and chronic GVHD: a plasmablast link","title02":"Microbiota and chronic GVHD: a plasmablast link","journal":"Blood","issue":"2025 Jun 26;145(26):3073-3075.","author":"Rashidi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40569643"},{"title01":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","title02":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","journal":"Leukemia","issue":"2025 Jul 9. doi: 10.1038\/s41375-025-02685-5. Online ahead of print.","author":"Rettinger E, Heckl D, Gibson B, Sauer M, Turkiewicz D, Kleinschmidt K, Kalwak K, Reinhardt D, Locatelli F, Klusmann JH; Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40634512"},{"title01":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study","title02":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e505-e515.","author":"Strati P, Castro J, Goodman A, Bachanova V, Kamdar M, Awan FT, Solomon SR, Wong L, Wong C, Patel D, Bickers C, Zhao W, Bashir Z, Valamehr B, Elstrom RL, Patel K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610174"},{"title01":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","title02":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e542-e554.","author":"Damaj G, Bazarbachi A, Berning P, Cottereau AS, Fox CP, Kyriakou C, Cwynarski K, Zinzani PL, Tournilhac O, Jurczak W, Karsten IE, Wang F, Marcais A, Tanase A, Nguyen-Quoc S, Serroukh Y, Aljurf M, Beauvais D, Wulf G, Sureda A, Corradini P, Hermine O, Hamadani M, Onida F, Ruggeri AL, Sanchez-Ortega I, Yakoub-Agha I, Dreger P, Schmitz N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610175"},{"title01":"Cardiac arrest linked to myeloid sarcoma after haematopoietic stem-cell transplantation","title02":"Cardiac arrest linked to myeloid sarcoma after haematopoietic stem-cell transplantation","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e560.","author":"Harrer DC, Mester P, Schmid S, Baborie A, Riemenschneider MJ, Fuchs A, Wolff D, Poeck H, Herr W, M\u00fcller M, Pavel V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610176"},{"title01":"DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT","title02":"DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT","journal":"Leukemia","issue":"2025 Jun 26. doi: 10.1038\/s41375-025-02661-z. Online ahead of print.","author":"Grassi F, Singh M, Moussaud S, Rodriguez GV, Ali Z, Janssen K, Cheray M, Leonard E, Andersson M, de Milito A, Qian H, Walfridsson J, H\u00f6glund A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40571744"},{"title01":"SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells","title02":"SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells","journal":"Leukemia","issue":"2025 Jun 30. doi: 10.1038\/s41375-025-02673-9. Online ahead of print.","author":"Wang M, Zhu R, Small D, Lin L, Li L, Ma S, Xia L, Luo S, He W, Yu J, Li J, Wei R, Zhang A, Shi W, Hu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40588567"},{"title01":"Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial","title02":"Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial","journal":"Leukemia","issue":"2025 Jun 30. doi: 10.1038\/s41375-025-02674-8. Online ahead of print.","author":"Gong X, Liu W, Liu Y, Fang Q, Gu R, Liu K, Lin D, Zhou C, Zhang G, Gong B, Wei S, Li Y, Li S, Wang Y, Hu Y, Qiu S, Liu B, Wang Y, Mi Y, Wei H, Wang J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40588568"},{"title01":"Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment","title02":"Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment","journal":"Leukemia","issue":"2025 Jul 3. doi: 10.1038\/s41375-025-02675-7. Online ahead of print.","author":"Ronnacker J, Ruhnke L, R\u00f6llig C, Middeke JM, Herbst R, Morgner A, Unglaub JM, Sauer T, Huber K, Baden D, Fransecky L, Gezer MN, Crysandt M, Jost E, Jentzsch M, Metzeler KH, Berdel AF, Urbahn MA, Kolloch L, Stelljes M, Platzbecker U, Br\u00fcmmendorf TH, Baldus C, M\u00fcller-Tidow C, H\u00e4nel M, Bornh\u00e4user M, Wethmar K, Krug U, Lenz G, Mikesch JH, Schliemann C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40603653"},{"title01":"Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia","title02":"Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e485-e487. doi: 10.1016\/S2352-3026(25)00169-3.","author":"Curran E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610169"},{"title01":"Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy","title02":"Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2025.288323. Online ahead of print.","author":"Molica S, Shanafelt TD, Giannarelli D, Allsup D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605690"},{"title01":"Relapsed acute lymphoblastic leukemia: back to the drawing board","title02":"Relapsed acute lymphoblastic leukemia: back to the drawing board","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2025.288191. Online ahead of print.","author":"Jacoby E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605705"},{"title01":"Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia","title02":"Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia","journal":"Haematologica","issue":"2025 Jul 3. doi: 10.3324\/haematol.2025.287794. Online ahead of print.","author":"Ahn JS, Park JH, Lee C, Song IC, Kim MY, Sohn SK, Yhim HY, Park Y, Kim I, Shin HJ, Park SK, Kim SH, Cheong JW, Lee HS, Lee H, Bae SH, Choi Y, Lee HG, Do YR, Han JJ, Kim MK, Park S, Kim HJ, Kim HJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605710"},{"title01":"Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes","title02":"Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes","journal":"Br J Haematol","issue":"2025 Jul 7. doi: 10.1111\/bjh.20226. Online ahead of print.","author":"Zu Y, Yue X, Zhan X, Liu X, Ma H, Qin F, Duan L, Zhao H, Zhang Y, He S, Zhao H, Zhang C, Xin X, Zhang W, Song Y, Liu B, Li W, Zhang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40624854"},{"title01":"ZIP10 as a potential therapeutic target in acute myeloid leukaemia","title02":"ZIP10 as a potential therapeutic target in acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 Jun 30. doi: 10.1111\/bjh.20229. Online ahead of print.","author":"Rolles B, Chatain N, G\u00f6rg R, Vieri M, Tillmann-Tr\u00f6ster N, Bourgeois MG, Christen D, Walter J, Hillerbrand AC, Romine KA, Taylor KM, Bertram J, Jost E, Koschmieder S, Beier F, Stahl M, Br\u00fcmmendorf TH, Rink L, Wessels I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40583520"},{"title01":"Integration of [(18)F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma","title02":"Integration of [(18)F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma","journal":"Leukemia","issue":"2025 Jul 8. doi: 10.1038\/s41375-025-02688-2. Online ahead of print.","author":"Dondolin R, Garrou F, Almasri M, Terzi Di Bergamo L, Cosentino C, Bruscaggin A, Salehi M, Talotta D, Bruna R, Rivolta GM, Bellia M, Nabki J, Al Deeban B, Cividini L, Mouhssine S, Maher N, Ghanej J, Maiellaro F, Andorno A, Mercalli F, Leutner M, Lorenzi A, Mahmoud AM, Al Essa W, Diop NM, Secomandi E, Deambrogi C, Rasi S, Boldorini RL, Gentile M, Palumbo GA, Gattei V, Fo\u00e0 R, Rossi D, Sacchetti GM, Gaidano G, Moia R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40629066"},{"title01":"Off-the-shelf iPSC natural killer-cell therapy: a new chapter for B-cell lymphoma?","title02":"Off-the-shelf iPSC natural killer-cell therapy: a new chapter for B-cell lymphoma?","journal":"Lancet Haematol","issue":"2025 Jul;12(7):e484-e485.","author":"Tix T, Rejeski K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40610168"},{"title01":"Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades","title02":"Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades","journal":"Br J Haematol","issue":"2025 Jul 2. doi: 10.1111\/bjh.20239. Online ahead of print.","author":"Alzahrani M, Gerrie AS, Sehn LH, Scott DW, Venner CP, Savage KJ, Villa D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40598970"},{"title01":"Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis","title02":"Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis","journal":"Blood","issue":"2025 Jul 7:blood.2024027197. doi: 10.1182\/blood.2024027197. Online ahead of print.","author":"Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, Finel H, Kulagin AD, Glass B, Corradini P, Herrera AF, Blaise D, Kharfan-Dabaja MA, Halahleh K, Ahmed S, Martinez C, Giebel S, Montoto S, Jones RJ, Ahmed N, Lynch RC, de Lima MJ, Shadman M, Sauter CS, Ahn KW, Hamadani M, Bazarbachi A, Sureda A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40623049"},{"title01":"Targeting proteostasis in multiple myeloma through inhibition of LTK","title02":"Targeting proteostasis in multiple myeloma through inhibition of LTK","journal":"Leukemia","issue":"2025 Jul 9. doi: 10.1038\/s41375-025-02682-8. Online ahead of print.","author":"V\u00e5tsveen TK, Giliberto M, Bjornsdottir V, Centonze F, Besse A, Frey Y, Sk\u00e5nland SS, Tveita A, Alirezaylavasani A, Imbery JF, Misund K, Reiterer V, Zahoor M, Driessen C, Besse L, Tasken K, Schjesvold FH, Farhan H, Munthe LA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40634511"},{"title01":"The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","title02":"The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","journal":"Leukemia","issue":"2025 Jul 2. doi: 10.1038\/s41375-025-02677-5. Online ahead of print.","author":"Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Koutoulidis V, Trapali M, Kastritis E, Terpos E, Dimopoulos MA, Gavriatopoulou M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40603652"},{"title01":"The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper consideration","title02":"The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper consideration","journal":"Leukemia","issue":"2025 Jul 4. doi: 10.1038\/s41375-025-02691-7. Online ahead of print.","author":"Focosi D, Casadevall A, Sullivan DJ, Joyner MJ, Franchini M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40615657"},{"title01":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","title02":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","journal":"Leukemia","issue":"2025 Jul 9. doi: 10.1038\/s41375-025-02685-5. Online ahead of print.","author":"Rettinger E, Heckl D, Gibson B, Sauer M, Turkiewicz D, Kleinschmidt K, Kalwak K, Reinhardt D, Locatelli F, Klusmann JH; Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40634512"},{"title01":"Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients","title02":"Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients","journal":"Leukemia","issue":"2025 Jun 26. doi: 10.1038\/s41375-025-02579-6. Online ahead of print.","author":"Welch BM, Parikh SA, Kay NE, Medina KL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40571743"},{"title01":"A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS","title02":"A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS","journal":"Br J Haematol","issue":"2025 Jul 1. doi: 10.1111\/bjh.20224. Online ahead of print.","author":"Searle E, Cluzeau T, O'Nions J, Recher C, Gyan E, Morillo D, Esteve J, Kulasekararaj A, Raffoux E, Walter HS, Pigneux A, Valc\u00e1rcel D, Daskalakis N, Bussolari J, Pietsch EC, Kuduk S, Bush T, Zhang X, Philippar U, Oluwasanjo A, Bradford K, Miller J, Van Bogaert C, Curtis M, Chang SY, Guttke C, Gaj S, Pearson R, Murphy J, van Dijck W, Alfonso Pi\u00e9rola A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40598790"},{"title01":"Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population-based cohort study","title02":"Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population-based cohort study","journal":"Br J Haematol","issue":"2025 Jul 2. doi: 10.1111\/bjh.20238. Online ahead of print.","author":"Nielsen NN, Jensen JF, \u00d8vlisen A, Zenas DR, Sch\u00f6llkopf C, Toft N, \u00d8rskov AD, Hansen DL, M\u00f8lle I, Kristensen DT, Severinsen MT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40603258"},{"title01":"Successful combined anti-CD19 immunotherapy of relapsed acute lymphoblastic leukaemia in a child with Nijmegen breakage syndrome","title02":"Successful combined anti-CD19 immunotherapy of relapsed acute lymphoblastic leukaemia in a child with Nijmegen breakage syndrome","journal":"Br J Haematol","issue":"2025 Jul 2. doi: 10.1111\/bjh.20244. Online ahead of print.","author":"Oszer A, Mielcarek-Siedziuk M, Marschollek P, Gamrot Z, Karolczyk G, Urbanska Z, Ussowicz M, Janczar S, M\u0142ynarski W, Pastorczak A, Ka\u0142wak K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40603265"},{"title01":"Therapy-related juvenile myelomonocytic leukemia","title02":"Therapy-related juvenile myelomonocytic leukemia","journal":"Blood","issue":"2025 Jul 3;146(1):127.","author":"Mohamed A, Richardson AI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608348"},{"title01":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia","title02":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia","journal":"Blood","issue":"2025 Jul 3:blood.2025028935. doi: 10.1182\/blood.2025028935. Online ahead of print.","author":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine AJ, Andreeff M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608889"},{"title01":"Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes","title02":"Multiple TET2<\/i> mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes","journal":"Leukemia","issue":"2025 Jun 24. doi: 10.1038\/s41375-025-02648-w. Online ahead of print.","author":"Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40555734"},{"title01":"Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML","title02":"Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1<\/i>-Mutated or KMT2A<\/i>-Rearranged AML","journal":"J Clin Oncol","issue":"2025 Jun 12:JCO2500914. doi: 10.1200\/JCO-25-00914. Online ahead of print.","author":"Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller G, Nichols A, Odenike O, Traer E, Lachowiez C, Duong VH, Hochman MJ, Cai SF, Smith C, Stefanos M, Martycz M, Huang Y, Rosenberg L, Marcus S, Chen TL, Yocum AO, Druker BJ, Levine RL, Borate U, Byrd JC, Mims AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504618"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus<\/i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287326. Online ahead of print.","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kr\u00f6ger N, Passweg J, Salmenniemi U, It\u00e4la-Remes M, Poir\u00e9 X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell \/ myeloid mixed phenotype acute leukemia","title02":"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1<\/i>-negative B-cell \/ myeloid mixed phenotype acute leukemia","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.287932. Online ahead of print.","author":"Azevedo RS, Jen WY, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568715"},{"title01":"Predictors of outcomes with covalent BTK inhibitor treatment in relapsed\/refractory TP53-mutant mantle cell lymphoma","title02":"Predictors of outcomes with covalent BTK inhibitor treatment in relapsed\/refractory TP53<\/i>-mutant mantle cell lymphoma","journal":"Br J Haematol","issue":"2025 Jun 23. doi: 10.1111\/bjh.20202. Online ahead of print.","author":"Uppal M, Joseph A, Drill E, Hamlin P, Falchi L, Noy A, Owens C, Epstein-Peterson ZD, Salles G, Zelenetz AD, Kumar A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40551465"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus<\/i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287326. Online ahead of print.","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kr\u00f6ger N, Passweg J, Salmenniemi U, It\u00e4la-Remes M, Poir\u00e9 X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"Upadacitinib, a selective JAK1 inhibitor, for the treatment of steroid refractory chronic graft-versus-host disease: A multicentre real-world study","title02":"Upadacitinib, a selective JAK1 inhibitor, for the treatment of steroid refractory chronic graft-versus-host disease: A multicentre real-world study","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20183. Online ahead of print.","author":"Niu L, Hu M, Xia Y, Lv M, Deng D, Cao L, Kong J, Zhao Y, Mo X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40518809"},{"title01":"Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy","title02":"Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20208. Online ahead of print.","author":"Konuma T, Shimomura Y, Mizuno S, Yamasaki S, Yui S, Uchida N, Doki N, Tanaka M, Yoshihara S, Eto T, Katayama Y, Katsuoka Y, Tokunaga M, Ota S, Sakata-Yanagimoto M, Ishiwata K, Kanda Y, Kawakita T, Onizuka M, Kanda J, Fukuda T, Atsuta Y, Yanada M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40518826"},{"title01":"Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm","title02":"Different clearance of KIT<\/i>D816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm","journal":"Br J Haematol","issue":"2025 Jun 17. doi: 10.1111\/bjh.20211. Online ahead of print.","author":"Niederwieser C, Badbaran A, Massoud R, Gagelmann N, Kunte A, Klyuchnikov E, Seyedi N, Heidenreich S, Rudolph I, Zeck G, L\u00fcck C, Janson D, Wolschke C, Ayuk F, Kr\u00f6ger N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40528506"},{"title01":"Socioeconomic factors and transplant access","title02":"Socioeconomic factors and transplant access","journal":"Blood","issue":"2025 Jun 19;145(25):3061.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40536776"},{"title01":"Chronic GVHD: one more promising player enters the arena","title02":"Chronic GVHD: one more promising player enters the arena","journal":"Blood","issue":"2025 Jun 12;145(24):2804-2807.","author":"Ayuk FA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504511"},{"title01":"A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD","title02":"A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD","journal":"Blood","issue":"2025 Jun 12:blood.2024027239. doi: 10.1182\/blood.2024027239. Online ahead of print.","author":"Gerdemann U, Kimler K, Warren MR, McGuckin C, Fleming RA, D'Ambra MR, Eran A, Albanese A, Chen E, Winschel MB, Cagnin L, Lane J, Gorfinkel L, Adams BW, Kwun J, Lanieri L, Hoban MD, Lamothe TL, Hyzy SL, Olson LM, Panoskaltsis-Mortari A, Prockop SE, Blazar BR, Kean LS, Tkachev V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504994"},{"title01":"Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes","title02":"Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes","journal":"N Engl J Med","issue":"2025 Jun 20. doi: 10.1056\/NEJMoa2506549. Online ahead of print.","author":"Reichman TW, Markmann JF, Odorico J, Witkowski P, Fung JJ, Wijkstrom M, Kandeel F, de Koning EJP, Peters AL, Mathieu C, Kean LS, Bruinsma BG, Wang C, Mascia M, Sanna B, Marigowda G, Pagliuca F, Melton D, Ricordi C, Rickels MR; VX-880-101 FORWARD Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40544428"},{"title01":"Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation","title02":"Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation","journal":"J Clin Oncol","issue":"2025 Jun 23:JCO2500378. doi: 10.1200\/JCO-25-00378. Online ahead of print.","author":"El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb J, Fausto J, Traeger L, Greer JA, Jackson V, Horick N, Rabideau DJ, Fenech A, Newcomb R, Ufere NN, Caruso E, Pepper J, DeFilipp Z, Chen YB, Lee SJ, Temel JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40549982"},{"title01":"Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","title02":"Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","journal":"J Clin Oncol","issue":"2025 Jun 16:JCO2500856. doi: 10.1200\/JCO-25-00856. Online ahead of print.","author":"Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, Leckrone E, Wu J, Stefanski HE, Auletta JJ, Spellman SR, Malmberg C, Askar M, Cusatis R, Shaffer BC, Modi D, Khimani F, Gooptu M, Hamadani M, Madbouly A, Maiers M, Fingerson S, Cook R, Ballen K, Loren A, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Shaw BE, Devine SM, Jimenez Jimenez AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40523209"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus<\/i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287326. Online ahead of print.","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kr\u00f6ger N, Passweg J, Salmenniemi U, It\u00e4la-Remes M, Poir\u00e9 X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of allogeneic HSCT","title02":"Impact of CHEK2<\/i> germline variants on haematological malignancy risk and outcomes of allogeneic HSCT","journal":"Br J Haematol","issue":"2025 Jun 12. doi: 10.1111\/bjh.20196. Online ahead of print.","author":"Lahtinen AK, Karu M, Koski JR, Ritari J, Hyv\u00e4rinen K, Koskela S, Nihtil\u00e4 J, Partanen J, Vettenranta K, Koskenvuo M, Niittyvuopio R, Salmenniemi U, It\u00e4l\u00e4-Remes M, Jahnukainen K, Kilpivaara O, Wartiovaara-Kautto U.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40506802"},{"title01":"Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm","title02":"Different clearance of KIT<\/i>D816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm","journal":"Br J Haematol","issue":"2025 Jun 17. doi: 10.1111\/bjh.20211. Online ahead of print.","author":"Niederwieser C, Badbaran A, Massoud R, Gagelmann N, Kunte A, Klyuchnikov E, Seyedi N, Heidenreich S, Rudolph I, Zeck G, L\u00fcck C, Janson D, Wolschke C, Ayuk F, Kr\u00f6ger N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40528506"},{"title01":"Inflammatory Memory of Stem Cells: Implications for Hematological Diseases","title02":"Inflammatory Memory of Stem Cells: Implications for Hematological Diseases","journal":"Blood","issue":"2025 Jun 25:blood.2024028197. doi: 10.1182\/blood.2024028197. Online ahead of print.","author":"Zhao D, Reddy P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40561216"},{"title01":"A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD","title02":"A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD","journal":"Blood","issue":"2025 Jun 12:blood.2024027239. doi: 10.1182\/blood.2024027239. Online ahead of print.","author":"Gerdemann U, Kimler K, Warren MR, McGuckin C, Fleming RA, D'Ambra MR, Eran A, Albanese A, Chen E, Winschel MB, Cagnin L, Lane J, Gorfinkel L, Adams BW, Kwun J, Lanieri L, Hoban MD, Lamothe TL, Hyzy SL, Olson LM, Panoskaltsis-Mortari A, Prockop SE, Blazar BR, Kean LS, Tkachev V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504994"},{"title01":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study","title02":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.287720. Online ahead of print.","author":"Bernaudin F, Arnaud C, Kamdem A, Youn J, Vasile M, Hau I, Madhi F, Malterre A, Delestrain C, Epaud R, Jung C, Verlhac S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568713"},{"title01":"TNF\u03b1 signaling restores steady-state hematopoiesis in a TNF\u03b1KO mouse model of anemia of inflammation","title02":"TNF\u03b1 signaling restores steady-state hematopoiesis in a TNF\u03b1KO mouse model of anemia of inflammation","journal":"Blood","issue":"2025 Jun 13:blood.2025029352. doi: 10.1182\/blood.2025029352. Online ahead of print.","author":"Guerra A, Lo Presti V, Chen DW, Martins AC, Rivera A, Hamilton N, Sharma P, Ginzburg YZ, Castruccio Castracani C, Casu C, Gupta R, Gozzelino R, Behrens EM, Bennett L, Paulson RF, Kurre P, Rivella S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40512402"},{"title01":"Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via up-regulating the PKA\/Orai1\/ERK1\/2 pathway","title02":"Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via up-regulating the PKA\/Orai1\/ERK1\/2 pathway","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2024.287287. Online ahead of print.","author":"Zhou M, Han H, Qi J, Zhang Z, Song X, Li X, Chu T, Wu D, Han Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534501"},{"title01":"Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries","title02":"Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.287408. Online ahead of print.","author":"Moulis G, Chen F, Carli G, Ghanima W, Trautmann-Grill K, Stauch T, Schifferli A, Miah H, Rueter M, Ghiotto L, Tomasello R, Georgi A, McDonald V, Zaja F, Pettersen HH, K\u00fchne T, Lozano ML, Gonz\u00e1lez-L\u00f3pez TJ, Provan D, Michel M, Cooper N, Rodeghiero F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568720"},{"title01":"Early response and long-term prognosis of paediatric ITP: Exploration of future management strategies","title02":"Early response and long-term prognosis of paediatric ITP: Exploration of future management strategies","journal":"Br J Haematol","issue":"2025 Jun 17. doi: 10.1111\/bjh.20209. Online ahead of print.","author":"Zhang M, Wang X, Pu T, Jiao X, Li T, Wei J, Cheng Y, Zhang W, Peng J, Zhang A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40524564"},{"title01":"Rilzabrutinib, the first-in-class BTK inhibitor for ITP","title02":"Rilzabrutinib, the first-in-class BTK inhibitor for ITP","journal":"Blood","issue":"2025 Jun 12;145(24):2810-2812.","author":"Michel M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504514"},{"title01":"Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed\/Refractory Large B-Cell Lymphoma: The Role of KIR Matching","title02":"Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed\/Refractory Large B-Cell Lymphoma: The Role of KIR Matching","journal":"J Clin Oncol","issue":"2025 Jun 23:JCO2500955. doi: 10.1200\/JCO-25-00955. Online ahead of print.","author":"Locke FL, Le Gall JB, Fisher PW, Neelapu SS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40549998"},{"title01":"Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study","title02":"Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study","journal":"J Clin Oncol","issue":"2025 Jun 13:JCO2500183. doi: 10.1200\/JCO-25-00183. Online ahead of print.","author":"de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, Rouanet J, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Labussi\u00e8re-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Mar\u00e7ais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Soci\u00e9 G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators, Groupe Fran\u00e7ais d\u2019Etude des Lymphomes Cutan\u00e9s and Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et Th\u00e9rapie Cellulaire.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40513043"},{"title01":"Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826","title02":"Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826","journal":"J Clin Oncol","issue":"2025 Jun 16:JCO2500204. doi: 10.1200\/JCO-25-00204. Online ahead of print.","author":"Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, Parsons SK, Unger JM, Perry AM, Casulo C, Bartlett NL, Tuscano JM, Hess BT, Torka P, Kumar P, Jacobs R, Song JY, Castellino SM, Kahl B, Leonard JP, Smith SM, Friedberg JW, Evens AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40523203"},{"title01":"Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study","title02":"Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study","journal":"J Clin Oncol","issue":"2025 Jun 18:JCO2500481. doi: 10.1200\/JCO-25-00481. Online ahead of print.","author":"Minson A, Verner E, Giri P, Butler J, Janowski W, Cheah CY, Ratnasingam S, Wong SM, Ku M, Hertzberg M, Herbert K, Hamad N, Yannakou CK, Swain F, Neeson P, Steiner TM, Saghebi J, Blombery P, Hunter SM, Robertson M, Lau LS, Bennett R, Harrop S, Xie J, Seymour JF, Dickinson MJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40532125"},{"title01":"Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patients","title02":"Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patients","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.288145. Online ahead of print.","author":"Atallah-Yunes SA, Rees MJ, Habermann TM, Wang Y, Munoz J, Iqbal M, Villasboas JC, McPhail ED, Witzig TE, Ansell SM, Nowakowski GS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534511"},{"title01":"Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma","title02":"Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma","journal":"Br J Haematol","issue":"2025 Jun 23. doi: 10.1111\/bjh.20231. Online ahead of print.","author":"Wei C, Zhang Y, Zhao D, Zhang W, Zhou D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40551559"},{"title01":"Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed\/refractory\u00a0large B-cell lymphoma, including in the CAR T-cell era","title02":"Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed\/refractory\u00a0large B-cell lymphoma, including in the CAR T-cell era","journal":"Br J Haematol","issue":"2025 Jun 25. doi: 10.1111\/bjh.20217. Online ahead of print.","author":"Molina F, Sureda A, Mussetti A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40557698"},{"title01":"Arborising telangiectasia in intravascular large B-cell lymphoma","title02":"Arborising telangiectasia in intravascular large B-cell lymphoma","journal":"Br J Haematol","issue":"2025 Jun 12. doi: 10.1111\/bjh.20172. Online ahead of print.","author":"Huiying Z, Congwei J, Yue C, Lu Z, Yan Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40506798"},{"title01":"The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas","title02":"The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20219. Online ahead of print.","author":"Lakhotia R, Melani C, Pittaluga S, Gordon MJ, Phelan JD, Muppidi JR, Tadese A, Evans S, Jaffe ES, Staudt LM, Wilson WH, Roschewski M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40524014"},{"title01":"Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group’s large B-cell lymphoma cohort","title02":"Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group’s large B-cell lymphoma cohort","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20111. Online ahead of print.","author":"Y\u0131lmaz U, Terzi Demirsoy E, Keklik Karada\u011f F, Hatipo\u011flu U, Uluk\u00f6yl\u00fc Meng\u00fc\u00e7 M, Pekg\u00fc\u00e7 E, Tan T, Nuho\u011flu Kantarc\u0131 E, Mastanzade M, Durdu A, Apayd\u0131n Kayer M, \u00d6zbalak M, Elverdi T, Y\u0131lmaz AF, G\u00f6ren D, Topta\u015f T, Ula\u015f T, Mehtap \u00d6, Dal MS, Akay OM, Ar MC, Saydam G, Altunta\u015f F, Birta\u015f Ate\u015fo\u011flu E, Ferhano\u011flu B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40524448"},{"title01":"Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma","title02":"Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287563. Online ahead of print.","author":"Feliciani G, Loi E, Amadori E, Antognoni E, Iamurri AP, Diano D, Bruno D, Cattabriga A, Caroli P, Marchesini M, Bezzi D, Cangini D, Matteucci F, Barone D, Nappi D, Musuraca G, Ceccolini M, Ronconi S, Azzali I, Martinelli G, Maffioli LS, Normanno N, Sarnelli A, Rossi A, Cerchione C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534490"},{"title01":"Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma","title02":"Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287985. Online ahead of print.","author":"Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R, Kwok M, Cicero KI, Hirayama AV, Basom R, Khouderchah C, Shadman M, Fong L, Cowan AJ, Gauthier J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534492"},{"title01":"Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma","title02":"Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.288008. Online ahead of print.","author":"Palacios JA, Bernal M, V\u00edlchez JR, Garrido P, Jim\u00e9nez P, Guti\u00e9rrez-Bautista JF, Barrera-Aguilera MC, Ballesta L, Rodr\u00edguez T, Olivares-Dur\u00e1n MJ, Ruiz-Cabello F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534500"},{"title01":"Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5\/8-CXCR2 axis","title02":"Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5\/8-CXCR2 axis","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.287312. Online ahead of print.","author":"Dong M, He D, Zhang J, Yan H, Chen H, Zhang E, Feng Y, He J, Huang X, Chen G, Sun X, Cheng F, Gu H, Wang H, Xie A, Cai Z, Lab C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568729"},{"title01":"Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies","title02":"Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies","journal":"Br J Haematol","issue":"2025 Jun 19. doi: 10.1111\/bjh.20218. Online ahead of print.","author":"Shameli A, Catey T, Woodings V, Koepke O, Fromm JR, Cherian S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40538116"},{"title01":"Can we identify individuals at risk to develop multiple myeloma? A\u00a0machine learning-based predictive model","title02":"Can we identify individuals at risk to develop multiple myeloma? A\u00a0machine learning-based predictive model","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20136. Online ahead of print.","author":"Mittelman M, Israel A, Oster HS, Leshchinsky M, Ben-Shlomo Y, Kepten E, Dolberg OJ, Balicer R, Shaham G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40524461"},{"title01":"A natural head start to MRD negativity in multiple myeloma","title02":"A natural head start to MRD negativity in multiple myeloma","journal":"Blood","issue":"2025 Jun 19;145(25):2936-2937..","author":"Meermeier EW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40536779"},{"title01":"Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST","title02":"Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST","journal":"Blood","issue":"2025 Jun 12:blood.2025028330. doi: 10.1182\/blood.2025028330. Online ahead of print.","author":"Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, von Tresckow B, Wulf GG, Weisel KC, Blau I, Engelhardt M, W\u00e4sch R, Schub N, Teipel R, Hecker JS, Waldschmidt JM, Besemer B, Baermann BN, Call S, Hansmann L, Ayuk FA, Raab MS, Einsele H, Platzbecker U, Kr\u00f6ger N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504993"},{"title01":"Autologous Transplantation of the Entire Bulbar Ocular Surface","title02":"Autologous Transplantation of the Entire Bulbar Ocular Surface","journal":"N Engl J Med","issue":"2025 Jun 26;392(24):2487-2489.","author":"Sarnicola E, Sarnicola C, Machetta F, Reibaldi M, Sarnicola V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40561537"},{"title01":"Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin","title02":"Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin","journal":"N Engl J Med","issue":"2025 Jun 13. doi: 10.1056\/NEJMoa2503189. Online ahead of print.","author":"Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR; Australasian Leukaemia and Lymphoma Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40513032"},{"title01":"Case 17-2025: A 61-Year-Old Man with Respiratory Failure and Shock after Kidney Transplantation","title02":"Case 17-2025: A 61-Year-Old Man with Respiratory Failure and Shock after Kidney Transplantation","journal":"N Engl J Med","issue":"2025 Jun 19;392(23):2368-2378.","author":"Kotton CN, Cochran RL, Sanders AM, Safa K, Roth MT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40532155"},{"title01":"Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation","title02":"Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation","journal":"J Clin Oncol","issue":"2025 Jun 23:JCO2500378. doi: 10.1200\/JCO-25-00378. Online ahead of print.","author":"El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb J, Fausto J, Traeger L, Greer JA, Jackson V, Horick N, Rabideau DJ, Fenech A, Newcomb R, Ufere NN, Caruso E, Pepper J, DeFilipp Z, Chen YB, Lee SJ, Temel JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40549982"},{"title01":"Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study","title02":"Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study","journal":"J Clin Oncol","issue":"2025 Jun 25:JCO2402477. doi: 10.1200\/JCO-24-02477. Online ahead of print.","author":"Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40561385"},{"title01":"Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study","title02":"Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study","journal":"J Clin Oncol","issue":"2025 Jun 13:JCO2500183. doi: 10.1200\/JCO-25-00183. Online ahead of print.","author":"de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, Rouanet J, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Labussi\u00e8re-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Mar\u00e7ais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Soci\u00e9 G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators, Groupe Fran\u00e7ais d\u2019Etude des Lymphomes Cutan\u00e9s and Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et Th\u00e9rapie Cellulaire.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40513043"},{"title01":"Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","title02":"Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","journal":"J Clin Oncol","issue":"2025 Jun 16:JCO2500856. doi: 10.1200\/JCO-25-00856. Online ahead of print.","author":"Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, Leckrone E, Wu J, Stefanski HE, Auletta JJ, Spellman SR, Malmberg C, Askar M, Cusatis R, Shaffer BC, Modi D, Khimani F, Gooptu M, Hamadani M, Madbouly A, Maiers M, Fingerson S, Cook R, Ballen K, Loren A, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Shaw BE, Devine SM, Jimenez Jimenez AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40523209"},{"title01":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study","title02":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287457. Online ahead of print.","author":"Maahs L, Avila AM, Koshy M, Sweiss K, Ahn KH, Chen Z, Uzoka C, Galvez C, Sanchez M, Rubinstein P, Quigley J, Zucchetti E, Mahmud N, Aydogan B, Patel P, Rondelli D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534485"},{"title01":"Randomized trial of anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease in haploidentical transplantation","title02":"Randomized trial of anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease in haploidentical transplantation","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287504. Online ahead of print.","author":"Xu ZL, Han TT, Zhu XL, Liu J, Lv M, Sun YQ, Mo XD, Cheng YF, Xu LP, Zhang XH, Huang XJ, Wang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534493"},{"title01":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-word data study","title02":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-word data study","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.288067. Online ahead of print.","author":"Masetti R, Barbara G, Muratore E, Marasco G, Cremon C, Marangoni A, Brigidi P, Putignani L, Angelino G, Quagliarella F, Galaverna F, Leardini D, Lazzarotto T, Gabelli M, Savarino E, Zecca M, Faraci M, Prete A, Biffi A, Locatelli F, Merli P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568731"},{"title01":"A prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation","title02":"A prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Jun 18. doi: 10.1111\/bjh.20215. Online ahead of print.","author":"Velasco CM, Inoue Y, Cioccio J, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Ehmann C, Mierski J, Silar B, Vajdic C, Greiner R, Brown V, Mineishi S, Shike H, Minagawa K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534233"},{"title01":"Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed\/refractory\u00a0large B-cell lymphoma, including in the CAR T-cell era","title02":"Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed\/refractory\u00a0large B-cell lymphoma, including in the CAR T-cell era","journal":"Br J Haematol","issue":"2025 Jun 25. doi: 10.1111\/bjh.20217. Online ahead of print.","author":"Molina F, Sureda A, Mussetti A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40557698"},{"title01":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study","title02":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287457. Online ahead of print.","author":"Maahs L, Avila AM, Koshy M, Sweiss K, Ahn KH, Chen Z, Uzoka C, Galvez C, Sanchez M, Rubinstein P, Quigley J, Zucchetti E, Mahmud N, Aydogan B, Patel P, Rondelli D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534485"},{"title01":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-word data study","title02":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-word data study","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.288067. Online ahead of print.","author":"Masetti R, Barbara G, Muratore E, Marasco G, Cremon C, Marangoni A, Brigidi P, Putignani L, Angelino G, Quagliarella F, Galaverna F, Leardini D, Lazzarotto T, Gabelli M, Savarino E, Zecca M, Faraci M, Prete A, Biffi A, Locatelli F, Merli P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568731"},{"title01":"A prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation","title02":"A prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation","journal":"Br J Haematol","issue":"2025 Jun 18. doi: 10.1111\/bjh.20215. Online ahead of print.","author":"Velasco CM, Inoue Y, Cioccio J, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Ehmann C, Mierski J, Silar B, Vajdic C, Greiner R, Brown V, Mineishi S, Shike H, Minagawa K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534233"},{"title01":"Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed\/refractory\u00a0large B-cell lymphoma, including in the CAR T-cell era","title02":"Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed\/refractory\u00a0large B-cell lymphoma, including in the CAR T-cell era","journal":"Br J Haematol","issue":"2025 Jun 25. doi: 10.1111\/bjh.20217. Online ahead of print.","author":"Molina F, Sureda A, Mussetti A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40557698"},{"title01":"Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy","title02":"Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20208. Online ahead of print.","author":"Konuma T, Shimomura Y, Mizuno S, Yamasaki S, Yui S, Uchida N, Doki N, Tanaka M, Yoshihara S, Eto T, Katayama Y, Katsuoka Y, Tokunaga M, Ota S, Sakata-Yanagimoto M, Ishiwata K, Kanda Y, Kawakita T, Onizuka M, Kanda J, Fukuda T, Atsuta Y, Yanada M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40518826"},{"title01":"Precision pre-HSCT conditioning by targeting cMPL","title02":"Precision pre-HSCT conditioning by targeting cMPL","journal":"Blood","issue":"2025 Jun 19;145(25):2933-2934.","author":"Manz MG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40536782"},{"title01":"Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia","title02":"Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia","journal":"Leukemia","issue":"2025 Jun 23. doi: 10.1038\/s41375-025-02611-9. Online ahead of print.","author":"Mashima K, Kuang Y, Fernandes SM, Xu S, Hanna B, Shupe S, Mikhaleva M, Santos RA, Predko P, Fardoun R, Bidgoli A, Martindale SP, Naeem A, Davids MS, Paweletz C, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40550846"},{"title01":"Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia","title02":"Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia","journal":"Leukemia","issue":"Leukemia. 2025 Jun 24. doi: 10.1038\/s41375-025-02663-x. Online ahead of print.","author":"Lebon D, Da Rocha A, Cassinat B, Heiblig M, Bertoli S, Bonmati C, Zilliox A, Laloi M, Berthon C, Duployez N, Willekens C, Hernanz MPG, Ochmann M, Cluzeau T, Chermat F, Caulier A, R\u00e9cher C, Hunault-Berger M, Raffoux E, Fenaux P, Marolleau JP, Ad\u00e8s L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40555732"},{"title01":"Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice","title02":"Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice","journal":"Leukemia","issue":"2025 Jun 24. doi: 10.1038\/s41375-025-02662-y. Online ahead of print.","author":"Blombery P, Chatzikonstantinou T, Gerousi M, Rosenquist R, Gaidano G, Pospisilova S, Roberts AW, Birkinshaw RW, Rossi D, Scarfo L, Seymour JF, Stilgenbauer S, Wiestner A, Woyach JA, Brown JR, Ghia P, Stamatopoulos K; ERIC, the European Research Initiative on CLL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40555733"},{"title01":"Critical roles of IKAROS and HDAC1 in regulation of heterochromatin and tumor suppression in T-cell acute lymphoblastic leukemia","title02":"Critical roles of IKAROS and HDAC1 in regulation of heterochromatin and tumor suppression in T-cell acute lymphoblastic leukemia","journal":"Leukemia","issue":"2025 Jun 24. doi: 10.1038\/s41375-025-02651-1. Online ahead of print.","author":"Ding Y, He B, Bogush D, Schramm J, Singh C, Dovat K, Randazzo J, Tukaramrao D, Hengst J, Annageldiyev C, Kudva A, Desai D, Sharma A, Spiegelman VS, Huang S, Viet CT, Dorsam G, Saulnier Scholler G, Broach J, Yue F, Dovat S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40555735"},{"title01":"The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia","title02":"The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia","journal":"Leukemia","issue":"2025 Jun 25. doi: 10.1038\/s41375-025-02657-9. Online ahead of print.","author":"Yu H, Hong J, Shin DY, Lee CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40562788"},{"title01":"Sugar free transforming growth factor \u03b21 increases the fitness of myelodysplastic neoplasm \/ acute myeloid leukemia cells","title02":"Sugar free transforming growth factor \u03b21 increases the fitness of myelodysplastic neoplasm \/ acute myeloid leukemia cells","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.288156. Online ahead of print.","author":"Solary E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568718"},{"title01":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial","title02":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.287386. Online ahead of print.","author":"Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568722"},{"title01":"Asciminib for Philadelphia chromosome-positive leukemias","title02":"Asciminib for Philadelphia chromosome-positive leukemias","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2024.286798. Online ahead of print.","author":"Hughes TP, White DL, Yeung DT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568725"},{"title01":"Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice","title02":"Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice","journal":"Haematologica","issue":"2025 Jun 26. doi: 10.3324\/haematol.2025.287799. Online ahead of print.","author":"Frustaci AM, Galitzia A, Lucignano M, Appio L, Olivieri J, Sanna A, Barat\u00e9 C, Pane F, Schiattone L, Casadei B, Ferrarini I, Figuera A, Sportoletti P, Loseto G, Stelitano C, Visentin A, Celli M, Mauro FR, Palombi M, Coscia M, Innao V, Moia R, Motta M, Russo F, Tani M, Arcari A, Boccellato E, Borella C, Capochiani E, Ferrari A, Gentile M, Giachetti R, Giordano A, Bullo M, Lista E, Malandruccolo L, Musso M, Varettoni M, Vozella F, Cibien F, Merli M, Nocilli L, Pasquini MC, Romeo AA, Rossi V, Turri G, Vanazzi A, Cavaliere M, Gozzetti A, Crucitti L, Lucesole M, Deodato M, Tomasso A, Zappaterra A, Murru R, Patti C, Laurenti L, Tedeschi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568727"},{"title01":"Clinical management of CMML-State of the art","title02":"Clinical management of CMML-State of the art","journal":"Br J Haematol","issue":"2025 Jun 24. doi: 10.1111\/bjh.20213. Online ahead of print.","author":"Nachtkamp K, Schulz F, Gattermann N, Germing U.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40556336"},{"title01":"Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy","title02":"Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20208. Online ahead of print.","author":"Konuma T, Shimomura Y, Mizuno S, Yamasaki S, Yui S, Uchida N, Doki N, Tanaka M, Yoshihara S, Eto T, Katayama Y, Katsuoka Y, Tokunaga M, Ota S, Sakata-Yanagimoto M, Ishiwata K, Kanda Y, Kawakita T, Onizuka M, Kanda J, Fukuda T, Atsuta Y, Yanada M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40518826"},{"title01":"Efficacy and safety of oral decitabine\/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies","title02":"Efficacy and safety of oral decitabine\/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies","journal":"Br J Haematol","issue":"2025 Jun 16. doi: 10.1111\/bjh.20203. Online ahead of print.","author":"Savona MR, Odenike O, Roboz GJ, Amin H, DeZern AE, Griffiths EA, Dao KH, Zeidan AM, Bhatnagar B, Buckstein R, Leber B, Keating MM, Ball S, Oganesian A, Sano Y, Keer HN, Garcia-Manero G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40524338"},{"title01":"Access to AlloTx for AML: the value of the social phenotype","title02":"Access to AlloTx for AML: the value of the social phenotype","journal":"Blood","issue":"2025 Jun 19;145(25):2941-2942.","author":"Schiller G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40536784"},{"title01":"Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors","title02":"Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors","journal":"Blood","issue":"2025 Jun 20:blood.2024026417. doi: 10.1182\/blood.2024026417. Online ahead of print.","author":"Andricovich J, Lap CJ, Tzatsos A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40540751"},{"title01":"Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML","title02":"Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML","journal":"Blood","issue":"2025 Jun 25:blood.2024026113. doi: 10.1182\/blood.2024026113. Online ahead of print.","author":"Damaskou A, Wilson R, Gozdecka M, Giotopoulos G, Asby R, Eleftheriou M, Gu M, R\u00e9cher C, Mansat-De Mas V, Vergez F, Sahal A, Vick B, Papachristou EK, Sawle A, Yankova E, Dudek M, Liu X, Russell J, Rak J, Hilcenko C, D'Santos CS, Jeremias I, Sarry JE, Tzelepis K, Huntly BJ, Warren AJ, Tavana O, Vassiliou GS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40561247"},{"title01":"A small B-cell leukemia\/lymphoma with weak to negative expression of CD5","title02":"A small B-cell leukemia\/lymphoma with weak to negative expression of CD5","journal":"Blood","issue":"2025 Jun 12;145(24):2931.","author":"Selvarajah S, Xia D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504509"},{"title01":"Introduction to a Blood Spotlight series on acute myeloid leukemia","title02":"Introduction to a Blood Spotlight series on acute myeloid leukemia","journal":"Blood","issue":"2025 Jun 12;145(24):2801-2802.","author":"Luger SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504510"},{"title01":"Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes","title02":"Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes","journal":"Leukemia","issue":"2025 Jun 25. doi: 10.1038\/s41375-025-02666-8. Online ahead of print.","author":"Pepe S, Vitale C, Giannarelli D, Visentin A, Sanna A, Frustaci AM, Olivieri J, Quaglia FM, Gozzetti A, Sportoletti P, Murru R, Innocenti I, Reda G, Pupo L, Levato L, Porrazzo M, Ilariucci F, Moia R, Foglietta M, Rigolin GM, Chiurazzi F, Trastulli F, Cellini A, Deodato M, Martino E, Laurenti L, Coscia M, Cuneo A, Gaidano G, Rossi D, Gentile M, Mauro FR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40562789"},{"title01":"Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed\/Refractory Large B-Cell Lymphoma: The Role of KIR Matching","title02":"Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed\/Refractory Large B-Cell Lymphoma: The Role of KIR Matching","journal":"J Clin Oncol","issue":"2025 Jun 23:JCO2500394. doi: 10.1200\/JCO-25-00394. Online ahead of print.","author":"Shimazu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40549996"},{"title01":"Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphoma","title02":"Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphoma","journal":"Br J Haematol","issue":"2025 Jun 17. doi: 10.1111\/bjh.20207. Online ahead of print.","author":"Chung K, Ng LS, Yee CI, Bansal R, Kharfan-Dabaja MA, Nowakowski GS, Rosenthal AC, Munoz J, Castro J, Ng WL, Murthy HS, Iqbal M, Lin Y, Wang Y, Hilal T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40524548"},{"title01":"Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma","title02":"Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma","journal":"Blood","issue":"2025 Jun 20:blood.2025028412. doi: 10.1182\/blood.2025028412. Online ahead of print.","author":"Rai S, Duns G, Frontzek F, Wong JCH, Yin Y, Li MY, Kishida M, Fujisawa M, Healy S, Vigan\u00f2 E, Jiang A, Woolcock B, Telenius A, Ben-Neriah S, Meissner B, Boyle M, Nakamura H, O Brien L, Cassidy C, Lytle A, Farinha P, Slack GW, Hilton LK, Morin RD, Venturutti L, Aoki T, Wretham N, Bush JW, Evgin L, Savage KJ, Scott DW, Steidl C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40540746"},{"title01":"A small B-cell leukemia\/lymphoma with weak to negative expression of CD5","title02":"A small B-cell leukemia\/lymphoma with weak to negative expression of CD5","journal":"Blood","issue":"2025 Jun 12;145(24):2931.","author":"Selvarajah S, Xia D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504509"},{"title01":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","title02":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","journal":"Blood","issue":"2025 Jun 12:blood.2025028375. doi: 10.1182\/blood.2025028375. Online ahead of print.","author":"M\u00fcller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A, Taubmann J, Kretschmann S, Kharboutli S, Krickau T, Naumann-Bartsch N, Benintende G, Spoerl S, Rothe T, Bruns H, Grieshaber-Bouyer R, Metzler M, Blumenthal DB, Graw F, Schett G, Mackensen A, V\u00f6lkl S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40504989"},{"title01":"First-in-world Trojan horse drug offered to multiple myeloma patients in England","title02":"First-in-world Trojan horse drug offered to multiple myeloma patients in England","journal":"Lancet Oncol","issue":"2025 Jun 19:S1470-2045(25)00373-0. doi: 10.1016\/S1470-2045(25)00373-0. Online ahead of print.","author":"Burki T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40544850"},{"title01":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia","title02":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia","journal":"N Engl J Med","issue":"2025 Jun 15. doi: 10.1056\/NEJMoa2504341. Online ahead of print.","author":"Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, Gohil S, Paneesha S, Pettitt A, Eyre T, Fox CP, Forconi F, Balotis C, Pemberton N, Sheehy O, Gribben J, Elmusharaf N, Gatto S, Preston G, Schuh A, Walewska R, Duley L, Webster N, Dalal S, Rawstron A, Howard D, Hockaday A, Jackson S, Greatorex N, Bell S, Stones D, Brown JM, Patten PEM, Hillmen P; UK CLL Trials Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40521799"},{"title01":"Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes","title02":"Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes","journal":"Leukemia","issue":"2025 Jun 25. doi: 10.1038\/s41375-025-02666-8. Online ahead of print.","author":"Pepe S, Vitale C, Giannarelli D, Visentin A, Sanna A, Frustaci AM, Olivieri J, Quaglia FM, Gozzetti A, Sportoletti P, Murru R, Innocenti I, Reda G, Pupo L, Levato L, Porrazzo M, Ilariucci F, Moia R, Foglietta M, Rigolin GM, Chiurazzi F, Trastulli F, Cellini A, Deodato M, Martino E, Laurenti L, Coscia M, Cuneo A, Gaidano G, Rossi D, Gentile M, Mauro FR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40562789"},{"title01":"Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia","title02":"Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia","journal":"Leukemia","issue":"2025 Jun 18. doi: 10.1038\/s41375-025-02650-2. Online ahead of print.","author":"Vit F, Bittolo T, Zucchetto A, Papotti R, Tissino E, Pozzo F, Gaglio A, Stacchetti A, Zaina E, Cattarossi I, Varaschin P, Nanni P, Berton M, Braida A, Rossi FM, Degan M, Polesel J, Laureana R, Chiarenza A, Olivieri J, Biagi A, D'Arena G, Rossi M, Laurenti L, Tafuri A, Bulian P, Zam\u00f2 A, Leich E, Rosenwald A, Arons E, Kreitman R, Gentile M, Postorino M, Zaja F, Di Raimondo F, Del Principe MI, Gattei V, Bomben R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40533497"},{"title01":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","title02":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","journal":"Lancet Haematol","issue":"2025 Jun 13:S2352-3026(25)00144-9. doi: 10.1016\/S2352-3026(25)00144-9. Online ahead of print.","author":"Jabbour E, Lussana F, Mart\u00ednez-S\u00e1nchez P, Torrent A, Rif\u00f3n JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hern\u00e1ndez-Rivas JM, Rijneveld A, Fleming S, Vucinic V, B\u00f6ll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, Gonz\u00e1lez-Campos J, Chen Y, Wong H, Choudhry J, Zugmaier G, Guest E, Gordon P, Kantarjian H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40532723"},{"title01":"Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML","title02":"Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML","journal":"J Clin Oncol","issue":"2025 Jun 13:JCO2500640. doi: 10.1200\/JCO-25-00640. Online ahead of print.","author":"DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40513054"},{"title01":"The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells","title02":"The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.287352. Online ahead of print.","author":"Gil KB, Borg J, Pereira RM, Inguva-Sheth A, Araujo G, Rahkola J, Showers W, Grier A, D'Alessandro A, Smith C, McMahon C, Pollyea DA, Gillen AE, Amaya ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534505"},{"title01":"Olverembatinib in chronic myeloid leukemia: is less actually better?","title02":"Olverembatinib in chronic myeloid leukemia: is less actually better?","journal":"Haematologica","issue":"2025 Jun 19. doi: 10.3324\/haematol.2025.288065. Online ahead of print.","author":"Perusini MA, Kim DDH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534512"},{"title01":"Zanubrutinib and Venetoclax for Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With and Without Del(17p)\/TP53 Mutation: SEQUOIA Arm D Results","title02":"Zanubrutinib and Venetoclax for Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With and Without Del(17p)\/TP53<\/i> Mutation: SEQUOIA Arm D Results","journal":"J Clin Oncol","issue":"2025 May 31:JCO2500758. doi: 10.1200\/JCO-25-00758. Online ahead of print.","author":"Shadman M, Munir T, Ma S, Lasica M, Tani M, Robak T, Flinn IW, Brown JR, Ghia P, Ferrant E, Tam CS, Janowski W, Jurczak W, Xu L, Tian T, Lefebure M, Agresti S, Hirata J, Tedeschi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40448577"},{"title01":"Atypical acute promyelocytic leukemia with tripartite fusion gene PML::RARG::LINE-L2a is resistant to ATRA but sensitive to arsenic-based therapy","title02":"Atypical acute promyelocytic leukemia with tripartite fusion gene PML::RARG::LINE-L2a<\/i> is resistant to ATRA but sensitive to arsenic-based therapy","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2025.287318. Online ahead of print.","author":"Wu S, Yu Y, Lin X, Zhou X, Zhou Y, Luo P, Shen H, He J, Liu L, Liu X, Zhang DL, Liu Y, Xiao H, Zhou F, Liu H, Zhang Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501402"},{"title01":"Zanubrutinib and Venetoclax for Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With and Without Del(17p)\/TP53 Mutation: SEQUOIA Arm D Results","title02":"Zanubrutinib and Venetoclax for Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With and Without Del(17p)\/TP53<\/i> Mutation: SEQUOIA Arm D Results","journal":"J Clin Oncol","issue":"2025 May 31:JCO2500758. doi: 10.1200\/JCO-25-00758. Online ahead of print.","author":"Shadman M, Munir T, Ma S, Lasica M, Tani M, Robak T, Flinn IW, Brown JR, Ghia P, Ferrant E, Tam CS, Janowski W, Jurczak W, Xu L, Tian T, Lefebure M, Agresti S, Hirata J, Tedeschi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40448577"},{"title01":"Graft-versus-leukemia","title02":"Graft-versus<\/i>-leukemia","journal":"Haematologica","issue":"2025 Jun 1;110(6):1243-1244.","author":"Appelbaum FR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40458939"},{"title01":"Graft-versus-leukemia","title02":"Graft-versus<\/i>-leukemia","journal":"Haematologica","issue":"2025 Jun 1;110(6):1243-1244.","author":"Appelbaum FR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40458939"},{"title01":"Towards graft-versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia","title02":"Towards graft-versus<\/i>-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2024.286544. Online ahead of print.","author":"Oved JH, Bacigalupo A, DeZern AE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438974"},{"title01":"EASIX score predicts non-relapse mortality and severe infection in elderly patients undergoing allo-HSCT","title02":"EASIX score predicts non-relapse mortality and severe infection in elderly patients undergoing allo-HSCT","journal":"Br J Haematol","issue":"2025 Jun 10. doi: 10.1111\/bjh.20210. Online ahead of print.","author":"Liu L, Xiang S, Cao J, Lai X, Shi J, Zhao Y, Yu J, Yang L, Zhang P, Ye B, Wang X, Shi P, Xiao H, Fu H, Wu Y, Chen Y, Xu Y, Hu H, Jiang H, Tan Y, Lan J, Ouyang G, Lu Y, Huang H, Luo Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40495403"},{"title01":"Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)","title02":"Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)","journal":"Br J Haematol","issue":"2025 Jun 11. doi: 10.1111\/bjh.20199. Online ahead of print.","author":"Kazmi M, Muraro PA, Mehra V, Gabriel I, De Matteis E, Brittain G, Mariottini A, Nicholas R, Silber E, Lee J, Pearce R, Paul R, Sormani MP, Signori A, Potter V, Olavarria E, Malladi R, Sharrack B, Snowden JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40500866"},{"title01":"Real-world clinical experience with NGS-based chimerism analyses in haematopoietic stem cell transplant patients","title02":"Real-world clinical experience with NGS-based chimerism analyses in haematopoietic stem cell transplant patients","journal":"Br J Haematol","issue":"2025 Jun 4. doi: 10.1111\/bjh.20191. Online ahead of print.","author":"Kim JJ, Kwon SS, Choi YJ, Kang Y, Park YJ, Shin S, Lee ST, Choi JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40464116"},{"title01":"Higher risk of platelet engraftment failure and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T-cell therapy compared to chemotherapy: A propensity score-matched analysis","title02":"Higher risk of platelet engraftment failure and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T-cell therapy compared to chemotherapy: A propensity score-matched analysis","journal":"Br J Haematol","issue":"2025 Jun 4. doi: 10.1111\/bjh.20180. Online ahead of print.","author":"Yang L, Lai X, Liu L, Shi J, Zhao Y, Yu J, Wu Y, Fu H, Hu Y, Zhang M, Huang H, Luo Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40464130"},{"title01":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","title02":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","journal":"Blood","issue":"2025 Jun 9:blood.2025028617. doi: 10.1182\/blood.2025028617. Online ahead of print.","author":"Soci\u00e9 G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40489636"},{"title01":"BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy","title02":"BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy","journal":"N Engl J Med","issue":"2025 Jun 12;392(22):2282-2284.","author":"Zhang L, Gao Z, Pan H, Li R, Fang L, Li W, Zhao J, Yu X, Kuang Z, Nie N, Li J, Huang J, Zhao X, Ge M, Zheng Y, Luo Y, Shi J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40499177"},{"title01":"Debating Race and the Diagnosis of Anemia – How Medicine Moved Away from Race-Based Standards","title02":"Debating Race and the Diagnosis of Anemia – How Medicine Moved Away from Race-Based Standards","journal":"N Engl J Med","issue":"2025 Jun 5;392(21):2168-2173.","author":"Xue W, Jones DS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40466072"},{"title01":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial","title02":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2024.287055. Online ahead of print.","author":"Mei C, Xu G, Zheng C, Xie Y, Li M, Shao Y, Yao R, Tao S, Jiang W, Guo J, Zheng Z, Wang W, Zhou X, Ma L, Ye L, Luo Y, Yang C, Yu W, Xie W, Jin J, Tong H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501398"},{"title01":"Towards graft-versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia","title02":"Towards graft-versus<\/i>-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2024.286544. Online ahead of print.","author":"Oved JH, Bacigalupo A, DeZern AE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438974"},{"title01":"Increased ultra-large von Willebrand factor multimers in immune thrombocytopenia","title02":"Increased ultra-large von Willebrand factor multimers in immune thrombocytopenia","journal":"Br J Haematol","issue":"2025 Jun 10. doi: 10.1111\/bjh.20205. Online ahead of print.","author":"Garabet L, Ghanima W, Bussel J, Tran H, Brodin E, Mathisen \u00c5B, Lae S, Le MS, Hillarp A, Henriksson CE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40494825"},{"title01":"Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study","title02":"Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287506. Online ahead of print.","author":"Shan X, Kuiper R, Ding C, Munshi PN, Stadtmauer EA, Susanibar-Adaniya SP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438975"},{"title01":"Radiation therapy to manage isolated relapse after chimeric antigen receptor T-cell therapy in multiple myeloma","title02":"Radiation therapy to manage isolated relapse after chimeric antigen receptor T-cell therapy in multiple myeloma","journal":"Haematologica","issue":"2025 Jun 5. doi: 10.3324\/haematol.2025.287358. Online ahead of print.","author":"Srinivas S, Zhu LL, Raje N, Patel CG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468959"},{"title01":"Outcomes for unselected, newly diagnosed multiple myeloma patients","title02":"Outcomes for unselected, newly diagnosed multiple myeloma patients","journal":"Haematologica","issue":"2025 Jun 5. doi: 10.3324\/haematol.2025.287458. Online ahead of print.","author":"Moore JT, Mettias SM, Cheung J, Swift R, Eades B, Eshaghian S, Schwartz G, Berenson JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468965"},{"title01":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis","title02":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287485. Online ahead of print.","author":"De Groot FA, Stedema FG, Kret EJ, De Haan LM, Jansen PM, B\u00f6hringer S, Diepstra A, Van der Poel MWM, Hamid MA, Te Boome LCJ, Terpstra V, Brink M, Veelken H, De Groen RAL, Dekker TJA, Nijland M, Vermaat JSP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438976"},{"title01":"Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed\/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)","title02":"Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed\/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)","journal":"Br J Haematol","issue":"2025 Jun 10. doi: 10.1111\/bjh.20204. Online ahead of print.","author":"Novo M, Frascione PMM, Castellino A, Marcheselli L, Dattoli SD, Vannucchi M, Rota-Scalabrini D, Tucci A, Gini G, Tarantini G, Mannina D, Arcari A, Liso A, Scarpa E, Marino D, Spina M, Gorgone A, Di Renzo N, Mancuso S, Petrucci L, Tafuri A, Botto B, Bonello F, Santambrogio E, Vitolo U.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40495420"},{"title01":"Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)","title02":"Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)","journal":"Br J Haematol","issue":"2025 Jun 11. doi: 10.1111\/bjh.20199. Online ahead of print.","author":"Kazmi M, Muraro PA, Mehra V, Gabriel I, De Matteis E, Brittain G, Mariottini A, Nicholas R, Silber E, Lee J, Pearce R, Paul R, Sormani MP, Signori A, Potter V, Olavarria E, Malladi R, Sharrack B, Snowden JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40500866"},{"title01":"Low rates of endothelial cell dysfunction and transplant-related mortality in 537 children receiving fludarabine-treosulfan conditioning for all transplant indications: A retrospective multicentre study on behalf of the UK Paediatric BMT group","title02":"Low rates of endothelial cell dysfunction and transplant-related mortality in 537 children receiving fludarabine-treosulfan conditioning for all transplant indications: A retrospective multicentre study on behalf of the UK Paediatric BMT group","journal":"Br J Haematol","issue":"2025 Jun 1. doi: 10.1111\/bjh.20184. Online ahead of print.","author":"Altmann T, Rao K, Hanasoge-Nataraj R, Patrick K, Carpenter B, Hough R, Ewins AM, Tewari S, Mirci-Danicar O, Slatter M, Wynn R, Lum SH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40452282"},{"title01":"Real-world clinical experience with NGS-based chimerism analyses in haematopoietic stem cell transplant patients","title02":"Real-world clinical experience with NGS-based chimerism analyses in haematopoietic stem cell transplant patients","journal":"Br J Haematol","issue":"2025 Jun 4. doi: 10.1111\/bjh.20191. Online ahead of print.","author":"Kim JJ, Kwon SS, Choi YJ, Kang Y, Park YJ, Shin S, Lee ST, Choi JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40464116"},{"title01":"Higher risk of platelet engraftment failure and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T-cell therapy compared to chemotherapy: A propensity score-matched analysis","title02":"Higher risk of platelet engraftment failure and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T-cell therapy compared to chemotherapy: A propensity score-matched analysis","journal":"Br J Haematol","issue":"2025 Jun 4. doi: 10.1111\/bjh.20180. Online ahead of print.","author":"Yang L, Lai X, Liu L, Shi J, Zhao Y, Yu J, Wu Y, Fu H, Hu Y, Zhang M, Huang H, Luo Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40464130"},{"title01":"The advent of multiomics in experimental transplantation","title02":"The advent of multiomics in experimental transplantation","journal":"Blood","issue":"2025 Jun 5;145(23):2681-2682.","author":"Socie G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40471623"},{"title01":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","title02":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","journal":"Blood","issue":"2025 Jun 9:blood.2025028617. doi: 10.1182\/blood.2025028617. Online ahead of print.","author":"Soci\u00e9 G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40489636"},{"title01":"BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation","title02":"BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation","journal":"J Clin Oncol","issue":"2025 May 30:JCO2500713. doi: 10.1200\/JCO-25-00713. Online ahead of print.","author":"Jacobs JM, Traeger L, Freese M, Barata A, Newcomb R, Rabideau D, Horick N, DeFilipp Z, Chen YB, Gray T, Pepper J, Caruso E, Amonoo HL, Lee SJ, Greer JA, Temel JS, El-Jawahri A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40444925"},{"title01":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis","title02":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287485. Online ahead of print.","author":"De Groot FA, Stedema FG, Kret EJ, De Haan LM, Jansen PM, B\u00f6hringer S, Diepstra A, Van der Poel MWM, Hamid MA, Te Boome LCJ, Terpstra V, Brink M, Veelken H, De Groen RAL, Dekker TJA, Nijland M, Vermaat JSP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438976"},{"title01":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor","title02":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor","journal":"Haematologica","issue":"2025 Jun 5. doi: 10.3324\/haematol.2025.287637. Online ahead of print.","author":"Stenzinger M, Beck S, Ourailidis I, Volckmar AL, Paramasivam N, Ahadova A, Portilla ALL, La Yen P, Nilsson B, Bermejo JL, Bonig H, Budczies J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468967"},{"title01":"Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","title02":"Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2025.288284. Online ahead of print.","author":"Lia K, J\u00f8rgensen RRK, Wikman P, Wold BL, \u00d6vergaard N, Fluge \u00d8, Fagerli UM, Bersvendsen H, B\u00f8 IB, Bhargava S, Molin D, Foss\u00e5 A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501391"},{"title01":"Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia\/lymphoma","title02":"Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia\/lymphoma","journal":"Br J Haematol","issue":"2025 Jun 3. doi: 10.1111\/bjh.20177. Online ahead of print.","author":"Dittus C, Weinstock MJ, Barnes J, Sandoval-Sus J, Grover NS, Beaven A, Hoye K, Shelton A, Tan X, Srinivasan MD, El-Jawahri A, Sarosiek S, Sloan JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40459047"},{"title01":"Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease","title02":"Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease","journal":"Blood","issue":"2025 Jun 5;145(23):2799.","author":"Kitagawa Y, Jaffe ES.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40471621"},{"title01":"Exploiting tumor-derived IL-10 activity in lymphoma therapy","title02":"Exploiting tumor-derived IL-10 activity in lymphoma therapy","journal":"Blood","issue":"2025 Jun 5;145(23):2676-2678.","author":"Tooze R, Klein U.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40471622"},{"title01":"Burkitt lymphoma: click here to add to CAR-T?","title02":"Burkitt lymphoma: click here to add to CAR-T?","journal":"Blood","issue":"2025 Jun 5;145(23):2678-2680.","author":"Hawkes EA, Gregory GP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40471624"},{"title01":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","title02":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","journal":"Blood","issue":"2025 Jun 11:blood.2024027727. doi: 10.1182\/blood.2024027727. Online ahead of print.","author":"Claudel A, Cottereau AS, Bachy E, Itti E, Feugier P, Rossi C, Lemonnier F, Camus V, Daguindau N, Cartron G, Nicolas Virelizier E, Mbouma DL, Cardoso C, Bommier C, Tessoulin B, Fruchart C, Gilbert A, Durot E, Fleck E, Pica GM, Zerazhi H, Guidez S, Cheminant M, Sarkozy C, Xerri L, Vercellino L, Trabelsi N, Gomes L, Portugues C, Viailly PJ, Delfau-Larue MH, Morschhauser F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40499012"},{"title01":"Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma","title02":"Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma","journal":"Blood","issue":"2025 May 29;145(22):2671.","author":"Shah B, Nejati R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40440039"},{"title01":"Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma","title02":"Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma","journal":"N Engl J Med","issue":"2025 Jun 3. doi: 10.1056\/NEJMoa2505133. Online ahead of print.","author":"Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Mohty M, Leleu X, Manier S, Mariette C, Chaleteix C, Braun T, De Prijck B, Avet-Loiseau H, Mary JY, Corre J, Moreau P, Touzeau C; MIDAS Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40459097"},{"title01":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","title02":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","journal":"J Clin Oncol","issue":"2025 Jun 9:JCO2401893. doi: 10.1200\/JCO-24-01893. Online ahead of print.","author":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva SB, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Pr\u00f3sper F, Munshi NC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40489728"},{"title01":"Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","title02":"Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","journal":"J Clin Oncol","issue":"2025 Jun 3:JCO2500760. doi: 10.1200\/JCO-25-00760. Online ahead of print.","author":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40459151"},{"title01":"Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study","title02":"Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study","journal":"J Clin Oncol","issue":"2025 Jun 3:101200JCO2500744. doi: 10.1200\/JCO-25-00744. Online ahead of print.","author":"Ailawadhi S, \u0160pi\u010dka I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Be\u015f\u0131\u015f\u0131k SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Mina\u0159\u00edk J, Goldschmidt H, Zhang R, S\u00e9miond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40459178"},{"title01":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era","title02":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2025.287545. Online ahead of print.","author":"Broughton M, Bhatta S, Sonali D, Bumma N, Khan AM, Devarakonda S, Umyarova E, Benson D, Rosko A, Cottini F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501390"},{"title01":"Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice","title02":"Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2025.287717. Online ahead of print.","author":"Ling W, Zangari M, Van Rhee F, Barlogie B, Yaccoby S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501401"},{"title01":"Hyperdiploid myeloma: The silent majority","title02":"Hyperdiploid myeloma: The silent majority","journal":"Br J Haematol","issue":"2025 Jun 9. doi: 10.1111\/bjh.20190. Online ahead of print.","author":"Wiedmeier-Nutor JE, Fonseca R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40491071"},{"title01":"Temporal patterns in US population-based patient survival among adults treated with chemotherapy and\/or immunotherapy for multiple myeloma, 2000-2020","title02":"Temporal patterns in US population-based patient survival among adults treated with chemotherapy and\/or immunotherapy for multiple myeloma, 2000-2020","journal":"Br J Haematol","issue":"2025 Jun 10. doi: 10.1111\/bjh.20192. Online ahead of print.","author":"Dores GM, Vo JB, Schonfeld SJ, Shing JZ, Taparra K, Morton LM, Curtis RE, Linet MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40495370"},{"title01":"Systemic capillary leak syndrome associated with smouldering multiple myeloma treated by bortezomib plus dexamethasone: A\u00a0case report","title02":"Systemic capillary leak syndrome associated with smouldering multiple myeloma treated by bortezomib plus dexamethasone: A\u00a0case report","journal":"Br J Haematol","issue":"2025 Jun 4. doi: 10.1111\/bjh.20193. Online ahead of print.","author":"Bu Q, Zhou H, Gao W, Chen W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468636"},{"title01":"Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma","title02":"Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma","journal":"Blood","issue":"2025 Jun 9:blood.2024027949. doi: 10.1182\/blood.2024027949. Online ahead of print.","author":"Claveau JS, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Christenson LH, Kourelis TV, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40489635"},{"title01":"Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma","title02":"Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma","journal":"Blood","issue":"2025 Jun 10:blood.2024028107. doi: 10.1182\/blood.2024028107. Online ahead of print.","author":"Diamond BT, Baughn LB, Poorebrahim M, Poos AM, Lee H, Kaddoura M, Wiedmeier-Nutor JE, Durante MA, Otteson GE, Jevremovic D, Tang H, Fr\u00f6hling S, Baertsch MA, Papadimitriou M, Ziccheddu B, Jel\u00ednek T, Lemoine C, Rak A, Green DJ, Landgren CO, Neri P, Bergsagel PL, Braggio E, Kumar SK, Raab MS, Fonseca R, Bahlis N, Weinhold N, Maura F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40493883"},{"title01":"High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial","title02":"High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial","journal":"Blood","issue":"2025 Jun 11:blood.2025028313. doi: 10.1182\/blood.2025028313. Online ahead of print.","author":"Lahuerta JJ, San-Miguel JF, Jim\u00e9nez-Ubieto A, Alonso Fern\u00e1ndez R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernandez M, R\u00edos-Tamayo R, Oriol A, Blanchard MJ, Carrillo-Cruz E, Mart\u00ednez-Mart\u00ednez R, Bargay J, Sureda A, de la Rubia J, Hernandez Garcia MT, Caba\u00f1as V, Casado Montero LF, Palomera Bernal L, Gonzalez-Montes Y, Mart\u00ednez-L\u00f3pez J, Rodriguez-Otero P, Krsnik I, Argui\u00f1ano JM, Gonzalez-Garcia ME, Ocio EM, de la Cruz J, Mateos MV, Rosi\u00f1ol L, Blad\u00e9 J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40499010"},{"title01":"Guidance on the interpretation of CRBN mutations in myeloma","title02":"Guidance on the interpretation of CRBN mutations in myeloma","journal":"Blood","issue":"2025 May 29;145(22):2542.","author":"Kort\u00fcm KM, Einsele H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40440041"},{"title01":"BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation","title02":"BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation","journal":"J Clin Oncol","issue":"2025 May 30:JCO2500713. doi: 10.1200\/JCO-25-00713. Online ahead of print.","author":"Jacobs JM, Traeger L, Freese M, Barata A, Newcomb R, Rabideau D, Horick N, DeFilipp Z, Chen YB, Gray T, Pepper J, Caruso E, Amonoo HL, Lee SJ, Greer JA, Temel JS, El-Jawahri A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40444925"},{"title01":"Blinatumomab and better BCR::ABL1 inhibition begets better bone marrow transplant outcomes","title02":"Blinatumomab and better BCR::ABL1 inhibition begets better bone marrow transplant outcomes","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2025.288068. Online ahead of print.","author":"Luskin MR, Leonard JT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501389"},{"title01":"Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia","title02":"Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2025.287881. Online ahead of print.","author":"Heckl D, Rettinger E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501411"},{"title01":"Chronic lymphocytic leukemia and associated chronic lung diseases","title02":"Chronic lymphocytic leukemia and associated chronic lung diseases","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287533. Online ahead of print.","author":"Tadmor T, Hardak E, Melamed G, Alapi H, Rokach L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438985"},{"title01":"Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1","title02":"Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1","journal":"Br J Haematol","issue":"2025 Jun 6. doi: 10.1111\/bjh.20195. Online ahead of print.","author":"Garciaz S, Montersino C, Bourgoin M, Jacquel A, Castellano R, Guille A, Chaffanet M, Bertucci F, Hospital MA, Ad\u00e9la\u00efde J, Auberger P, Vey N, Collette Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40474797"},{"title01":"A prospective study evaluating the safety and pharmacokinetics of ponatinib at a fixed dose in six paediatric patients with philadelphia chromosome-positive leukaemia: JCCG PedPona19 study","title02":"A prospective study evaluating the safety and pharmacokinetics of ponatinib at a fixed dose in six paediatric patients with philadelphia chromosome-positive leukaemia: JCCG PedPona19 study","journal":"Br J Haematol","issue":"2025 Jun 9. doi: 10.1111\/bjh.20146. Online ahead of print.","author":"Kodama Y, Nishi M, Sato A, Imamura CK, Deguchi T, Hirakawa A, Kiyokawa N, Ohki K, Shima H, Kato K, Kato M, Kawasaki H, Sakaguchi H, Hiramatsu H, Goto H, Yamamoto S, Ito M, Tanizawa A, Yuza Y, Saito AM, Ogawa C, Taga T, Adachi S, Shimada H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40491170"},{"title01":"The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission","title02":"The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission","journal":"Br J Haematol","issue":"2025 Jun 10. doi: 10.1111\/bjh.20200. Online ahead of print.","author":"Tinajero J, Ngo D, Motta M, Agrawal V, Koller P, Pourhassan H, Murphy L, Arslan S, Forman S, Stein A, Marcucci G, Pullarkat V, Aldoss I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40492422"},{"title01":"Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells","title02":"Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells","journal":"Br J Haematol","issue":"2025 Jun 11. doi: 10.1111\/bjh.20162. Online ahead of print.","author":"Chiriac R, Baseggio L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40497315"},{"title01":"Are you ready for it? VEN-HMA for younger patients with AML","title02":"Are you ready for it? VEN-HMA for younger patients with AML","journal":"Blood","issue":"2025 May 29;145(22):2543-2544.","author":"Lin TL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40440045"},{"title01":"Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia","title02":"Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia","journal":"Blood","issue":"2025 Jun 2:blood.2025028570. doi: 10.1182\/blood.2025028570. Online ahead of print.","author":"Wierda WG, Eichhorst BF, Hallek MJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40456120"},{"title01":"Phase III Trial of Pirtobrutinib Versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (BRUIN CLL-321)","title02":"Phase III Trial of Pirtobrutinib Versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (BRUIN CLL-321)","journal":"J Clin Oncol","issue":"2025 Jun 6:JCO2500166. doi: 10.1200\/JCO-25-00166. Online ahead of print.","author":"Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, M\u00e1trai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40479620"},{"title01":"Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches","title02":"Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches","journal":"J Clin Oncol","issue":"2025 May 29:JCO2500146. doi: 10.1200\/JCO-25-00146. Online ahead of print.","author":"Eyre TA, Cheah CY, Sarkozy C, Kumar A, Le Gouill S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40440566"},{"title01":"Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance","title02":"Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance","journal":"Haematologica","issue":"2025 Jun 12. doi: 10.3324\/haematol.2024.287162. Online ahead of print.","author":"Schmidt C, Scheubeck G, Jurinovic V, S\u00f6kler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, H\u00e4nel M, Liersch R, D\u00fcrig J, Pott C, Hoster E, Unterhalt M, Hiddemann W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501414"},{"title01":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis","title02":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287485. Online ahead of print.","author":"De Groot FA, Stedema FG, Kret EJ, De Haan LM, Jansen PM, B\u00f6hringer S, Diepstra A, Van der Poel MWM, Hamid MA, Te Boome LCJ, Terpstra V, Brink M, Veelken H, De Groen RAL, Dekker TJA, Nijland M, Vermaat JSP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438976"},{"title01":"CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study","title02":"CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287528. Online ahead of print.","author":"Magni M, Jonnalagadda S, Bonifazi F, Bonafe M, Ljevar S, Zanirato G, De Matteis S, Stella F, Barone A, Bertolini G, Bermema A, Chiappella A, Tisi MC, Cutini I, Novo M, Grillo G, Farina M, Martino M, Krampera M, Massaia M, Arcaini L, Bramanti S, Zinzani PL, Dodero A, Corradini P, Carniti C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438977"},{"title01":"When ‘simplified’ may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","title02":"When ‘simplified’ may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","journal":"Haematologica","issue":"2025 Jun 5. doi: 10.3324\/haematol.2025.288186. Online ahead of print.","author":"Huang K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468946"},{"title01":"Persistent Epstein-Barr virus viremia in NK-\/T-cell lymphoma: bad boys for life!","title02":"Persistent Epstein-Barr virus viremia in NK-\/T-cell lymphoma: bad boys for life!","journal":"Haematologica","issue":"2025 Jun 5. doi: 10.3324\/haematol.2025.287922. Online ahead of print.","author":"Xavier AC, Liao Y, Cairo MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468963"},{"title01":"Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed\/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)","title02":"Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed\/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)","journal":"Br J Haematol","issue":"2025 Jun 10. doi: 10.1111\/bjh.20204. Online ahead of print.","author":"Novo M, Frascione PMM, Castellino A, Marcheselli L, Dattoli SD, Vannucchi M, Rota-Scalabrini D, Tucci A, Gini G, Tarantini G, Mannina D, Arcari A, Liso A, Scarpa E, Marino D, Spina M, Gorgone A, Di Renzo N, Mancuso S, Petrucci L, Tafuri A, Botto B, Bonello F, Santambrogio E, Vitolo U.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40495420"},{"title01":"Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells","title02":"Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells","journal":"Br J Haematol","issue":"2025 Jun 11. doi: 10.1111\/bjh.20162. Online ahead of print.","author":"Chiriac R, Baseggio L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40497315"},{"title01":"Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia","title02":"Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia","journal":"N Engl J Med","issue":"2025 Jun 12;392(22):2286.","author":"Hodder A, Vora A, Samarasinghe S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40499181"},{"title01":"Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply","title02":"Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply","journal":"N Engl J Med","issue":"2025 Jun 12;392(22):2286-2287.","author":"Gupta S, Rau RE, Loh ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40499182"},{"title01":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia","title02":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia","journal":"N Engl J Med","issue":"2025 Jun 5;392(21):2180-2181.","author":"Mohty M, Kharfan-Dabaja MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40466081"},{"title01":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. Reply","title02":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. Reply","journal":"N Engl J Med","issue":"2025 Jun 5;392(21):2181.","author":"Brown JR, Miller K, Munugalavadla V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40466082"},{"title01":"Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)","title02":"Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)","journal":"Leukemia","issue":"2025 Jun 2. doi: 10.1038\/s41375-025-02649-9. Online ahead of print.","author":"Cesaro S, Ljungman P, Mikulska M, Hirsch HH, Navarro D, Cordonnier C, Mehra V, Styczynski J, Marchesi F, Pinana JL, Beutel G, Einsele H, Maertens J; ECIL-10; de la Camara R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40456838"},{"title01":"NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL","title02":"NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL","journal":"Leukemia","issue":"2025 Jun 2. doi: 10.1038\/s41375-025-02632-4. Online ahead of print.","author":"Ehrmann AS, Quijada-\u00c1lamo M, Close V, Guo M, Carracoi V, P\u00e9rez-Carretero C, Corchete LA, Friedrich T, Giaimo BD, Yosifov DY, Bloehdorn J, Rodr\u00edguez-S\u00e1nchez A, Tausch E, Schneider C, D\u00f6hner H, Kietzmann T, Borggrefe T, Stilgenbauer S, Oswald F, Hern\u00e1ndez-Rivas JM, Mertens D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40456839"},{"title01":"Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1\/2 trial","title02":"Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1\/2 trial","journal":"Lancet Haematol","issue":"2025 May 28:S2352-3026(25)00103-6. doi: 10.1016\/S2352-3026(25)00103-6. Online ahead of print.","author":"Kontro M, Stein AS, Py\u00f6r\u00e4l\u00e4 M, Rimpil\u00e4inen J, Siitonen T, Ylitalo A, Fj\u00e4llskog ML, Jalkanen J, Aakko S, Pawlitzky I, Hollm\u00e9n M, Daver N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40449509"},{"title01":"Phase III Trial of Pirtobrutinib Versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (BRUIN CLL-321)","title02":"Phase III Trial of Pirtobrutinib Versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (BRUIN CLL-321)","journal":"J Clin Oncol","issue":"2025 Jun 6:JCO2500166. doi: 10.1200\/JCO-25-00166. Online ahead of print.","author":"Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, M\u00e1trai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40479620"},{"title01":"Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia","title02":"Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia","journal":"Haematologica","issue":"2025 Jun 12:0. doi: 10.3324\/haematol.2024.287265. Online ahead of print.","author":"Ikeda J, Kunimoto H, Saito Y, Tsujimoto SI, Takeuchi M, Miura A, Kurosawa T, Murakami K, Kato I, Funakoshi-Tago M, Yokoyama A, Shiba N, Adachi S, Tomizawa D, Tamura T, Ito S, Nakajima H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501394"},{"title01":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia","title02":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia","journal":"Haematologica","issue":"2025 Jun 12:0. doi: 10.3324\/haematol.2024.287119. Online ahead of print.","author":"Gong B, Yang M, Qiu S, Liu B, Wang Y, Mi Y, Wei H, Wang J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501400"},{"title01":"Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia\/lymphoma","title02":"Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia\/lymphoma","journal":"Br J Haematol","issue":"2025 Jun 3. doi: 10.1111\/bjh.20177. Online ahead of print.","author":"Dittus C, Weinstock MJ, Barnes J, Sandoval-Sus J, Grover NS, Beaven A, Hoye K, Shelton A, Tan X, Srinivasan MD, El-Jawahri A, Sarosiek S, Sloan JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40459047"},{"title01":"Getting to the root of high-risk leukemias","title02":"Getting to the root of high-risk leukemias","journal":"Blood","issue":"2025 Jun 5;145(23):2673-2674.","author":"Poeschla M, Sankaran VG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40471625"},{"title01":"I+Ve got a question: how long should we treat relapsed CLL?","title02":"I+Ve got a question: how long should we treat relapsed CLL?","journal":"Blood","issue":"2025 May 29;145(22):2536-2538.","author":"F\u00fcrstenau M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40440043"},{"title01":"Correspondence to “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development”","title02":"Correspondence to “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development”","journal":"Leukemia","issue":"2025 May 20. doi: 10.1038\/s41375-025-02643-1. Online ahead of print.","author":"Wang X, Yao H, Chen J, Liu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40394212"},{"title01":"Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed \/ refractory B-cell acute lymphoblastic leukemia by dual CD19 and CD22-targeted chimeric antigen receptor T-cell therapy","title02":"Durable remission achieved in pediatric patients with TCF3-HLF<\/i>-positive relapsed \/ refractory B-cell acute lymphoblastic leukemia by dual CD19 and CD22-targeted chimeric antigen receptor T-cell therapy","journal":"Haematologica","issue":"2025 May 22. doi: 10.3324\/haematol.2024.287023. Online ahead of print.","author":"Wan X, Wang T, Yang J, Yang X, Li W, Ding L, Yang L, Zhang J, Su M, An K, Zhou Z, Li Y, Wang X, Zhu H, Luo C, Gu L, Chen J, Song L, Tang Y, Li B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400462"},{"title01":"Dexamethasing acute myeloid leukemia: new opportunities for an “old” drug","title02":"Dexamethasing acute myeloid leukemia: new opportunities for an “old” drug","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287404. Online ahead of print.","author":"Duque-Afonso J, List J, L\u00fcbbert M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438984"},{"title01":"Comment on “Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report”","title02":"Comment on “Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report”","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2025.288110. Online ahead of print.","author":"Borkhardt A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371896"},{"title01":"Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia: a review","title02":"Uncommon phenotypes of BCR::ABL1<\/i>-positive chronic myelogenous leukemia: a review","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2025.287792. Online ahead of print.","author":"Jajosky AN, Lichtman MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371899"},{"title01":"Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia","title02":"Prognostic value of CEBPA<\/i> bZIP signatures in cytogenetically normal acute myeloid leukaemia","journal":"Br J Haematol","issue":"2025 May 26. doi: 10.1111\/bjh.20164. Online ahead of print.","author":"Wu LX, Liao MY, Zhao MY, Yan N, Zhang P, Liu LX, Qin JY, Cao SB, Feng J, Jiang Q, Chang YJ, Xu LP, Zhang XH, Huang XJ, Jiang H, Zhang HY, Ruan GR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40419412"},{"title01":"Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model","title02":"Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model","journal":"Leukemia","issue":"2025 May 20. doi: 10.1038\/s41375-025-02628-0. Online ahead of print.","author":"Tari Crochet G, Ari-Yuka S, Fischer A, Chour M, Claudel A, Sako N, Robe C, Naudet J, Gonon A, Mboumba DL, Ortonne N, Alcazer V, Delfau-Larue MH, Siebert R, Gaulard P, Lemonnier F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40394210"},{"title01":"Radiate equity: the inclusion of radiation oncology and other specialties in lymphoma collaborative groups","title02":"Radiate equity: the inclusion of radiation oncology and other specialties in lymphoma collaborative groups","journal":"Lancet Haematol","issue":"2025 May 16:S2352-3026(25)00080-8. doi: 10.1016\/S2352-3026(25)00080-8. Online ahead of print.","author":"Saifi O, Pinnix CC, Kelsey CR, Ballas LK, Milgrom SA, Advani R, Kasner MT, Flampouri S, Terezakis SA, Sellmyer M, Plastaras JP, Hoppe BS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40388957"},{"title01":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma","title02":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma","journal":"J Clin Oncol","issue":"2025 May 19:JCO2500568. doi: 10.1200\/JCO-25-00568. Online ahead of print.","author":"Arunachalam AK, Gilmour CK, Melenhorst JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40388673"},{"title01":"Evaluation of MYD88 p.L265P detection by digital droplet polymerase chain reaction in cerebrospinal fluid for integrated diagnosis of primary large B-cell lymphoma of the central nervous system","title02":"Evaluation of MYD88<\/i> p.L265P detection by digital droplet polymerase chain reaction in cerebrospinal fluid for integrated diagnosis of primary large B-cell lymphoma of the central nervous system","journal":"Br J Haematol","issue":"2025 May 25. doi: 10.1111\/bjh.20167. Online ahead of print.","author":"Harlay V, Gallardo C, Beaufils N, Astier A, Testud B, Amri A, Fritz S, Abbou N, Robert P, Garcia J, Roll P, Ouafik L, Schenone L, Petrirena G, Bertucci A, Bequet C, Chinot O, Tabouret E, Nanni I, Appay R, Kaspi E, Frankel D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40415280"},{"title01":"Immunotherapy response: is it all in the DLBCL-IQs?","title02":"Immunotherapy response: is it all in the DLBCL-IQs?","journal":"Blood","issue":"2025 May 22;145(21):2402-2403.","author":"Okosun J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40402529"},{"title01":"Adult T-cell leukemia\/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder","title02":"Adult T-cell leukemia\/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder","journal":"Blood","issue":"2025 May 15;145(20):2396.","author":"Wang X, Yi H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40372737"},{"title01":"An Updated Understanding of Follicular Lymphoma Transformation","title02":"An Updated Understanding of Follicular Lymphoma Transformation","journal":"Blood","issue":"2025 May 15:blood.2024026016. doi: 10.1182\/blood.2024026016. Online ahead of print.","author":"Parry EM, Okosun J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40373273"},{"title01":"A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia\/Lymphoma","title02":"A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia\/Lymphoma","journal":"Blood","issue":"2025 May 15:blood.2024027902. doi: 10.1182\/blood.2024027902. Online ahead of print.","author":"Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y Dr, Hidaka T, Nosaka K, Sasaki H, Rai S, Tamura S, Owatari S, Koh KR, Nakamura D, Tokunaga M, Sekine M, Sakamoto Y, Inagaki H, Ishida T, Ishitsuka K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40373281"},{"title01":"Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma","title02":"Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma","journal":"Haematologica","issue":"2025 May 22. doi: 10.3324\/haematol.2025.287526. Online ahead of print.","author":"Cantafio MEG, Valentino I, Torcasio R, Ganino L, Veneziano C, Murfone P, Mesuraca M, Perrotta I, Tallarigo F, Agosti V, De Marco C, Pasqua T, Giallongo C, Cappello AR, Fiorillo M, Gentile M, Tibullo D, Viglietto G, Neri A, Amodio N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400476"},{"title01":"Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing","title02":"Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287586. Online ahead of print.","author":"Liu L, Sun H, Feng F, Sun X, Ma J, Lv R, Yu T, Ye L, Li X, Yu Z, Zhang X, Jing H, Yao Y, Ma F, Qiu L, Hao M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438979"},{"title01":"Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma","title02":"Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2025.287559. Online ahead of print.","author":"Poletti A, Taurisano B, Mazzocchetti G, Lionetti M, Martello M, Vuong VM, Solli V, Marzocchi G, Maeda A, Vigliotta I, Borsi E, Armuzzi S, Pistis I, Marella A, Fabris S, Tacchetti P, Mancuso K, Rizzello I, Pantani L, Testoni N, Cavo M, Zamagni E, Bolli N, Terragna C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371906"},{"title01":"Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies","title02":"Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2024.286264. Online ahead of print.","author":"Susca N, Borrelli P, Botta C, Solimando AG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371907"},{"title01":"Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: Analysis from the EuLITE trial","title02":"Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: Analysis from the EuLITE trial","journal":"Br J Haematol","issue":"2025 May 25. doi: 10.1111\/bjh.20168. Online ahead of print.","author":"McIlroy G, Giles HV, Rollins A, Malin G, Jones L, Wright NJ, Berlanga O, North S, Cook M, Hutchison C, Heyne N, Weisel K, Pinney J, Harding S, Cockwell P, Pratt G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40415308"},{"title01":"The progression of multiple myeloma is regulated by LILRB1 via the GATA2-SAGE1 pathway","title02":"The progression of multiple myeloma is regulated by LILRB1 via the GATA2-SAGE1 pathway","journal":"Br J Haematol","issue":"2025 May 25. doi: 10.1111\/bjh.20144. Online ahead of print.","author":"Chen C, Zhou X, Cao L, Yang W, Weng L, Yuan J, Zhou W, Yu Z, Zheng J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40415416"},{"title01":"Classic hairy cell leukemia and concomitant smoldering myeloma","title02":"Classic hairy cell leukemia and concomitant smoldering myeloma","journal":"Blood","issue":"2025 May 22;145(21):2533.","author":"Jum'ah H, Viswanatha D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40402524"},{"title01":"Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment","title02":"Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment","journal":"Blood","issue":"2025 May 22:blood.2025029234. doi: 10.1182\/blood.2025029234. Online ahead of print.","author":"Lasa M, Gonzalez C, Notarfranchi L, Zherniakova A, Alignani D, Burgos L, Calasanz MJ, Rodriguez-Otero P, Perez JJ, Gomez C, Gonzalez-Calle V, de Arriba F, Palomera Bernal L, Alvarez Rivas MA, Clavero Sanchez E, Ocio EM, Gonzalez-Rodriguez AP, Lakhwani S, Iba\u00f1ez A, Oriol A, Sureda A, Rosi\u00f1ol L, Siewert C, Orfao A, Lahuerta JJ, Blad\u00e9 J, Mateos MV, San-Miguel JF, Cedena MT, Martinez-Lopez J, Puig N, Paiva B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40403320"},{"title01":"Right time: stopping multiple myeloma maintenance","title02":"Right time: stopping multiple myeloma maintenance","journal":"Blood","issue":"2025 May 15;145(20):2241-2242.","author":"McCarthy P, Mohammadpour H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40372740"},{"title01":"It takes two to tango: allogeneic stem cell transplantation and FLT3 tyrosin kinase inhibitor therapy","title02":"It takes two to tango: allogeneic stem cell transplantation and FLT3 tyrosin kinase inhibitor therapy","journal":"Haematologica","issue":"2025 May 22. doi: 10.3324\/haematol.2025.287627. Online ahead of print.","author":"Cornelissen JJ, Versluis J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400473"},{"title01":"Kaposi sarcoma and Kaposi inflammatory cytokine syndrome following allogeneic haematopoietic stem cell transplantation: A case report","title02":"Kaposi sarcoma and Kaposi inflammatory cytokine syndrome following allogeneic haematopoietic stem cell transplantation: A case report","journal":"Br J Haematol","issue":"2025 May 20. doi: 10.1111\/bjh.20158. Online ahead of print.","author":"Laspa E, Neofytos D, Boutboul D, Giannotti F, Masouridi-Levrat S, Simonetta F, Royer-Chardon C, de Leval L, Blum S, Chalandon Y, Mamez AC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40394966"},{"title01":"Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukaemia: A multicentre cohort study","title02":"Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukaemia: A multicentre cohort study","journal":"Br J Haematol","issue":"2025 May 21. doi: 10.1111\/bjh.20147. Online ahead of print.","author":"Ye Y, Liu X, Dai H, Hu J, Yu G, Zhang Y, Weng G, Lin D, Du X, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Xu N, Fan Z, Xuan L, Lin R, Yin Z, Huang F, Dai M, Li Z, Liu Q, Jin H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40399765"},{"title01":"It takes two to tango: allogeneic stem cell transplantation and FLT3 tyrosin kinase inhibitor therapy","title02":"It takes two to tango: allogeneic stem cell transplantation and FLT3 tyrosin kinase inhibitor therapy","journal":"Haematologica","issue":"2025 May 22. doi: 10.3324\/haematol.2025.287627. Online ahead of print.","author":"Cornelissen JJ, Versluis J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400473"},{"title01":"Kaposi sarcoma and Kaposi inflammatory cytokine syndrome following allogeneic haematopoietic stem cell transplantation: A case report","title02":"Kaposi sarcoma and Kaposi inflammatory cytokine syndrome following allogeneic haematopoietic stem cell transplantation: A case report","journal":"Br J Haematol","issue":"2025 May 20. doi: 10.1111\/bjh.20158. Online ahead of print.","author":"Laspa E, Neofytos D, Boutboul D, Giannotti F, Masouridi-Levrat S, Simonetta F, Royer-Chardon C, de Leval L, Blum S, Chalandon Y, Mamez AC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40394966"},{"title01":"Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukaemia: A multicentre cohort study","title02":"Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukaemia: A multicentre cohort study","journal":"Br J Haematol","issue":"2025 May 21. doi: 10.1111\/bjh.20147. Online ahead of print.","author":"Ye Y, Liu X, Dai H, Hu J, Yu G, Zhang Y, Weng G, Lin D, Du X, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Xu N, Fan Z, Xuan L, Lin R, Yin Z, Huang F, Dai M, Li Z, Liu Q, Jin H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40399765"},{"title01":"Haploidentical HSCT: more curative options for patients with CGD","title02":"Haploidentical HSCT: more curative options for patients with CGD","journal":"Blood","issue":"2025 May 22;145(21):2408-2409.","author":"Morris EC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40402531"},{"title01":"PERK Maintains Hematopoietic Stem Cell Pool Integrity under Endoplasmic Reticulum Stress by Promoting Proliferation","title02":"PERK Maintains Hematopoietic Stem Cell Pool Integrity under Endoplasmic Reticulum Stress by Promoting Proliferation","journal":"Blood","issue":"2025 May 28:blood.2024027846. doi: 10.1182\/blood.2024027846. Online ahead of print.","author":"Zheng M, Peng Q, Kropp EM, Shen Z, Liu S, Yin Z, Matono S, Iwawaki T, Wang X, Inoki K, Mei Y, Li Q, Liu L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40435413"},{"title01":"Myopathy, lactic acidosis and sideroblastic anemia syndrome 1 (MLASA1) : clinical hallmarks in a large pedigree with a novel PUS1 R144Q mutation, remarkable response to somatropin, and review of the literature","title02":"Myopathy, lactic acidosis and sideroblastic anemia syndrome 1 (MLASA1) : clinical hallmarks in a large pedigree with a novel PUS1<\/i> R144Q mutation, remarkable response to somatropin, and review of the literature","journal":"Haematologica","issue":"2025 May 29. doi: 10.3324\/haematol.2025.287393. Online ahead of print.","author":"Parisi L, Escher R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438980"},{"title01":"Physical activity, vaso-occlusive crises and pain in patients with sickle cell anaemia in Senegal","title02":"Physical activity, vaso-occlusive crises and pain in patients with sickle cell anaemia in Senegal","journal":"Br J Haematol","issue":"2025 May 19. doi: 10.1111\/bjh.20150. Online ahead of print.","author":"Diaw M, Coly MS, Charlot K, Gallou-Guyot M, Miyachi M, Yoshida T, Gadji M, Diop S, Faye BF, Mbengue A, Samb A, Skinner S, Nader E, Ranque B, Connes P, Tripette J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40390109"},{"title01":"Imaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic Anemia","title02":"Imaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic Anemia","journal":"Blood","issue":"2025 May 22:blood.2025028723. doi: 10.1182\/blood.2025028723. Online ahead of print.","author":"Pool ES, Luk SJ, IJsselsteijn ME, van Unen V, de Miranda NFCC, Falkenburg JHF, Koning F, Heemskerk MHM, Tjon JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40403228"},{"title01":"Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia","title02":"Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia","journal":"N Engl J Med","issue":"2025 May 29;392(20):2069-2071.","author":"Sun T, Chen Y, Zhang L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40435473"},{"title01":"Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study","title02":"Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study","journal":"Lancet Haematol","issue":"2025 May 23:S2352-3026(25)00107-3. doi: 10.1016\/S2352-3026(25)00107-3. Online ahead of print.","author":"Grace RF, Leblebisatan G, Aydinok Y, \u00dcnal \u015e, Grainger JD, Zhang J, Smallwood L, de Le\u00f3n E, Jamieson BD; AVA-PED-301 Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40418942"},{"title01":"Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based real-world cohort study from Denmark and France","title02":"Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based real-world cohort study from Denmark and France","journal":"Haematologica","issue":"2025 May 22. doi: 10.3324\/haematol.2025.287330. Online ahead of print.","author":"Mannering N, Zadro Y, Hansen DL, Maquet J, Lafaurie M, Potteg\u00e5rd A, Moulis G, Frederiksen H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400464"},{"title01":"CD19(+)IL-10(+) regulatory B cells induced by IL-12p35 regulates functional T-cell subsets in patients with immune thrombocytopenia","title02":"CD19(+)IL-10(+) regulatory B cells induced by IL-12p35 regulates functional T-cell subsets in patients with immune thrombocytopenia","journal":"Br J Haematol","issue":"2025 May 25. doi: 10.1111\/bjh.20173. Online ahead of print.","author":"Hua F, Sun L, Li Y, Meng Y, Fan X, Wang X, Lu Y, Cheng Y, Li F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40415408"},{"title01":"The ‘Stop TPO-RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering","title02":"The ‘Stop TPO-RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering","journal":"Br J Haematol","issue":"2025 May 19. doi: 10.1111\/bjh.20100. Online ahead of print.","author":"Nelson VS, Amini SN, Netelenbos T, Kartachova MS, Schutgens REG, Visser O, Westerweel PE, Zwaginga JJ, Hofstede-van Egmond S, Kapur R, de Haas M, Porcelijn L, Schipperus MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40384450"},{"title01":"Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo","title02":"Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo","journal":"Leukemia","issue":"2025 May 20. doi: 10.1038\/s41375-025-02626-2. Online ahead of print.","author":"Auer F, Morcos MNF, Sipola M, Akhtar I, Moisio S, Vogt J, Haag R, Lahnalampi M, Tuononen TJ, Hanel A, Viitasalo A, Friedrich UA, Dahl A, Prexler C, Pandyra AA, Stepensky P, Takagi M, Borkhardt A, Hein\u00e4niemi M, Hauer J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40394211"},{"title01":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-\u03b21-driven macrophage polarization in myeloid leukemias","title02":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-\u03b21-driven macrophage polarization in myeloid leukemias","journal":"Haematologica","issue":"2025 May 22. doi: 10.3324\/haematol.2024.287091. Online ahead of print.","author":"Feng J, Gou J, Wang Y, Wei W, Ma Y, Ren X, Zhao C, Cheng X, Lei L, Tan Z, Guan F, Li X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400458"},{"title01":"Characteristics and outcomes of newly diagnosed pediatric acute myeloid leukemia patients who were removed from standard regimens and received alternative therapy","title02":"Characteristics and outcomes of newly diagnosed pediatric acute myeloid leukemia patients who were removed from standard regimens and received alternative therapy","journal":"Haematologica","issue":"2025 May 22. doi: 10.3324\/haematol.2025.287487. Online ahead of print.","author":"Wahba A, Catueno S, Na K, Dickson S, Stevens A, Cuglievan B, Redell MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400478"},{"title01":"Treatment-related mutagenic processes in acute lymphoblastic leukemia","title02":"Treatment-related mutagenic processes in acute lymphoblastic leukemia","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2025.287774. Online ahead of print.","author":"Van der Ham CG, Van Leeuwen FN, Kuiper RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371888"},{"title01":"RETRACTION: IPO-trimethylation of Histone H3-lysine(9) Associated with P210 BCR-ABL Tyrosine Kinase of Chronic Myeloid Leukaemia","title02":"RETRACTION: IPO-trimethylation of Histone H3-lysine(9) Associated with P210 BCR-ABL Tyrosine Kinase of Chronic Myeloid Leukaemia","journal":"Br J Haematol","issue":"2025 May 23. doi: 10.1111\/bjh.20189. Online ahead of print.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40405758"},{"title01":"Diagnosis and treatment of early T-cell precursor acute lymphoblastic leukaemia","title02":"Diagnosis and treatment of early T-cell precursor acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2025 May 23. doi: 10.1111\/bjh.20163. Online ahead of print.","author":"Xu K, Maharaj C, Kaffo E, Vitsaras E, Orfinada K, Baker R, Nacheva E, Wilson A, O'Nions J, Gupta R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40407010"},{"title01":"RETRACTION: P210 Bcr-abl Tyrosine Kinase Interaction with Histone Deacetylase 1 Modifies Histone H4 Acetylation and Chromatin Structure of Chronic Myeloid Leukaemia Haematopoietic Progenitors","title02":"RETRACTION: P210 Bcr-abl Tyrosine Kinase Interaction with Histone Deacetylase 1 Modifies Histone H4 Acetylation and Chromatin Structure of Chronic Myeloid Leukaemia Haematopoietic Progenitors","journal":"Br J Haematol","issue":"2025 May 26. doi: 10.1111\/bjh.20188. Online ahead of print.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40415499"},{"title01":"Hairy cell leukaemia and pregnancy: A systematic review and review of literature","title02":"Hairy cell leukaemia and pregnancy: A systematic review and review of literature","journal":"Br J Haematol","issue":"2025 May 19. doi: 10.1111\/bjh.20174. Online ahead of print.","author":"Borja-Montes OF, Toro-Pedroza A, Epperla N, Andritsos LA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40389354"},{"title01":"Venetoclax-based non-intensive combinations for relapsed\/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme","title02":"Venetoclax-based non-intensive combinations for relapsed\/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme","journal":"Br J Haematol","issue":"2025 May 20. doi: 10.1111\/bjh.20149. Online ahead of print.","author":"Wood H, O'Nions J, Chan WY, Borg A, Veitch S, Elder P, Jain M, Aries J, Leak S, Mitchell E, Pavlu J, Othman J, Dillon R, Mehta P, Murthy V, Knapper S, Potter V, Copland M, Craddock C, Krishnamurthy P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40394961"},{"title01":"Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukaemia: A multicentre cohort study","title02":"Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukaemia: A multicentre cohort study","journal":"Br J Haematol","issue":"2025 May 21. doi: 10.1111\/bjh.20147. Online ahead of print.","author":"Ye Y, Liu X, Dai H, Hu J, Yu G, Zhang Y, Weng G, Lin D, Du X, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Xu N, Fan Z, Xuan L, Lin R, Yin Z, Huang F, Dai M, Li Z, Liu Q, Jin H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40399765"},{"title01":"Classic hairy cell leukemia and concomitant smoldering myeloma","title02":"Classic hairy cell leukemia and concomitant smoldering myeloma","journal":"Blood","issue":"2025 May 22;145(21):2533.","author":"Jum'ah H, Viswanatha D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40402524"},{"title01":"Chromatin dynamics in CLL: a matter of balance","title02":"Chromatin dynamics in CLL: a matter of balance","journal":"Blood","issue":"2025 May 22;145(21):2403-2405.","author":"Rosenquist R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40402525"},{"title01":"Inflammation conjoins differentiation and resistance in AML","title02":"Inflammation conjoins differentiation and resistance in AML","journal":"Blood","issue":"2025 May 22;145(21):2405-2407.","author":"Janssen M, M\u00fcller-Tidow C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40402530"},{"title01":"RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation","title02":"RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation","journal":"Blood","issue":"2025 May 28:blood.2024027712. doi: 10.1182\/blood.2024027712. Online ahead of print.","author":"Mayday MY, Biancon G, Wei M, Ramirez C, Moratti I, Pintado-Urbanc AP, Espinosa JA, Chen M, Wang L, Simon MD, Ofir-Rosenfeld Y, Rausch O, Tebaldi T, Halene S, Krause DS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40435410"},{"title01":"HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia","title02":"HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia","journal":"Blood","issue":"2025 Apr 15:blood.2024026848. doi: 10.1182\/blood.2024026848. Online ahead of print.","author":"De Kesel J, Fijalkowski I, Pieters T, Borin C, Christensen KT, Wittouck M, Van Laere J, Guerrero L, Reunes L, Caruso M, Thakkar B, Sleeckx W, Xu LK, Van Nieuwerburgh F, Deforce D, De Keersmaecker K, Lammens T, Goossens S, Taghon T, Han C, Veltri G, Serafin V, Palhais B, Sharma ND, Huang H, Liu H, Matlawska-Wasowska K, Milovanovic A, Novoa EM, Wang E, Ntziachristos P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40435411"},{"title01":"Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin","title02":"Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin","journal":"Blood","issue":"2025 May 28:blood.2024028215. doi: 10.1182\/blood.2024028215. Online ahead of print.","author":"Escherich CS, Li Z, Barnett KR, Li Y, Walker M, Yoshimura S, Yang W, Huang X, Yu J, Stock W, Paietta E, Konopleva MY, Kornblau SM, Jabbour E, Litzow MR, Inaba H, Pui CH, Loh ML, Evans WE, Savic D, Yang JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40435412"},{"title01":"Adult T-cell leukemia\/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder","title02":"Adult T-cell leukemia\/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder","journal":"Blood","issue":"2025 May 15;145(20):2396.","author":"Wang X, Yi H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40372737"},{"title01":"How I Evaluate and Treat Resistance and Relapse in CML","title02":"How I Evaluate and Treat Resistance and Relapse in CML","journal":"Blood","issue":"2025 May 15:blood.2024026511. doi: 10.1182\/blood.2024026511. Online ahead of print.","author":"Soverini S, Castagnetti F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40373278"},{"title01":"A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia\/Lymphoma","title02":"A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia\/Lymphoma","journal":"Blood","issue":"2025 May 15:blood.2024027902. doi: 10.1182\/blood.2024027902. Online ahead of print.","author":"Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y Dr, Hidaka T, Nosaka K, Sasaki H, Rai S, Tamura S, Owatari S, Koh KR, Nakamura D, Tokunaga M, Sekine M, Sakamoto Y, Inagaki H, Ishida T, Ishitsuka K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40373281"},{"title01":"Common origin and somatic mutation patterns of composite lymphomas and leukemias","title02":"Common origin and somatic mutation patterns of composite lymphomas and leukemias","journal":"Leukemia","issue":"2025 May 22. doi: 10.1038\/s41375-025-02549-y. Online ahead of print.","author":"Berg V, Lollies A, Schneider M, Johansson P, Weniger MA, Albertini E, Facchetti F, Ascani S, Moawia A, Bens S, Fischer A, Siebert R, Klapper W, Lorenzi L, Tiacci E, Hartmann S, Budeus B, Hansmann ML, K\u00fcppers R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40404986"},{"title01":"A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells","title02":"A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells","journal":"Leukemia","issue":"2025 May 27. doi: 10.1038\/s41375-025-02647-x. Online ahead of print.","author":"Feng S, Kong R, Wang C, Hao Q, Xie X, Wang H, Han J, Zhang Y, Elsner J, Mendy D, Haughey M, Krenitsky P, Plantevin-Krenitsky V, Papa P, Mercurio F, Xie W, Zhou X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40425803"},{"title01":"Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response","title02":"Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2024.287241. Online ahead of print.","author":"Eertink JJ, Heymans MW, Wiegers SE, Bes AL, Duhrsen U, Huttmann A, Kurch L, Barrington SF, Mikhaeel GN, Lugtenburg PJ, Ceriani L, Zucca E, Gyorke T, Czibor S, Zwezerijnen GJC, Boellaard R, Zijlstra JM, Hanoun C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371889"},{"title01":"Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study","title02":"Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2024.287141. Online ahead of print.","author":"Brisou G, Paillassa J, Bernard S, Tournilhac O, Fornecker LM, Maloisel F, Gastaud L, Durot E, Tempescul A, Braun T, Ivanov V, Cherel B, Serrier C, Delage J, El Yamani A, Delapierre B, Lebras L, Lestang E, Villesuzanne C, Agape P, Escure G, Fouillet L, Nicol C, Olivier G, Levy A, Le Bris AS, Cassuto O, Jacquemelle L, Haioun C, Herbaux C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371897"},{"title01":"Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab","title02":"Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab","journal":"Haematologica","issue":"2025 May 15. doi: 10.3324\/haematol.2025.287532. Online ahead of print.","author":"Ardissino G, Angelillo P, Mancuso MC, Griffini S, Grovetti E, Porcaro L, Ria T, Marktel S, Peyvandi F, Luminari S, Ferreri AJM, Merli M, Cugno M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371898"},{"title01":"Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion","title02":"Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion","journal":"Br J Haematol","issue":"2025 May 25. doi: 10.1111\/bjh.20186. Online ahead of print.","author":"Hanajiri R, Wakabayashi H, Ishigiwa K, Ohara F, Hirano S, Yokota H, Kuwano S, Furukawa K, Shimada K, Sato T, Terakura S, Kiyoi H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40415166"},{"title01":"The role of PET\/CT in peripheral T-cell lymphoma: Results from the PET\/CT substudy of the UK NCRI phase 2 CHEMO-T trial","title02":"The role of PET\/CT in peripheral T-cell lymphoma: Results from the PET\/CT substudy of the UK NCRI phase 2 CHEMO-T trial","journal":"Br J Haematol","issue":"2025 May 26. doi: 10.1111\/bjh.20160. Online ahead of print.","author":"Gleeson M, Gonzalez Arias C, Cunningham D, Peckitt C, Thomas K, Du Y, Hujairi N, To YM, Chen HC, Patel S, Chau I, Johnson P, Wotherspoon A, Attygalle AD, Hawkes EA, Macheta MP, Collins GP, Cwynarski K, Chua S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40419413"},{"title01":"Involvement of the gastrointestinal tract by mantle cell lymphoma","title02":"Involvement of the gastrointestinal tract by mantle cell lymphoma","journal":"Br J Haematol","issue":"2025 May 15. doi: 10.1111\/bjh.20048. Online ahead of print.","author":"Hafi M, Iyengar S, Wotherspoon A, Cunningham D, Kohoutova D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40374582"},{"title01":"Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B-cell lymphoma, a Danish population-based analysis","title02":"Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B-cell lymphoma, a Danish population-based analysis","journal":"Br J Haematol","issue":"2025 May 15. doi: 10.1111\/bjh.20155. Online ahead of print.","author":"Haujir A, T\u00f8stesen M, El-Galaly TC, Larsen TS, Starklint J, Poulsen CB, Josefsson PL, Clasen-Linde E, Pedersen M, Dessau-Arp A, Clausen MR, M\u00e9sz\u00e1ros J\u00f8rgensen J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40375441"},{"title01":"Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline","title02":"Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline","journal":"Br J Haematol","issue":"2025 May 19. doi: 10.1111\/bjh.20129. Online ahead of print.","author":"Chaganti S, Fox CP, Maybury BD, Burton C, Barrington SF, Illidge T, Kalakonda N, Eyre TA, McKay P, Kuhnl A, Cwynarski K, Davies AJ; BSH Committee.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40384597"},{"title01":"Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed\/refractory classical Hodgkin lymphoma","title02":"Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed\/refractory classical Hodgkin lymphoma","journal":"Br J Haematol","issue":"2025 May 20. doi: 10.1111\/bjh.20148. Online ahead of print.","author":"Srinivasan S, Narayan A, Dhamne C, Chichra A, Khemani P, Dhariwal N, Ranjan R, Shah S, Shet T, Gollamudi VRM, Roy Moulik N, Banavali SD, Narula G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40394816"},{"title01":"Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities","title02":"Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities","journal":"Leukemia","issue":"2025 May 22. doi: 10.1038\/s41375-025-02645-z. Online ahead of print.","author":"Dembitz V, James SC, Gallipoli P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40404984"},{"title01":"KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML","title02":"KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML","journal":"Leukemia","issue":"2025 May 22. doi: 10.1038\/s41375-025-02642-2. Online ahead of print.","author":"Zou J, Kinosada H, Takayanagi SI, Ishii T, Amano T, Nihira K, Kanie S, Adachi M, Tahara H, Sakoda T, Kikushige Y, Akashi K, Satou H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40404985"},{"title01":"Common origin and somatic mutation patterns of composite lymphomas and leukemias","title02":"Common origin and somatic mutation patterns of composite lymphomas and leukemias","journal":"Leukemia","issue":"2025 May 22. doi: 10.1038\/s41375-025-02549-y. Online ahead of print.","author":"Berg V, Lollies A, Schneider M, Johansson P, Weniger MA, Albertini E, Facchetti F, Ascani S, Moawia A, Bens S, Fischer A, Siebert R, Klapper W, Lorenzi L, Tiacci E, Hartmann S, Budeus B, Hansmann ML, K\u00fcppers R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40404986"},{"title01":"Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia","title02":"Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia","journal":"Leukemia","issue":"2025 May 26. doi: 10.1038\/s41375-025-02653-z. Online ahead of print.","author":"Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, Kumar S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40419655"},{"title01":"High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial","title02":"High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial","journal":"Leukemia","issue":"2025 May 28. doi: 10.1038\/s41375-025-02655-x. Online ahead of print.","author":"Zhang Y, Feng Z, Du J, Liu H, Yu S, Liang X, Zhao W, Zhang Q, Zhang X, Nie D, Sun Z, Du X, Xu X, Yu G, Shi P, Liu Q, Shao R, Qu H, Xiong W, Wang S, Jiang Y, Zhang H, Guo Z, Dai M, Jiang X, Xu D, Huang F, Fan Z, Xu N, Liu C, Wu M, Lin R, Jin H, Sun J, Liu Q, Xuan L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40437173"},{"title01":"The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms","title02":"The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms","journal":"Leukemia","issue":"2025 May 15. doi: 10.1038\/s41375-025-02639-x. Online ahead of print.","author":"K\u00fchn MWM, Pemmaraju N, Heidel FH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40374809"},{"title01":"Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients","title02":"Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients","journal":"Br J Haematol","issue":"2025 May 26. doi: 10.1111\/bjh.20185. Online ahead of print.","author":"Hermans SJF, Versluis J, van Werkhoven ED, van Norden Y, Janssen JJWM, Huls GA, Pabst T, Breems DA, Berkx E, Dinmohamed AG, Huijgens PC, Str\u00e4ng E, Hern\u00e1ndez Rivas JM, Sobas M, Ayala Diaz R, Martinez Lopez J, Metzeler KH, Haferlach T, Thiede C, Uyl-de Groot CA, Bullinger L, L\u00f6wenberg B, Ossenkoppele GJ, Pignatti F, Cornelissen JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40419286"},{"title01":"CD49d promotes T-cell senescence in chronic lymphocytic leukaemia","title02":"CD49d promotes T-cell senescence in chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"2025 May 15. doi: 10.1111\/bjh.20135. Online ahead of print.","author":"Wang M, Guo Z, Zhao S, Liu L, Shi Y, Li H, Su J, Zhang N, Li J, Wu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40375447"},{"title01":"Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements","title02":"Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A<\/i> rearrangements","journal":"Leukemia","issue":"2025 May 9. doi: 10.1038\/s41375-025-02634-2. Online ahead of print.","author":"Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40346311"},{"title01":"Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia","title02":"Heterogeneity of IKZF1<\/i> genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia","journal":"Leukemia","issue":"2025 May 13. doi: 10.1038\/s41375-025-02633-3. Online ahead of print.","author":"Wang'ondu RW, Ashcraft E, Chang TC, Roberts KG, Brady SW, Fan Y, Evans W, Relling MV, Crews KR, Yang J, Yang W, Pounds S, Wu G, Devidas M, Maloney K, Mattano L, Schore RJ, Angiolillo A, Larsen E, Salzer W, Burke MJ, Loh ML, Jeha S, Pui CH, Inaba H, Cheng C, Mullighan CG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40360879"},{"title01":"ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker","title02":"ATM<\/i> aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM<\/i> mutations is an adverse-prognostic biomarker","journal":"Leukemia","issue":"2025 Apr 24. doi: 10.1038\/s41375-025-02615-5. Online ahead of print.","author":"Thorvaldsdottir B, Mansouri L, Sutton LA, Nadeu F, Meggendorfer M, Parker H, Brieghel C, Laidou S, Moia R, Rossi D, Kotaskova J, Delgado J, Rodr\u00edguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarf\u00f2 L, Mattsson M, Davis Z, Baliakas P, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Hern\u00e1ndez Rivas JM, Larr\u00e1yoz MJ, Calasanz MJ, Smedby KE, Espinet B, Puiggros A, Bullinger L, Bosch F, Taz\u00f3n-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hern\u00e1ndez-S\u00e1nchez M, Pospisilova S, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275070"},{"title01":"Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia","title02":"Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1<\/i>-positive acute lymphoblastic leukemia","journal":"Leukemia","issue":"2025 Apr 28. doi: 10.1038\/s41375-025-02609-3. Online ahead of print.","author":"Krizkova J, Polivkova V, Laznicka A, Curik N, Benesova A, Suchankova P, Smazik T, Vysinova V, Mikulenkova D, Klamova H, Markova MS, Srbova D, Zuna J, Zaliova M, Trka J, Salek C, Polakova KM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40295826"},{"title01":"S-adenosylmethionine addiction confers sensitivity to methionine restriction in KMT2A-rearranged acute lymphoblastic leukemia","title02":"S-adenosylmethionine addiction confers sensitivity to methionine restriction in KMT2A<\/i>-rearranged acute lymphoblastic leukemia","journal":"Haematologica","issue":"2025 Apr 24. doi: 10.3324\/haematol.2023.284869. Online ahead of print.","author":"Tee T, Ruiter TJJ, Wu S, Zhang W, Schenau DVI, Rodionova M, Wajon D, Vervoort BMT, Grunewald KJT, Bosma M, Hagelaar R, Baker-Hernandez J, Dahaoui A, Schneider P, Verhoeven-Duif NM, Van der Meer LT, Van Leeuwen FN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270205"},{"title01":"Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia","title02":"Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1<\/i> differ from those of CBFB::MYH11<\/i> acute myeloid leukemia","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.287293. Online ahead of print.","author":"Yang M, Wang W, Zhang G, Qiu S, Liu B, Mi Y, Wang Y, Wang J, Wei H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304077"},{"title01":"TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma","title02":"TP53<\/i> and CDKN2A<\/i> alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma","journal":"Leukemia","issue":"2025 May 2. doi: 10.1038\/s41375-025-02631-5. Online ahead of print.","author":"Ito Y, Shimono J, Kawamoto K, Hatanaka KC, Kogure Y, Tabata M, Saito Y, Mizuno K, Horie S, Mizukami Y, Koya J, Murakami K, Teshima T, Hatanaka Y, Chiba K, Okada A, Shiraishi Y, Miyoshi H, Matsuno Y, Ohshima K, Kataoka K, Nakagawa M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40316697"},{"title01":"Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma","title02":"Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma","journal":"N Engl J Med","issue":"2025 May 8;392(18):1858-1860.","author":"Maura F, Bergsagel PL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40334161"},{"title01":"Time for a paradigm shift in immunotherapy-based BCMA\/CD3 bispecific drug development in multiple myeloma","title02":"Time for a paradigm shift in immunotherapy-based BCMA\/CD3 bispecific drug development in multiple myeloma","journal":"Leukemia","issue":"2025 Apr 24. doi: 10.1038\/s41375-025-02610-w. Online ahead of print.","author":"Leleu X, Bobin A, Herbelin A, Gombert JM, Rajkumar SV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275071"},{"title01":"Evaluation of Sox4 levels in multiple myeloma patients","title02":"Evaluation of Sox4 levels in multiple myeloma patients","journal":"Haematologica","issue":"2025 May 8. doi: 10.3324\/haematol.2024.286794. Online ahead of print.","author":"Lombardi E, Kowal KE, Almanza G, Agostini F, Da Ros F, Valvasori M, Vicinanza C, Alzetta D, Montante B, Marangon M, Crestani S, Lamon G, Rupolo M, Mazzucato M, Durante C, Zanetti M, Michieli M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336320"},{"title01":"LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma","title02":"LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma","journal":"Haematologica","issue":"2025 May 8. doi: 10.3324\/haematol.2024.286835. Online ahead of print.","author":"Zuo L, Li Z, Cai L, Li Q, Fan F, Zhang B, Zhao F, Luo S, Zheng Y, Hu Y, Sun C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336322"},{"title01":"Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy","title02":"Myelodysplastic neoplasm with biallelic TP53<\/i> inactivation in a patient with plasma cell myeloma after cytotoxic therapy","journal":"Blood","issue":"2025 May 8;145(19):2230.","author":"He R, Chen D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40338571"},{"title01":"Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group","title02":"Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group","journal":"J Clin Oncol","issue":"2025 Apr 28:JCO2401841. doi: 10.1200\/JCO-24-01841. Online ahead of print.","author":"Huang BJ, Meyer LK, Alonzo TA, Wang YC, Lamble AJ, Ries RE, Wang W, Hirsch B, Raca G, Ma X, Gamis AS, Aplenc R, Kolb EA, Cooper TM, Tarlock K, Loken MR, Meshinchi S, Chewning JH, Woods WG, Horan JT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40294366"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy","journal":"Haematologica","issue":"2025 May 8. doi: 10.3324\/haematol.2025.287433. Online ahead of print.","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bola\u00f1os-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients","title02":"Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.286825. Online ahead of print.","author":"Baril\u00e0 G, Grassi A, Conticello C, Mina R, Marcon C, Fazio F, Cartia CS, Tinelli M, Del Giudice ML, Pilerci S, Belotti A, Pascarella A, Tafuri M, Rocchi S, Mancuso K, Sgherza N, Mele G, Scomazzon E, Gentile M, Porrazzo M, Pescosta N, Furlan A, Febbo MA, Clissa C, Casson A, Ribolla R, Maroccia A, Lisi C, Martino EA, Annibali O, Buda G, Antonioli E, Mangiacavalli S, Tosetto A, Musto P, Gay F, Zamagni E, Petrucci MT, Di Raimondo F, Patriarca F, Zambello R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304063"},{"title01":"A rare complication during autologous stem cell transplantation in multiple myeloma","title02":"A rare complication during autologous stem cell transplantation in multiple myeloma","journal":"Br J Haematol","issue":"2025 May 7. doi: 10.1111\/bjh.20130. Online ahead of print.","author":"Tomarchio V, Faiella E, Tafuri M, Armiento D, Rigacci L, Annibali O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40338808"},{"title01":"A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned","title02":"A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned","journal":"Br J Haematol","issue":"2025 May 5. doi: 10.1111\/bjh.20069. Online ahead of print.","author":"El Jurdi N, Holtzman NG, Hishmeh R, Mina A, Schulz E, Stokes A, Li G, Schmidt KT, Figg WD, Micheletti N, Mays JW, Cowen EW, Pavletic SZ, Pusic I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322855"},{"title01":"Cord blood transplants: Advancing leukaemia treatments and addressing health disparities","title02":"Cord blood transplants: Advancing leukaemia treatments and addressing health disparities","journal":"Br J Haematol","issue":"2025 May;206(5):1312-1314.","author":"Scaradavou A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275775"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world","journal":"Blood","issue":"2025 May 12:blood.2024026512. doi: 10.1182\/blood.2024026512. Online ahead of print.","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Donor regulatory\/conventional T-cell grafts for the GVHD win?","title02":"Donor regulatory\/conventional T-cell grafts for the GVHD win?","journal":"Blood","issue":"2025 May 1;145(18):1964-1965.","author":"Pierini A, Koreth J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40310660"},{"title01":"Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD","title02":"Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD","journal":"Blood","issue":"2025 Apr 25:blood.2024027301. doi: 10.1182\/blood.2024027301. Online ahead of print.","author":"Habenicht KM, Wanzek J, Bootz A, Sch\u00e4fer S, Vollmer L, Hiergeist A, Fante MA, Hasenbank JT, Schneider A, Vasova I, Spoerl S, Brandt A, Rehli M, Hoffmann P, Wirtz S, Kotorri J, Gerlach RG, Gessner A, Mackensen A, Winkler J, Wolff D, Winkler TH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40324063"},{"title01":"Phase 1\/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT","title02":"Phase 1\/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT","journal":"Blood","issue":"2025 May 7:blood.2024028303. doi: 10.1182\/blood.2024028303. Online ahead of print.","author":"Schulz E, Curtis LM, Holtzman NG, Sponaugle J, Wloka K, Ostojic A, Mina A, El Jurdi N, Pirsl F, Carpenter A, Golagha M, Sirajuddin A, Heller T, Shaffer BC, Hakim FT, Rubin JS, Gress RE, Pavletic SZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40331908"},{"title01":"A new variable to study in transplant: APOE variant status","title02":"A new variable to study in transplant: APOE<\/i> variant status","journal":"Blood","issue":"2025 Apr 24;145(17):1839-1840.","author":"Kaito S, DeWolf S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40272859"},{"title01":"High Incidence of Severe TA-TMA Increases Mortality in adult Allogeneic Transplant recipients: A prospective MIDAS Consortium study","title02":"High Incidence of Severe TA-TMA Increases Mortality in adult Allogeneic Transplant recipients: A prospective MIDAS Consortium study","journal":"Blood","issue":"2025 Apr 29:blood.2025028390. doi: 10.1182\/blood.2025028390. Online ahead of print.","author":"Vasu S, Zhao Q, Miller EG, Elder P, Langenberg L, Cataland SR, Davies SM, Bejanyan N, Hahn T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40300075"},{"title01":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","title02":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","journal":"N Engl J Med","issue":"2025 May 1;392(17):1765.","author":"Sanal MG, Jindal A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40305727"},{"title01":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","title02":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","journal":"N Engl J Med","issue":"2025 May 1;392(17):1765-1766.","author":"Zhang K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40305728"},{"title01":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A. Reply","title02":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A. Reply","journal":"N Engl J Med","issue":"2025 May 1;392(17):1766.","author":"Srivastava A, Spencer T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40305729"},{"title01":"Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-\u03b2-activated Alcam(+) bone lining cells, creating a self-sustaining environment","title02":"Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-\u03b2-activated Alcam(+) bone lining cells, creating a self-sustaining environment","journal":"Leukemia","issue":"2025 May 13. doi: 10.1038\/s41375-025-02640-4. Online ahead of print.","author":"Nguyen NTK, Yao H, Hosokawa K, Esaki Y, Yuta R, Adachi S, Arai F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40360881"},{"title01":"Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9)","title02":"Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9)","journal":"Lancet Haematol","issue":"2025 May;12(5):e389-e399.","author":"Mikulska M, van B\u00f6mmel F, Mouliade C, Indolfi G, Kefalakes H, von Lilienfeld-Toal M, Pischke S, Hermine O, Moradpour D, Wedemeyer H, Berg T, Ljungman P, Mallet V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306834"},{"title01":"Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group","title02":"Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group","journal":"J Clin Oncol","issue":"2025 Apr 28:JCO2401841. doi: 10.1200\/JCO-24-01841. Online ahead of print.","author":"Huang BJ, Meyer LK, Alonzo TA, Wang YC, Lamble AJ, Ries RE, Wang W, Hirsch B, Raca G, Ma X, Gamis AS, Aplenc R, Kolb EA, Cooper TM, Tarlock K, Loken MR, Meshinchi S, Chewning JH, Woods WG, Horan JT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40294366"},{"title01":"Targeting leukemic stem cell dormancy in NPM1c\/FLT3-ITD-driven acute myeloid leukemia","title02":"Targeting leukemic stem cell dormancy in NPM1c\/FLT3-ITD-driven acute myeloid leukemia","journal":"Haematologica","issue":"2025 May 8. doi: 10.3324\/haematol.2025.287644. Online ahead of print.","author":"Stelmach P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336317"},{"title01":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients","title02":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.287090. Online ahead of print.","author":"Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Gri\u0161kevi\u010dius L, Juliusson G, Van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, L\u00f6wenberg B, Ossenkoppele GJ, De Leeuw DC, Cloos J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304060"},{"title01":"Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients","title02":"Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.286825. Online ahead of print.","author":"Baril\u00e0 G, Grassi A, Conticello C, Mina R, Marcon C, Fazio F, Cartia CS, Tinelli M, Del Giudice ML, Pilerci S, Belotti A, Pascarella A, Tafuri M, Rocchi S, Mancuso K, Sgherza N, Mele G, Scomazzon E, Gentile M, Porrazzo M, Pescosta N, Furlan A, Febbo MA, Clissa C, Casson A, Ribolla R, Maroccia A, Lisi C, Martino EA, Annibali O, Buda G, Antonioli E, Mangiacavalli S, Tosetto A, Musto P, Gay F, Zamagni E, Petrucci MT, Di Raimondo F, Patriarca F, Zambello R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304063"},{"title01":"A rare complication during autologous stem cell transplantation in multiple myeloma","title02":"A rare complication during autologous stem cell transplantation in multiple myeloma","journal":"Br J Haematol","issue":"2025 May 7. doi: 10.1111\/bjh.20130. Online ahead of print.","author":"Tomarchio V, Faiella E, Tafuri M, Armiento D, Rigacci L, Annibali O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40338808"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world","journal":"Blood","issue":"2025 May 12:blood.2024026512. doi: 10.1182\/blood.2024026512. Online ahead of print.","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Phase 1\/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT","title02":"Phase 1\/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT","journal":"Blood","issue":"2025 May 7:blood.2024028303. doi: 10.1182\/blood.2024028303. Online ahead of print.","author":"Schulz E, Curtis LM, Holtzman NG, Sponaugle J, Wloka K, Ostojic A, Mina A, El Jurdi N, Pirsl F, Carpenter A, Golagha M, Sirajuddin A, Heller T, Shaffer BC, Hakim FT, Rubin JS, Gress RE, Pavletic SZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40331908"},{"title01":"Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT","title02":"Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT","journal":"Blood","issue":"2025 May 7:blood.2023023056. doi: 10.1182\/blood.2023023056. Online ahead of print.","author":"Flamann CS, Shaikh H, Matos C, Kreutz M, Ali H, Kern MA, B\u00fcttner-Herold M, Jacobs B, V\u00f6lkl S, Lischer C, Kellner C, Berges J, Bitterer K, Saul D, Goel M, Link-Rachner C, Zernecke A, Weber DA, Mougiakakos D, Mackensen A, Beilhack A, Bruns H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40332470"},{"title01":"STINGing leukemia stem cells through PSTK inhibition","title02":"STINGing leukemia stem cells through PSTK inhibition","journal":"Blood","issue":"2025 Apr 24;145(17):1833-1835.","author":"Garciaz S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40272853"},{"title01":"Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes","title02":"Myelodysplastic neoplasms with ring sideroblasts without SF3B1<\/i> mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes","journal":"Leukemia","issue":"2025 May 7. doi: 10.1038\/s41375-025-02629-z. Online ahead of print.","author":"Novoa-J\u00e1uregui S, Huber S, Gabarr\u00f3s-Subir\u00e0 M, Chen-Liang TH, Torres-Esquius S, Carrillo-Tornel S, Santiago M, Bernal Del Castillo T, Mart\u00edn-Castillo I, Hernandez FM, Del Rey M, Liquori A, Tormo M, Cervera J, Bosch F, Valc\u00e1rcel D, Haferlach C, D\u00edez-Campelo M, Montoro MJ, Haferlach T, Jerez A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40335618"},{"title01":"The effects of revised haemoglobin cutoffs on the global burden of anaemia","title02":"The effects of revised haemoglobin cutoffs on the global burden of anaemia","journal":"Lancet Haematol","issue":"2025 May;12(5):e325-e326.","author":"Luo H, Liu L, Young MF, Suchdev PS; BRINDA working group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306825"},{"title01":"Prognostic and biological characteristics associated with multiple myeloma presenting only with anemia","title02":"Prognostic and biological characteristics associated with multiple myeloma presenting only with anemia","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.286457. Online ahead of print.","author":"Shamir G, Rouvio O, Reiner-Benaim A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304075"},{"title01":"Increased incidence of autoimmune haemolytic anaemia with paroxysmal cold haemoglobinuria features in paediatric cases in a changing viral environment post-COVID-19 pandemic","title02":"Increased incidence of autoimmune haemolytic anaemia with paroxysmal cold haemoglobinuria features in paediatric cases in a changing viral environment post-COVID-19 pandemic","journal":"Br J Haematol","issue":"2025 May 8. doi: 10.1111\/bjh.20128. Online ahead of print.","author":"Harju T, Raiskila S, Lohi O, J\u00e4rvel\u00e4 L, Niinim\u00e4ki R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40342099"},{"title01":"Cholesterol-conjugated miR-29b induces fetal haemoglobin expression via \u03b3-globin promoter demethylation in the Townes mouse model for sickle cell anaemia","title02":"Cholesterol-conjugated miR-29b induces fetal haemoglobin expression via \u03b3-globin<\/i> promoter demethylation in the Townes mouse model for sickle cell anaemia","journal":"Br J Haematol","issue":"2025 May 4. doi: 10.1111\/bjh.20107. Online ahead of print.","author":"Palani CD, Smith A, Cao X, Li B, Pace BS, Starlard-Davenport A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40320590"},{"title01":"Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia","title02":"Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia","journal":"Blood","issue":"2025 May 7:blood.2025029006. doi: 10.1182\/blood.2025029006. Online ahead of print.","author":"Gao Z, Pan H, Zhang L, Li W, Li R, Zhao J, Luo Y, Lian Y, Yu X, Kuang Z, Nie N, Li J, Huang J, Zhao X, Li Y, Fang L, Ge M, Zheng Y, Shi J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40331918"},{"title01":"Echinococcus granulosus antigen B regulates T-cell function through inhibition of signal transducer and activator of transcription 3 in experimental immune thrombocytopenia","title02":"Echinococcus granulosus<\/i> antigen B regulates T-cell function through inhibition of signal transducer and activator of transcription 3 in experimental immune thrombocytopenia","journal":"Br J Haematol","issue":"2025 May 5. doi: 10.1111\/bjh.20064. Online ahead of print.","author":"Yue Y, Zhang Y, Cheng Y, Jiao H, Yan M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40325612"},{"title01":"Acute stroke in children with immune thrombocytopenia: A systematic review and meta-analysis","title02":"Acute stroke in children with immune thrombocytopenia: A systematic review and meta-analysis","journal":"Br J Haematol","issue":"2025 May;206(5):1450-1457.","author":"Ly A, Ahmad SA, Liu O, Feng SN, Kalra A, Dev A, Spann M, Chaturvedi S, Hong S, Cho SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40269507"},{"title01":"PF4-associated immune thrombocytopenia and thrombosis (PITT)-More than heparin and vaccines","title02":"PF4-associated immune thrombocytopenia and thrombosis (PITT)-More than heparin and vaccines","journal":"Br J Haematol","issue":"2025 Apr 28. doi: 10.1111\/bjh.20125. Online ahead of print.","author":"Makris M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40289696"},{"title01":"BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia","title02":"BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia","journal":"Blood","issue":"2025 May 7:blood.2024027170. doi: 10.1182\/blood.2024027170. Online ahead of print.","author":"Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, Yousuf M, Natu A, Csizmar CM, Gurney M, Lasho TL, Finke CM, Kanagal-Shamanna R, Hammond D, Chien KS, Bazinet A, DiNardo CD, Kadia TM, Mangaonkar AA, Daver NG, Pardanani AD, Borthakur G, Zepeda-Mendoza CJ, Reichard KK, He R, Loghavi S, Passamonti F, Ravandi F, Sasaki K, Larson D, Garcia-Manero G, Onida F, Gangat N, Montalban-Bravo G, Patnaik MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40332442"},{"title01":"STINGing leukemia stem cells through PSTK inhibition","title02":"STINGing leukemia stem cells through PSTK inhibition","journal":"Blood","issue":"2025 Apr 24;145(17):1833-1835.","author":"Garciaz S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40272853"},{"title01":"Beyond conVENtional 7+3 in acute myeloid leukemia","title02":"Beyond conVENtional 7+3 in acute myeloid leukemia","journal":"Blood","issue":"2025 Apr 24;145(17):1831-1832.","author":"McMahon CM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40272856"},{"title01":"Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure","title02":"Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure","journal":"N Engl J Med","issue":"2025 May 8;392(18):1824-1835.","author":"Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40334157"},{"title01":"Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma","title02":"Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma","journal":"N Engl J Med","issue":"2025 May 1;392(17):1760-1762.","author":"Prica A, Roschewski M, Beale P, Pittaluga S, Delabie J, Ortega C, Kridel R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40305722"},{"title01":"Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","title02":"Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","journal":"Leukemia","issue":"2025 May 13. doi: 10.1038\/s41375-025-02641-3. Online ahead of print.","author":"Eichenauer DA, Basaran A, B\u00fchnen I, Fuchs M, von Tresckow B, Rosenwald A, Hansmann ML, Bernd HW, Borchmann P, Klapper W, Hartmann S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40360880"},{"title01":"Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia\/lymphoma (B-ALL): insights from a decade of national data","title02":"Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia\/lymphoma (B-ALL): insights from a decade of national data","journal":"Leukemia","issue":"2025 Apr 24. doi: 10.1038\/s41375-025-02588-5. Online ahead of print.","author":"Zhou T, Short NJ, Jain N, Patel KP, Jabbour EJ, Kantarjian HM, Medeiros LJ, Iorgulescu JB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275068"},{"title01":"Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?","title02":"Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?","journal":"Leukemia","issue":"2025 Apr 24. doi: 10.1038\/s41375-025-02605-7. Online ahead of print.","author":"Gazeau N, Beauvais D, Tilmont R, Srour M, Ferrant E, Safar V, Fouillet L, Flandrin-Gresta P, Gower N, Chauvet P, Duployez N, Podvin B, Demaret J, Huet S, Sujobert P, Ghesqui\u00e8res H, Damaj G, Bachy E, Morschhauser F, Yakoub-Agha I, Heiblig M, Sesques P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275069"},{"title01":"Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma","title02":"Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma","journal":"Leukemia","issue":"2025 Apr 28. doi: 10.1038\/s41375-025-02627-1. Online ahead of print.","author":"Xagoraris I, Yang Y, Bougka E, Trogrlic D, Xyderou P, Stathopoulou K, Herold N, Lundqvist A, Rassidakis GZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40295827"},{"title01":"Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial","title02":"Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"2025 May 2:S2352-3026(25)00071-7. doi: 10.1016\/S2352-3026(25)00071-7. Online ahead of print.","author":"Wang XY, Zhang XM, Wang L, Gao LR, Chen K, Feng XL, Rao W, Zheng R, Wu YP, Song YW, Fang H, Chen B, Jin J, Liu YP, Jing H, Tang Y, Zhang WW, Zhai YR, Lu NN, Li N, Xia CF, Wang SL, Liu X, Li YX, Qi SN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40324445"},{"title01":"Rituximab versus active surveillance in patients with follicular lymphoma","title02":"Rituximab versus active surveillance in patients with follicular lymphoma","journal":"Lancet Haematol","issue":"2025 May;12(5):e320-e321.","author":"Kimby E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306823"},{"title01":"Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?","title02":"Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?","journal":"Lancet Haematol","issue":"2025 May;12(5):e332-e333.","author":"Smith J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306829"},{"title01":"Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?","title02":"Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?","journal":"Lancet Haematol","issue":"2025 May;12(5):e333-e334.","author":"Wilson MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306830"},{"title01":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial","title02":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial","journal":"Lancet Haematol","issue":"2025 May;12(5):e335-e345.","author":"Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, Martin TL, Townsend W, Young M, Miall F, Cunningham D, Walewski J, Ferhanoglu B, Linton K, Johnston A, Seymour JF, Linch DC, Ardeshna KM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306831"},{"title01":"Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma","title02":"Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma","journal":"J Clin Oncol","issue":"2025 May 1:101200JCO2500690. doi: 10.1200\/JCO-25-00690. Online ahead of print.","author":"Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S, Dreyling M; ECHO investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40311141"},{"title01":"A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","title02":"A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","journal":"Haematologica","issue":"2025 Apr 24. doi: 10.3324\/haematol.2025.287509. Online ahead of print.","author":"Lia K, J\u00f8rgensen RRK, Wikman P, Wold BL, \u00d6vergaard N, Fluge \u00d8, Fagerli UM, Bersvendsen H, B\u00f8 IB, Bhargava S, Molin D, Foss\u00e5 A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270216"},{"title01":"Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia\/lymphoma","title02":"Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia\/lymphoma","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2025.287521. Online ahead of print.","author":"Saito M, Sato T, Hasegawa H, Tanabe K, Yoshida-Furihata H, Horibe E, Coler-Reilly A, Nojiri N, Yamauchi S, Nakashima M, Araya N, Yagishita N, Takahashi K, Sasaki D, Sagara Y, Uchimaru K, Utsunomiya A, Ki-Ryang K, Kato T, Itonaga H, Miyazaki Y, Yanagihara K, Oshima K, Arai A, Watanabe T, Yamano Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304064"},{"title01":"Anaplastic large cell lymphoma in children and adolescents","title02":"Anaplastic large cell lymphoma in children and adolescents","journal":"Br J Haematol","issue":"2025 May 12. doi: 10.1111\/bjh.20154. Online ahead of print.","author":"Lowe EJ, Woessmann W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40351161"},{"title01":"Forecasting optimal treatments in relapsed\/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study","title02":"Forecasting optimal treatments in relapsed\/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study","journal":"Br J Haematol","issue":"2025 May 1. doi: 10.1111\/bjh.20063. Online ahead of print.","author":"Sorial MN, Han JX, Koh MJ, Boussi L, Li S, Duan R, Lu J, Lei MM, MacVicar CT, Freydman J, Malespini J, Aniagboso KN, McCabe SM, Peng L, Singh S, Iwasaki M, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, Garg A, Disciullo A, Chopra K, Ford J, Lenart A, Nwodo E, Barnes J, Koh MJ, Miranda E, Chiattone C, Stuver R, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim JS, Cho JY, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince HM, Hamouche R, Murdashvili T, Foss F, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Bhanushali F, Meharwal A, Mistry D, Kosovsky M, Yeterian M, O'Connor OA, Marchi E, Shen C, Shah D, Jain S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40310502"},{"title01":"Distinct characteristics and social determinants in adult T-cell leukaemia\/lymphoma patients at a tertiary cancer centre in Canada","title02":"Distinct characteristics and social determinants in adult T-cell leukaemia\/lymphoma patients at a tertiary cancer centre in Canada","journal":"Br J Haematol","issue":"2025 May 6. doi: 10.1111\/bjh.20132. Online ahead of print.","author":"Aoki T, Salib M, Suleman A, Ghanem N, Hong M, Boriano A, Vijenthira A, Prica A, Kuruvilla J, Kukreti V, Crump M, Kridel R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40328512"},{"title01":"An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators","title02":"An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators","journal":"Br J Haematol","issue":"2025 May 6. doi: 10.1111\/bjh.20115. Online ahead of print.","author":"Tang C, Downie C, Sagoo MS, Pringle E, Suleman A, Lewis KL, Zhang L, Quinn D, Poon LM, Hann W, Cherepanoff S, Coyle L, Kassam S, McKay P, Cheah CY, Prica A, Smith J, Hamad N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40328516"},{"title01":"Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2\/MCL-1 signaling axis","title02":"Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2\/MCL-1 signaling axis","journal":"Br J Haematol","issue":"2025 May 6. doi: 10.1111\/bjh.20137. Online ahead of print.","author":"Luo Y, Fu Y, Kuang M, Wang J, Zhao R, Luo S, Wang L, Chen J, Xu S, Zhou C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40328636"},{"title01":"Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed\/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group","title02":"Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed\/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group","journal":"Br J Haematol","issue":"2025 Apr 26. doi: 10.1111\/bjh.20109. Online ahead of print.","author":"Herbaux C, Bachy E, Bouabdallah R, Guidez S, Casasnovas O, Feugier P, Damaj G, Tilly H, Ysebaert L, Le Gouill S, Morineau N, Gyan E, Gressin R, Houot R, Cheminant M, Morschhauser F, Thieblemont C, Haioun C, Nicolas-Virelizier E, Fornecker LM, Daguindau N, Cartron G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40285420"},{"title01":"Aberrant antioxidant responses in B-cell non-Hodgkin lymphoma","title02":"Aberrant antioxidant responses in B-cell non-Hodgkin lymphoma","journal":"Br J Haematol","issue":"2025 Apr 30. doi: 10.1111\/bjh.20108. Online ahead of print.","author":"Vallet N, Picou F, Arbion F, Doyen H, Gyan E, H\u00e9rault O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40307193"},{"title01":"A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA","title02":"A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA","journal":"Blood","issue":"2025 May 13:blood.2024027355. doi: 10.1182\/blood.2024027355. Online ahead of print.","author":"Pirosa MC, Bruscaggin A, Terzi di Bergamo L, Salehi M, Jauk F, Forestieri G, Bocchetta S, Piffaretti D, Moia R, Cristaldi V, di Trani M, Galimberti GA, Pini K, Spina V, Giordano C, Condoluci A, Romano I, Annunziata S, Bergesio F, Boldorini R, Borsatti E, Bulian P, Calabretta E, Chauvie S, Corrado F, Crisci S, Cuzzocrea M, De Filippi R, Gerber B, Kurlapski M, Larocca LM, Merlo E, Rinaldi A, Rodari M, Romanowicz G, Sacchetti GM, Stathis A, Stussi G, Zangrilli I, Pinto A, Mazzucchelli L, Gattei V, Zaucha JM, Santoro A, Hohaus S, Cavalli F, Tzankov A, Carlo-Stella C, Gaidano G, Ceriani L Prof, Zucca E, Rossi D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40359477"},{"title01":"Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment","title02":"Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment","journal":"Blood","issue":"2025 May 13:blood.2024027877. doi: 10.1182\/blood.2024027877. Online ahead of print.","author":"Pelzl R, Benintende G, Gsottberger F, Scholz JK, Ruebner M, Yao H, Wendland K, Rejeski K, Altmann H, Petkovic S, Mellenthin L, K\u00fcbel S, Schmiedeberg M, Klein P, Petrera A, Baur R, Eckstein S, Hoepffner-Grundy S, R\u00f6llig C, Subklewe M, Huebner H, Schett G, Mackensen A, Laurenti L, Graw F, V\u00f6lkl S, Nganou-Makamdop K, M\u00fcller F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40359478"},{"title01":"When lymphoma mimics adenocarcinoma: signet ring morphology in follicular lymphoma","title02":"When lymphoma mimics adenocarcinoma: signet ring morphology in follicular lymphoma","journal":"Blood","issue":"2025 May 1;145(18):2104.","author":"Parisi X, Medeiros LJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40310656"},{"title01":"Class struggle in DLBCL","title02":"Class struggle in DLBCL","journal":"Blood","issue":"2025 May 1;145(18):1967-1969.","author":"Krupka JA, Hodson DJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40310657"},{"title01":"The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma","title02":"The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma","journal":"Haematologica","issue":"2025 Apr 24. doi: 10.3324\/haematol.2025.287523. Online ahead of print.","author":"Yan W, Qiu C, Zhou J, Xu J, Cui J, Liu Y, Du C, Yu T, Zhang S, Sui W, Deng S, Xu Y, Zou D, Yuan W, Qiu L, Hao M, Chu Y, An G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270198"},{"title01":"Prognostic and biological characteristics associated with multiple myeloma presenting only with anemia","title02":"Prognostic and biological characteristics associated with multiple myeloma presenting only with anemia","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.286457. Online ahead of print.","author":"Shamir G, Rouvio O, Reiner-Benaim A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304075"},{"title01":"A rare complication during autologous stem cell transplantation in multiple myeloma","title02":"A rare complication during autologous stem cell transplantation in multiple myeloma","journal":"Br J Haematol","issue":"2025 May 7. doi: 10.1111\/bjh.20130. Online ahead of print.","author":"Tomarchio V, Faiella E, Tafuri M, Armiento D, Rigacci L, Annibali O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40338808"},{"title01":"Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells","title02":"Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells","journal":"Blood","issue":"2025 May 13:blood.2024025536. doi: 10.1182\/blood.2024025536. Online ahead of print.","author":"Kasap C, Izgutdina A, Pati\u00f1o-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Al\u00f3s D, Sobh A, Dup\u00e9r\u00e9-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin T, Wolf JL, Wong S, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon W, Barwick BG, Wiita A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40359480"},{"title01":"A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed\/refractory multiple myeloma","title02":"A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed\/refractory multiple myeloma","journal":"Blood","issue":"2025 Apr 25:blood.2024027873. doi: 10.1182\/blood.2024027873. Online ahead of print.","author":"Holstein SA, Atrash S, Mian H, Dimopoulos MA, Schjesvold F, Popat R, Shah N, Gatt ME, Gocke CB, Frenzel L, Touzeau C, Beksac M, Manier S, Magen H, Travis P, Nadeem O, Suryanarayan K, Li C, Li S, Nelson A, Cherepanov D, Parot X, Vogl DT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40279508"},{"title01":"The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma","title02":"The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma","journal":"Blood","issue":"2025 Apr 29:blood.2024026340. doi: 10.1182\/blood.2024026340. Online ahead of print.","author":"Perini T, Zordan P, Del Pizzo R, Resnati M, Viviani L, Stefanoni D, Cassina L, Orfanelli UP, Trudu M, Oliva L, Lacidogna D, Samur MK, Materozzi M, Drago D, Andolfo A, Patrone M, Degano M, Boletta A, Milan E, Ciceri F, Munshi NC, Bellone M, Cenci S MD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40300074"},{"title01":"Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9)","title02":"Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9)","journal":"Lancet Haematol","issue":"2025 May;12(5):e389-e399.","author":"Mikulska M, van B\u00f6mmel F, Mouliade C, Indolfi G, Kefalakes H, von Lilienfeld-Toal M, Pischke S, Hermine O, Moradpour D, Wedemeyer H, Berg T, Ljungman P, Mallet V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306834"},{"title01":"Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia\/lymphoma (B-ALL): insights from a decade of national data","title02":"Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia\/lymphoma (B-ALL): insights from a decade of national data","journal":"Leukemia","issue":"2025 Apr 24. doi: 10.1038\/s41375-025-02588-5. Online ahead of print.","author":"Zhou T, Short NJ, Jain N, Patel KP, Jabbour EJ, Kantarjian HM, Medeiros LJ, Iorgulescu JB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275068"},{"title01":"Possible impacts of cosmic radiation on leukemia development during human deep space exploration","title02":"Possible impacts of cosmic radiation on leukemia development during human deep space exploration","journal":"Leukemia","issue":"2025 Apr 24. doi: 10.1038\/s41375-025-02624-4. Online ahead of print.","author":"Ghani F, Zubair AC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275072"},{"title01":"Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia","title02":"Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia","journal":"Leukemia","issue":"2025 Apr 28. doi: 10.1038\/s41375-025-02622-6. Online ahead of print.","author":"Mecklenbrauck R, Borchert N, Gabdoulline R, Poll P, Funke C, Brandes M, Dallmann LK, Fiedler W, Krauter J, Trummer A, Hertenstein B, M\u00fcller M, L\u00fcbbert M, Schwalenberg M, Voss A, Di Donato N, Bergmann A, Gaidzik V, D\u00f6hner K, D\u00f6hner H, Ganser A, Heidel FH, Thol FR, Heuser M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40295828"},{"title01":"Wnt5a induces ROR1 dependent NF-\u03baB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia","title02":"Wnt5a induces ROR1 dependent NF-\u03baB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia","journal":"Leukemia","issue":"2025 Apr 28. doi: 10.1038\/s41375-025-02616-4. Online ahead of print.","author":"Hasan MK, Widhopf Ii GF, Ghia EM, Kipps TJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40295829"},{"title01":"Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials","title02":"Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials","journal":"Lancet Haematol","issue":"2025 May;12(5):e346-e356.","author":"Potter N, Jovanovic J, Ivey A, Othman J, Thomas A, Gilkes A, Runglall M, Kanda A, Thomas I, Johnson S, Canham J, Villiers W, Knapper S, Khwaja A, McMullin MF, Cavenagh J, Overgaard UM, Clark RE, Solomon E, Freeman SD, Hills R, Burnett A, Russell N, Dillon R; UK AML Research Network.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306832"},{"title01":"Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9)","title02":"Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9)","journal":"Lancet Haematol","issue":"2025 May;12(5):e389-e399.","author":"Mikulska M, van B\u00f6mmel F, Mouliade C, Indolfi G, Kefalakes H, von Lilienfeld-Toal M, Pischke S, Hermine O, Moradpour D, Wedemeyer H, Berg T, Ljungman P, Mallet V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40306834"},{"title01":"Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group","title02":"Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group","journal":"J Clin Oncol","issue":"2025 Apr 28:JCO2401841. doi: 10.1200\/JCO-24-01841. Online ahead of print.","author":"Huang BJ, Meyer LK, Alonzo TA, Wang YC, Lamble AJ, Ries RE, Wang W, Hirsch B, Raca G, Ma X, Gamis AS, Aplenc R, Kolb EA, Cooper TM, Tarlock K, Loken MR, Meshinchi S, Chewning JH, Woods WG, Horan JT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40294366"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy","journal":"Haematologica","issue":"2025 May 8. doi: 10.3324\/haematol.2025.287433. Online ahead of print.","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bola\u00f1os-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"Targeting leukemic stem cell dormancy in NPM1c\/FLT3-ITD-driven acute myeloid leukemia","title02":"Targeting leukemic stem cell dormancy in NPM1c\/FLT3-ITD-driven acute myeloid leukemia","journal":"Haematologica","issue":"2025 May 8. doi: 10.3324\/haematol.2025.287644. Online ahead of print.","author":"Stelmach P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336317"},{"title01":"The birth of a paradigm: leukemia-initiating cells in acute myeloid leukemia","title02":"The birth of a paradigm: leukemia-initiating cells in acute myeloid leukemia","journal":"Haematologica","issue":"2025 May 1;110(5):1051-1052.","author":"Cruz-Rodriguez N, Deininger MW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40321000"},{"title01":"Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment","title02":"Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment","journal":"Haematologica","issue":"2025 Apr 24. doi: 10.3324\/haematol.2024.287206. Online ahead of print.","author":"Vel\u00e1zquez GF, Weller JF, Rubeck A, Arndt T, Schiele S, Mezger M, Lengerke C, Bethge W, Trepel M, M\u00fcller G, Christopeit M, Schmid C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270206"},{"title01":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia","title02":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.287116. Online ahead of print.","author":"Zhang X, Yang Y, Liu B, Du X, Wang X, Zhu H, Yu L, Li Z, Zhao S, Yang L, Ma Y, Meng L, Zhang Y, Li G, Yang L, Wang B, Ran X, Huang J, Gao N, Wen Q, Wen Y, Zhao Y, Zhu Y, Han Y, Liu Z, Du X, Weng J, Gale RP, Zhou L, Zhang Y, Jiang Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304058"},{"title01":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients","title02":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2024.287090. Online ahead of print.","author":"Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Gri\u0161kevi\u010dius L, Juliusson G, Van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, L\u00f6wenberg B, Ossenkoppele GJ, De Leeuw DC, Cloos J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304060"},{"title01":"Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia\/lymphoma","title02":"Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia\/lymphoma","journal":"Haematologica","issue":"2025 Apr 30. doi: 10.3324\/haematol.2025.287521. Online ahead of print.","author":"Saito M, Sato T, Hasegawa H, Tanabe K, Yoshida-Furihata H, Horibe E, Coler-Reilly A, Nojiri N, Yamauchi S, Nakashima M, Araya N, Yagishita N, Takahashi K, Sasaki D, Sagara Y, Uchimaru K, Utsunomiya A, Ki-Ryang K, Kato T, Itonaga H, Miyazaki Y, Yanagihara K, Oshima K, Arai A, Watanabe T, Yamano Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304064"},{"title01":"Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations","title02":"Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations","journal":"Br J Haematol","issue":"2025 May 8. doi: 10.1111\/bjh.20133. Online ahead of print.","author":"Behrens YL, Reinkens T, Hofmann W, Gumann A, F\u00f6rster A, Gaschler L, Ghete T, Strasser R, Espenk\u00f6tter J, Haermeyer B, Losch M, Sembill S, Wotschofsky Z, von H\u00f6rsten S, Schuh W, Di Donato N, Suttorp M, Krumbholz M, Ripperger T, Schlegelberger B, G\u00f6hring G, Metzler M, Karow A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40344211"},{"title01":"The role of blinatumomab in adult acute B lymphoblastic leukaemia","title02":"The role of blinatumomab in adult acute B lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2025 May 14. doi: 10.1111\/bjh.20134. Online ahead of print.","author":"Wilke AC, G\u00f6kbuget N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40368871"},{"title01":"Global spatiotemporal distribution characteristics and regional risk stratification model of acute myeloid leukaemia based on molecular genetics and cytogenetic features","title02":"Global spatiotemporal distribution characteristics and regional risk stratification model of acute myeloid leukaemia based on molecular genetics and cytogenetic features","journal":"Br J Haematol","issue":"2025 May 5. doi: 10.1111\/bjh.20138. Online ahead of print.","author":"Xiao J, Xia Y, Yin F, Shi Z, Meng G, Ye J, Sun T, Ji C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40325927"},{"title01":"Distinct characteristics and social determinants in adult T-cell leukaemia\/lymphoma patients at a tertiary cancer centre in Canada","title02":"Distinct characteristics and social determinants in adult T-cell leukaemia\/lymphoma patients at a tertiary cancer centre in Canada","journal":"Br J Haematol","issue":"2025 May 6. doi: 10.1111\/bjh.20132. Online ahead of print.","author":"Aoki T, Salib M, Suleman A, Ghanem N, Hong M, Boriano A, Vijenthira A, Prica A, Kuruvilla J, Kukreti V, Crump M, Kridel R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40328512"},{"title01":"Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2\/MCL-1 signaling axis","title02":"Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2\/MCL-1 signaling axis","journal":"Br J Haematol","issue":"2025 May 6. doi: 10.1111\/bjh.20137. Online ahead of print.","author":"Luo Y, Fu Y, Kuang M, Wang J, Zhao R, Luo S, Wang L, Chen J, Xu S, Zhou C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40328636"},{"title01":"Cord blood transplants: Advancing leukaemia treatments and addressing health disparities","title02":"Cord blood transplants: Advancing leukaemia treatments and addressing health disparities","journal":"Br J Haematol","issue":"2025 May;206(5):1312-1314.","author":"Scaradavou A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275775"},{"title01":"Blastic erythrophagocytosis in monocytic AML with translocation t(8;22)","title02":"Blastic erythrophagocytosis in monocytic AML with translocation t(8;22)","journal":"Br J Haematol","issue":"2025 May;206(5):1270-1271.","author":"Faucheux L, Voirin E, Rault E, Herault O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40301671"},{"title01":"From prognostication to precision in acute myeloid leukemia","title02":"From prognostication to precision in acute myeloid leukemia","journal":"Blood","issue":"2025 May 8;145(19):2105-2106.","author":"Hourigan CS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40338575"},{"title01":"STING activation enhances immunotherapy of AML","title02":"STING activation enhances immunotherapy of AML","journal":"Blood","issue":"2025 May 8;145(19):2106-2108.","author":"Kabelitz D, Chitadze G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40338576"},{"title01":"GATA 2 much: stemness and resistance in AML chemotherapy","title02":"GATA 2 much: stemness and resistance in AML chemotherapy","journal":"Blood","issue":"2025 May 8;145(19):2110-2112.","author":"Mercher T, Arcangeli ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40338577"},{"title01":"How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapy","title02":"How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapy","journal":"Blood","issue":"2025 May 12:blood.2024027267. doi: 10.1182\/blood.2024027267. Online ahead of print.","author":"Aldoss I, Clark MC, Forman SJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354576"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world","journal":"Blood","issue":"2025 May 12:blood.2024026512. doi: 10.1182\/blood.2024026512. Online ahead of print.","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia","title02":"Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia","journal":"Blood","issue":"2025 May 13:blood.2025028938. doi: 10.1182\/blood.2025028938. Online ahead of print.","author":"Saorin A, Dehler A, Galvan B, Steffen FD, Ray M, Lu D, Yu X, Kim J, Drakul A, Kisele S, Wang J, Bourquin JP, Bornhauser B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40359431"},{"title01":"Mixed-phenotype acute leukemia revisited: omics lead the way","title02":"Mixed-phenotype acute leukemia revisited: omics lead the way","journal":"Blood","issue":"2025 May 1;145(18):1969-1971.","author":"Bullinger L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40310658"},{"title01":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","title02":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","journal":"Blood","issue":"2025 May 7:blood.2025028357. doi: 10.1182\/blood.2025028357. Online ahead of print.","author":"Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Zucenka A, De Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, K\u00fchn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, D\u00f6hner H, Greco C, Kovacsovics TJ, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40332046"},{"title01":"Ph-Positive Acute Lymphoblastic Leukemia – 25 Years of Progress","title02":"Ph-Positive Acute Lymphoblastic Leukemia – 25 Years of Progress","journal":"N Engl J Med","issue":"2025 May 15;392(19):1941-1952.","author":"Fo\u00e0 R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40367376"},{"title01":"Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia","title02":"Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia","journal":"Leukemia","issue":"2025 May 8. doi: 10.1038\/s41375-025-02638-y. Online ahead of print.","author":"Izumi S, Ohtani K, Matsumoto M, Shibata S, Rahmutulla B, Fukuyo M, Nishimoto M, Miyagawa H, Sakaida E, Yokote K, Kitabayashi I, Araki K, Kaneda A, Hoshii T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40341256"},{"title01":"Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-\u03b2-activated Alcam(+) bone lining cells, creating a self-sustaining environment","title02":"Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-\u03b2-activated Alcam(+) bone lining cells, creating a self-sustaining environment","journal":"Leukemia","issue":"2025 May 13. doi: 10.1038\/s41375-025-02640-4. Online ahead of print.","author":"Nguyen NTK, Yao H, Hosokawa K, Esaki Y, Yuta R, Adachi S, Arai F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40360881"},{"title01":"National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients","title02":"National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients","journal":"Leukemia","issue":"2025 Apr 23. doi: 10.1038\/s41375-025-02598-3. Online ahead of print.","author":"Wu JF, Feliciano EJG, Singh A, Tremblay D, Abid MB, Dee EC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40269270"},{"title01":"Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers","title02":"Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers","journal":"Haematologica","issue":"2025 Apr 24. doi: 10.3324\/haematol.2025.287429. Online ahead of print.","author":"Orgel E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270204"},{"title01":"Recycling is “bad to the bone” in patients with myeloma","title02":"Recycling is “bad to the bone” in patients with myeloma","journal":"Blood","issue":"2025 Apr 24;145(17):1832-1833.","author":"Miller KC, Lesokhin AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40272858"}]